US20190255165A1 - Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer - Google Patents

Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer Download PDF

Info

Publication number
US20190255165A1
US20190255165A1 US16/331,398 US201716331398A US2019255165A1 US 20190255165 A1 US20190255165 A1 US 20190255165A1 US 201716331398 A US201716331398 A US 201716331398A US 2019255165 A1 US2019255165 A1 US 2019255165A1
Authority
US
United States
Prior art keywords
complex
seq
peptide
epitopes
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/331,398
Other languages
English (en)
Inventor
Madiha Derouazi
Elodie BELNOUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amal Therapeutics SA
Original Assignee
Amal Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amal Therapeutics SA filed Critical Amal Therapeutics SA
Assigned to AMAL THERAPEUTICS SA reassignment AMAL THERAPEUTICS SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BELNOUE, Elodie, DEROUAZI, Madiha
Publication of US20190255165A1 publication Critical patent/US20190255165A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001119—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464496—Fusion proteins originating from gene translocation in cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to the field of vaccination, in particular to vaccines for the prevention and/or treatment of colorectal cancer (CRC).
  • CRC colorectal cancer
  • CRC Colorectal cancer
  • FAP like MAP (MUTYH-associated polyposis) (Sieber, O. M., et al., Multiple colorectal adenomas, classic adenomatous polyposis, and germ - line mutations in MYH . N Engl J Med, 2003. 348(9): p. 791-9) or Lynch syndrome (Lynch, H. T., et al., Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review . Gastroenterology, 1993. 104(5): p.
  • stage 1 the CRC patient's survival time depends on disease development stage. Patients with early stages (Stage 0, I and II) have good prognosis (more than 75%). Stages III have a more heterogeneous survival rate (from 90% down to 50%) depending on the tumor invasion on peripheral tissues. Finally, only stage IV is showing a fast and significant effect on the patient survival time: Only about 10% of patients are surviving more than 60 months after diagnosis.
  • VEGF vascular endothelial growth factor
  • EGFR Merck-Serono cetuximab/Erbitux®
  • Amgen's EGFR monoclonal antibody panitumumab/Vectibix®
  • Bayer's small molecule kinase inhibitor Regorafenib Basarga®
  • the VEGF monoclonal antibody Ramucirumab from Eli Lilly may be used.
  • radiation may be used to relieve symptoms such as pain.
  • CTLs tumor-specific cytotoxic T lymphocytes
  • cancer vaccines showed very limited clinical efficacy so far. Indeed, at the end of 2011, amongst the 300 hundred ongoing cancer vaccine clinical trials, only 19 phase III trials were reported ( globaldat, 2012). Amongst them, there are NeuVax, a peptide vaccine for breast cancer, Stimuvax, a liposome based vaccine for Non-Small Cell Lung Carcinoma (NSCLC) and breast cancer, TG4010, a vaccinia-based vaccine for NSCLC and GSK1572932A, an adjuvanted liposome for NSCLC. These four cancer vaccines are based on different technologies and have in common that they are targeting one single antigen.
  • Therapeutic cancer vaccines can be divided into two principal categories: personalized (autologous) and standardized vaccines, and further classified depending on the technology platform.
  • Current personalized vaccines include tumor lysate vaccines as well as dendritic cells based vaccine (hereinafter cell based).
  • cell based dendritic cells based vaccine
  • antigen loading can occur either with a pulse using tumor lysates, or transfection with RNA extracted from the tumors.
  • the antigens are tumor specific or associated, but are not clearly defined.
  • Dendritic cells can also be loaded with defined antigens either with peptide pulse or using a protein such as the Prostatic Acid Phosphatase (PAP) used to engineer the Provenge® vaccine.
  • PAP Prostatic Acid Phosphatase
  • subunits vaccines protein or peptides
  • APCs cell-based therapy
  • T cells T cells
  • CARs CARs
  • lysates subunits vaccines
  • subunits vaccines protein or peptides
  • the antigens are fully defined allowing for better immune-monitoring and reducing the risk of unwanted effects of vaccine component.
  • EGFR epidermal growth factor receptor
  • VEGF vascular endothelial growth factor
  • Adoptive cell transfer (ACT) therapy clinical trials for CRC have unfortunately returned poor results so far. Indeed the limited patient population for both non-engineered and engineered T-cells treatments seems being a major hurdle. Similarly, secondary effect observed on patients treated with T-cells fused with chimeric antigen receptors (CARs), failed to demonstrate ACT as a safe and efficient treatment (Koido, S., et al., Immunotherapy for colorectal cancer . World) Gastroenterol, 2013. 19(46): p. 8531-42; Xiang, B., et al., Colorectal cancer immunotherapy . Discov Med, 2013. 15(84): p. 301-8). Thus added to usual ACT drawbacks in terms of feasibility and cost and immune response memory seems blocking ACT option for the time being.
  • a therapeutic cancer vaccine is administrated to cancer patients to strengthen the capability of their immune system to recognize and kill the tumor cells.
  • the main goal of a therapeutic cancer vaccine is to generate killer T cells (also called cytotoxic T lymphocytes) specific for the tumor cells.
  • the vaccine must contain molecules called antigens that are also present in the tumor and that need to be delivered to Antigen Presenting Cells (APCs), especially dendritic cells (DCs), to allow cancer immunity to be initiated.
  • APCs Antigen Presenting Cells
  • DCs dendritic cells
  • the DCs process these tumor antigens into small peptides that are presented on cell surface expressed MHC class I or MHC class II molecules to T cells. Peptides that are then recognized by T cells and thereby induce their stimulation are called epitopes.
  • MHC class I and MHC class II molecules allow activation of two classes of T cells, CD8 + cytotoxic T lymphocytes (CTLs) and CD4 + helper T (T h ) cells, respectively.
  • CTLs cytotoxic T lymphocytes
  • T h helper T cells
  • co-stimulatory signal which is antigen non-specific and is provided by the interaction between co-stimulatory molecules expressed on the surface of APCs and the T cell. Therefore two major requirements for an efficient therapeutic cancer vaccine are the specificity of the tumor antigens and the ability to deliver them efficiently to DCs.
  • induction of a tumor specific immune response thus requires three main steps: (i) an antigen must be delivered to dendritic cells, which will process it into epitopes, (ii) dendritic cells should receive a suitable activation signal, and (iii) activated tumor antigen-loaded dendritic cells must generate T-cell mediated immune responses in the lymphoid organs.
  • multi-epitopic antigen delivery provides an advantage.
  • protein based vaccines allow multi-epitopic antigen delivery to antigen presenting cells (APCs) such as dendritic cells (DCs) without the limitation of restriction to a single MHC allele.
  • APCs antigen presenting cells
  • DCs dendritic cells
  • Another strength is long-lasting epitope presentation recently described in dendritic cells loaded with proteins (van Montfoort N, Camps M G, Khan S, Filippov D V, Weterings J J, Griffith J M, et al.
  • Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.
  • proteins require uptake and processing by DCs to achieve MHC restricted presentation of their constituent epitopes. This reduces the risk of inducing peripheral tolerance as has been shown after vaccination with short peptides that do not have such stringent processing requirements (Toes R E, Offringa R, Blom R J, Melief C J, Kast W M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proceedings of the National Academy of Sciences of the United States of America 1996; 93(15):7855-60).
  • peptide-pulsed DCs as vaccines have several limitations. For example, peptide degradation, rapid MHC class I turnover, and the disassociation of peptide from MHC class I molecules during the preparation and injection of DC/peptides may result in short half-lives of MHC class I/peptide complexes on the DC surface, leading to weak T-cell responses.
  • Cell penetrating peptides are peptides of 8 to 40 residues that have the ability to cross the cell membrane and enter into most cell types (Copolovici D M, Langel K, Eriste E, Langel U. Cell-penetrating peptides: design, synthesis, and applications. ACS nano 2014; 8(3):1972-94, Milletti F.
  • Cell-penetrating peptides classes, origin, and current landscape. Drug Discov Today 2012). Alternatively, they are also called protein transduction domain (PTDs) reflecting their origin as occurring in natural proteins.
  • PTDs protein transduction domain
  • Several potent CPPs have been identified from proteins, including the Tat protein of human immunodeficiency virus, the VP22 protein of herpes simplex virus, and fibroblast growth factor (Berry C C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine. 2008; 3:357-365; Deshayes S, Morris M C, Divita G, Heitz F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell Mol Life Sci.
  • T-cell activity elicited by DC/TAT-TRP2 was 3- to 10-fold higher than that induced by DUTRP2 (Wang H Y, Fu T, Wang G, Gang Z, Donna M P L, Yang J C, Restifo N P, Hwu P, Wang R F. Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest. 2002a; 109:1463-1470).
  • subunits vaccines are poorly immunogenic. Therefore in the context of therapeutic cancer vaccine, a potent adjuvant is mandatory to be added to the vaccine in order to increase the level of co-stimulatory molecules on DCs and therefore augment the immune system's response to the target antigens.
  • Adjuvants accomplish this task by mimicking conserved microbial components that are naturally recognized by the immune system. They include, lipopolysaccharide (LPS), components of bacterial cell walls, and nucleic acids such as double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), and unmethylated CpG dinucleotide-containing DNA. Their presence together with the vaccine can greatly increase the innate immune response to the antigen.
  • LPS lipopolysaccharide
  • dsRNA double-stranded RNA
  • ssDNA single-stranded DNA
  • unmethylated CpG dinucleotide-containing DNA unmethylated CpG dinucleotide-containing DNA.
  • this adjuvant should promote an adaptive immune response with CTLs and type polarized Th1 rather than a humoral immune response resulting in antibody production.
  • Different adjuvants have been evaluated, with a limited number having gained regulatory approval for human use. These include Alum, MPL (monophosphoryl lipid A) and ASO 4 (Alum and MPL) in the US, and MF59 (oil-in-water emulsion), ASO 4 liposomes in Europe (Lim, Y. T., Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease. Clin Exp Vaccine Res, 2015. 4(1): p. 54-8).
  • TLR Toll Like Receptor
  • TLR-3 poly I:C
  • TLR-4 monophosphoryl lipid A
  • MPL monophosphoryl lipid A
  • TLR-5 flagellin
  • TLR-7 imiquimod
  • TLR-9 CpG
  • TLR ligand-peptide conjugate vaccines toward clinical application. Adv Immunol. 2012; 114:177-201).
  • TLR ligands for conjugate vaccine are the TLR2 agonist Pam2Cys and Pam3Cys (Fujita, Y. and H. Taguchi, Overview and outlook of Toll - like receptor ligand - antigen conjugate vaccines . Ther Deliv, 2012. 3(6): p. 749-60).
  • T h cells are involved in the maintenance of long-lasting cellular immunity and tumor infiltration by T h cells is also an essential step for the recruitment and function of CD8 + CTLs.
  • Immunological memory is essential to protect against tumor relapse.
  • the term “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated member, integer or step but not the exclusion of any other non-stated member, integer or step.
  • the term “consist of” is a particular embodiment of the term “comprise”, wherein any other non-stated member, integer or step is excluded. In the context of the present invention, the term “comprise” encompasses the term “consist of”.
  • the term “comprising” thus encompasses “including” as well as “consisting” e.g., a composition “comprising” X may consist exclusively of X or may include something additional e.g., X+Y.
  • the present invention provides a complex comprising:
  • Such a complex for use according to the present invention provides simultaneous (i) stimulation of multi-epitopic cytotoxic T cell-mediated immunity, (ii) induction of T i , cells and (iii) promotion of immunological memory.
  • a complex for use according to the present invention provides a potent vaccine, in particular having improved anti-tumor activity.
  • the complex for use according to the present invention is a polypeptide or a protein, in particular a recombinant polypeptide or a recombinant protein, preferably a recombinant fusion protein or a recombinant fusion polypeptide.
  • recombinant as used herein means that it (here: the polypeptide or the protein) does not occur naturally.
  • the complex for use according to the present invention which is a recombinant polypeptide or a recombinant protein, typically comprises components a) to c), wherein components a) to c) are of different origins, i.e. do not naturally occur in this combination.
  • peptide refers to peptide, oligopeptide, oligomer or protein including fusion protein, respectively, comprising at least two amino acids joined to each other preferably by a normal peptide bond, or, alternatively, by a modified peptide bond, such as for example in the cases of isosteric peptides.
  • a peptide, polypeptide or protein can be composed of L-amino acids and/or D-amino acids.
  • a peptide, polypeptide or protein is either (entirely) composed of L-amino acids or (entirely) of D-amino acids, thereby forming “retro-inverso peptide sequences”.
  • the term “retro-inverso (peptide) sequences” refers to an isomer of a linear peptide sequence in which the direction of the sequence is reversed and the chirality of each amino acid residue is inverted (see e.g. Jameson et al., Nature, 368, 744-746 (1994); Brady et al., Nature, 368, 692-693 (1994)).
  • peptide in particular, the terms “peptide”, “polypeptide”, “protein also include “peptidomimetics” which are defined as peptide analogs containing non-peptidic structural elements, which peptides are capable of mimicking or antagonizing the biological action(s) of a natural parent peptide.
  • a peptidomimetic lacks classical peptide characteristics such as enzymatically scissile peptide bonds.
  • a peptide, polypeptide or protein can comprise amino acids other than the 20 amino acids defined by the genetic code in addition to these amino acids, or it can be composed of amino acids other than the 20 amino acids defined by the genetic code.
  • a peptide, polypeptide or protein in the context of the present invention can equally be composed of amino acids modified by natural processes, such as post-translational maturation processes or by chemical processes, which are well known to a person skilled in the art. Such modifications are fully detailed in the literature. These modifications can appear anywhere in the polypeptide: in the peptide skeleton, in the amino acid chain or even at the carboxy- or amino-terminal ends.
  • a peptide or polypeptide can be branched following an ubiquitination or be cyclic with or without branching. This type of modification can be the result of natural or synthetic post-translational processes that are well known to a person skilled in the art.
  • peptide in the context of the present invention in particular also include modified peptides, polypeptides and proteins.
  • peptide, polypeptide or protein modifications can include acetylation, acylation, ADP-ribosylation, amidation, covalent fixation of a nucleotide or of a nucleotide derivative, covalent fixation of a lipid or of a lipidic derivative, the covalent fixation of a phosphatidylinositol, covalent or non-covalent cross-linking, cyclization, disulfide bond formation, demethylation, glycosylation including pegylation, hydroxylation, iodization, methylation, myristoylation, oxidation, proteolytic processes, phosphorylation, prenylation, racemization, seneloylation, sulfatation, amino acid addition such as arginylation or ubiquitination.
  • the complex for use according to the present invention is a “classical” peptide, polypeptide or protein, whereby a “classical” peptide, polypeptide or protein is typically composed of amino acids selected from the 20 amino acids defined by the genetic code, linked to each other by a normal peptide bond.
  • the complex for use according to the present invention is a polypeptide or a protein, it is preferred that it comprises at least 50, at least 60, at least 70, preferably at least 80, at least 90, more preferably at least 100, at least 110, even more preferably at least 120, at least 130, particularly preferably at least 140, or most preferably at least 150 amino acid residues.
  • the CPP allows for efficient delivery, i.e. transport and loading, in particular of at least one antigen or antigenic epitope, into the antigen presenting cells (APCs), in particular into the dendritic cells (DCs) and thus to the dendritic cells' antigen processing machinery.
  • APCs antigen presenting cells
  • DCs dendritic cells
  • CPPs cell penetrating peptides
  • Cell penetrating peptides is generally used to designate short peptides that are able to transport different types of cargo molecules across plasma membrane, and, thus, facilitate cellular uptake of various molecular cargoes (from nanosize particles to small chemical molecules and large fragments of DNA).
  • Cellular internalization of the cargo molecule linked to the cell penetrating peptide generally means transport of the cargo molecule across the plasma membrane and thus entry of the cargo molecule into the cell.
  • the cargo molecule can, then, be released in the cytoplasm, directed to an intracellular organelle, or further presented at the cell surface.
  • Cell penetrating ability, or internalization, of the cell penetrating peptide or complex comprising said cell penetrating peptide, according to the invention can be checked by standard methods known to one skilled in the art, including flow cytometry or fluorescence microscopy of live and fixed cells, immunocytochemistry of cells transduced with said peptide or complex, and Western blot.
  • Cell penetrating peptides typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or have a sequence that contains an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids. These two types of structures are referred to as polycationic or amphipathic, respectively.
  • Cell-Penetrating peptides are of different sizes, amino acid sequences, and charges but all CPPs have a common characteristic that is the ability to translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or to an organelle of a cell.
  • CPP translocation distinguish three main entry mechanisms: direct penetration in the membrane, endocytosis-mediated entry, and translocation through the formation of a transitory structure.
  • CPP transduction is an area of ongoing research.
  • Cell-penetrating peptides have found numerous applications in medicine as drug delivery agents in the treatment of different diseases including cancer and virus inhibitors, as well as contrast agents for cell labeling and imaging.
  • cell penetrating peptides are peptides of 8 to 50 residues that have the ability to cross the cell membrane and enter into most cell types. Alternatively, they are also called protein transduction domain (PTDs) reflecting their origin as occurring in natural proteins. Frankel and Pabo simultaneously to Green and Lowenstein described the ability of the trans-activating transcriptional activator from the human immunodeficiency virus 1 (HIV-TAT) to penetrate into cells (Frankel, A. D. and C.O. Pabo, Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988. 55(6): p. 1189-93).
  • HAV-TAT human immunodeficiency virus 1
  • the first 16-mer peptide CPP called Penetratin having the amino acid sequence RQIKIYFQNRRMKWKK (SEQ ID NO: 1) was characterized from the third helix of the homeodomain of Antennapedia (Derossi, D., et al., The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem, 1994. 269(14): p. 10444-50), followed in 1998 by the identification of the minimal domain of TAT, having the amino acid sequence YGRKKRRQRRR (SEQ ID NO: 2) required for protein transduction (Vives, E., P. Brodin, and B.
  • venoms e.g. melittin (Dempsey, C. E., The actions of melittin on membranes. Biochim Biophys Acta, 1990. 1031(2): p. 143-61), mastoporan (Konno, K., et al., Structure and biological activities of eumenine mastoparan-AF (EMP-AF), a new mast cell degranulating peptide in the venom of the solitary wasp (Anterhynchium flavomarginatum micado). Toxicon, 2000. 38(11): p.
  • maurocalcin Esteve, E., et al., Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane. J Biol Chem, 2005. 280(13): p. 12833-9
  • crotamine Nascimento, F. D., et al., Crotamine mediates gene delivery into cells through the binding to heparan sulfate proteoglycans. J Biol Chem, 2007. 282(29): p. 21349-60
  • buforin Kobayashi, S., et al., Membrane translocation mechanism of the antimicrobial peptide buforin 2. Biochemistry, 2004.
  • CPPs were also designed including the poly-arginine (R8, R9, R10 and R12) (Futaki, S., et al., Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. Biol Chem, 2001. 276(8): p. 5836-40) or transportan (Pooga, M., et al., Cell penetration by transportan. FASEB J, 1998. 12(1): p. 67-77). Any of the above described CPPs may be used as cell penetrating peptide, i.e. as component a), in the complex for use according to the present invention.
  • the component a), i.e. the CPP, in the complex for use according to the present invention may comprise the minimal domain of TAT, having the amino acid sequence YGRKKRRQRRR (SEQ ID NO: 2).
  • the component a), i.e. the CPP, in the complex for use according to the present invention may comprise Penetratin having the amino acid sequence RQIKIYFQNRRMKWKK (SEQ ID NO: 1).
  • CPPs which can be used as cell penetrating peptide, i.e. as component a), in the complex for use according to the present invention, are also disclosed in the review: Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 17 (15-16): 850-60, 2012. In other words, the CPPs disclosed in Milletti, F., 2012, Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 17 (15-16): 850-60 can be used as cell penetrating peptide, i.e. as component a), in the complex for use according to the present invention.
  • the cell penetrating peptide which is comprised by the complex for use according to the present invention
  • the cell penetrating peptide which is comprised by the complex for use according to the present invention,
  • ZEBRA also known as Zta, Z, EB1, or BZLF1 generally means the basic-leucine zipper (bZIP) transcriptional activator of the Epstein-Barr virus (EBV).
  • bZIP basic-leucine zipper
  • EBV Epstein-Barr virus
  • the amino acid sequence of ZEBRA is disclosed under NCBI accession number YP_401673 and comprises 245 amino acids represented in SEQ ID NO: 3:
  • such a CPP can deliver multi-epitopic peptides to dendritic cells (DCs), and subsequently to promote CTL and Th cell activation and anti-tumor function.
  • DCs dendritic cells
  • Such a CPP can thus efficiently deliver the complex for use according to the present invention to antigen presenting cells (APCs) and lead to multi-epitopic MHC class I and II restricted presentation.
  • APCs antigen presenting cells
  • MHC class I designates one of the two primary classes of the Major Histocompatibility Complex molecules.
  • the MHC class I (also noted “MHC I”) molecules are found on every nucleated cell of the body.
  • the function of MHC class I is to display an epitope to cytotoxic cells (CTLs).
  • CTLs cytotoxic cells
  • MHC class I molecules consist of two polypeptide chains, ⁇ - and ⁇ 2-microglobulin (b2m). Only the ⁇ chain is polymorphic and encoded by a HLA gene, while the b2m subunit is not polymorphic and encoded by the Beta-2 microglobulin gene.
  • MHC class II designates the other primary class of the Major Histocompatibility Complex molecules.
  • the MHC class II also noted “MHC II” molecules are found only on a few specialized cell types, including macrophages, dendritic cells and B cells, all of which are dedicated antigen-presenting cells (APCs).
  • APCs dedicated antigen-presenting cells
  • the sequence variant of a fragment of the minimal domain of ZEBRA as described above shares, in particular over the whole length, at least 70%, at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% amino acid sequence identity with the fragment of the minimal domain of ZEBRA as described above without abrogating the cell penetrating ability of the cell penetrating peptide.
  • a “fragment” of the minimal domain of ZEBRA as defined above is preferably to be understood as a truncated sequence thereof, i.e.
  • an amino acid sequence which is N-terminally, C-terminally and/or intrasequentially truncated compared to the amino acid sequence of the native sequence.
  • a “fragment” of the minimal domain of ZEBRA has preferably a length of 5 to 50 amino acids in total, preferably of 10 to 45 amino acids in total, more preferably of 15 to 45 amino acids in total.
  • sequence variant refers to any alteration in a reference sequence.
  • sequence variant includes nucleotide sequence variants and amino acid sequence variants.
  • a reference sequence is any of the sequences listed in the “Table of Sequences and SEQ ID Numbers” (Sequence listing), i.e. SEQ ID NO: 1 to SEQ ID NO: 94.
  • a sequence variant shares, in particular over the whole length of the sequence, at least 70%, at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity with a reference sequence, whereby sequence identity is calculated as described below.
  • a sequence variant preserves the specific function of the reference sequence. Sequence identity is calculated as described below.
  • an amino acid sequence variant has an altered sequence in which one or more of the amino acids in the reference sequence is deleted or substituted, or one or more amino acids are inserted into the sequence of the reference amino acid sequence.
  • the amino acid sequence variant has an amino acid sequence which is at least 70%, at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% identical to the reference sequence.
  • variant sequences which are at least 90% identical have no more than 10 alterations, i.e. any combination of deletions, insertions or substitutions, per 100 amino acids of the reference sequence.
  • an amino acid sequence “sharing a sequence identity” of at least, for example, 95% to a query amino acid sequence of the present invention is intended to mean that the sequence of the subject amino acid sequence is identical to the query sequence except that the subject amino acid sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
  • up to 5% (5 of 100) of the amino acid residues in the subject sequence may be inserted or substituted with another amino acid or deleted, preferably within the above definitions of variants or fragments.
  • nucleic acid sequences also applies similarly to nucleic acid sequences.
  • a “% identity” of a first sequence may be determined with respect to a second sequence.
  • these two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting “gaps” in either one or both sequences, to enhance the degree of alignment.
  • a % identity may then be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.
  • programs available in the Wisconsin Sequence Analysis Package, version 9.1 may be used to determine the % identity between two polynucleotides and the % identity and the % homology or identity between two polypeptide sequences.
  • BESTFIT uses the “local homology” algorithm of (Smith and Waterman (1981), J. Mol. Biol. 147, 195-197.) and finds the best single region of similarity between two sequences.
  • the fragments of the cell penetrating peptide according to the invention or the variants thereof as described above further retain said peptide's ability to present a cargo molecule such as antigens or antigenic epitopes at the surface of a cell, such as an antigen-presenting cell, in the context of MHC class I and/or MHC class II molecules.
  • a cargo molecule such as antigens or antigenic epitopes at the surface of a cell, such as an antigen-presenting cell, in the context of MHC class I and/or MHC class II molecules.
  • a cell penetrating peptide or complex comprising said cell penetrating peptide to present a cargo molecule such as antigens or antigenic epitopes at the surface of a cell in the context of MHC class I and/or MHC class II molecules can be checked by standard methods known to one skilled in the art, including capacity to stimulate proliferation and/or function of MHC-restricted CD4 + or CD8 + T cells with specificity for these epitopes.
  • substitutions for one or more amino acids present in the referenced amino acid sequence should be made conservatively.
  • conservative substitutions include substitution of one aliphatic residue for another, such as Ile, Val, Leu, or Ala for one another, or substitutions of one polar residue for another, such as between Lys and Arg; Glu and Asp; or Gln and Asn.
  • Other such conservative substitutions for example, substitutions of entire regions having similar hydrophobicity properties, are well known (Kyte and Doolittle, 1982 , J. Mot. Biol. 157(0:105-134.
  • Substitutions of one or more L-amino acids with one or more D-amino acids are to be considered as conservative substitutions in the context of the present invention.
  • Exemplary amino acid substitutions are presented in Table 1 below:
  • the preferred cell penetrating peptide which
  • such a preferred cell penetrating peptide has an amino acid sequence comprising a sequence according to the following general formula (I):
  • such a peptide, polypeptide or protein is either (entirely) composed of L-amino acids or (entirely) of D-amino acids, thereby forming “retro-inverso peptide sequences”.
  • the term “retro-inverso (peptide) sequences” refers to an isomer of a linear peptide sequence in which the direction of the sequence is reversed and the chirality of each amino acid residue is inverted (see e.g. Jameson et al., Nature, 368, 744-746 (1994); Brady et at, Nature, 368, 692-693 (1994)).
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 1 is K.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 2 is R.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 3 is Y.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 4 is K.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 5 is N.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 6 is R.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 7 is V.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 8 is A.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 9 is S.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 10 is R.
  • the cell penetrating !peptide according to the invention is as generically defined above by general formula (I), wherein X 11 is K.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 13 is R.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 14 is A.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 15 is K.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 16 is F.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein X 17 is K.
  • the cell penetrating peptide according to the invention is as generically defined above by general formula (I), wherein the amino acid at position equivalent to position 12 relative to general formula (I) is a Ser (S).
  • a cell penetrating peptide which has an amino acid sequence comprising or consisting of an amino acid sequence according to SEQ ID NO: 6 (CPP3/Z13), SEQ ID NO: 7 (CPP4/Z14), SEQ ID NO: 8 (CPP5/Z15), or SEQ ID NO: 11 (CPP8/Z18), or sequence variants thereof without abrogating said peptide's cell penetrating ability, preferably sequence variants having 0, 1, 2, 3, 4, or 5 amino acids substituted, deleted and/or added without abrogating said peptide's cell penetrating ability.
  • a cell penetrating peptide is more preferred, which has an amino acid sequence comprising or consisting of an amino acid sequence according to SEQ ID NO: 6 (CPP3/Z13) or SEQ ID NO: 7 (CPP4/Z14) or sequence variants thereof without abrogating said peptide's cell penetrating ability, preferably sequence variants having 0, 1, 2, 3, 4, or 5 amino acids substituted, deleted and/or added without abrogating said peptide's cell penetrating ability.
  • a cell penetrating peptide which has an amino acid sequence comprising or consisting of an amino acid sequence according to SEQ ID NO: 6 (CPP3/Z13) or sequence variants thereof without abrogating said peptide's cell penetrating ability, preferably sequence variants having 0, 1, 2, 3, 4, or 5 amino acids substituted, deleted and/or added without abrogating said peptide's cell penetrating ability.
  • the cell penetrating peptide comprises or consists of a peptide having an amino acid sequence according to SEQ ID NO: 6 (CPP3/Z13) or a functional sequence variant thereof having at least 70% sequence identity, preferably at least 75% sequence identity, more preferably at least 80% sequence identity, even more preferably at least 85% sequence identity, still more preferably at least 90% sequence identity, particularly preferably at least 95% sequence identity, most preferably at least 99% sequence identity.
  • a “functional sequence variant” is a sequence variant wherein said peptide's cell penetrating ability is maintained.
  • the cell penetrating peptide according to the invention has an amino acid sequence comprising or consisting of SEQ ID NO: 6 (CPP3/Z13).
  • the cell penetrating peptide according to the invention has an amino acid sequence comprising or consisting of SEQ ID NO: 7 (CPP4/Z14).
  • the cell penetrating peptide according to the invention has an amino acid sequence comprising or consisting of SEQ ID NO: 8 (CPP5/Z15).
  • the cell penetrating peptide according to the invention has an amino acid sequence comprising or consisting of SEQ ID NO: 11 (CPP8/Z18).
  • the primary amino acid sequence of the cell penetrating peptide of the invention may further be post-translationally modified, such as by glycosylation or phosphorylation, without departing from the invention.
  • the cell penetrating peptide according to the invention optionally further comprises, in addition to its amino acid sequence as described above, any one of, or any combination of:
  • the cell penetrating peptide according to the invention is linked to an antigen or antigenic epitope and facilitates the cellular internalization of said antigen or antigenic epitope.
  • the complex for use according to the present invention may comprise one single cell penetrating peptide or more than one cell penetrating peptides.
  • the complex for use according to the present invention comprises no more than five cell penetrating peptides, more preferably the complex for use according to the present invention comprises no more than four cell penetrating peptides, even more preferably the complex for use according to the present invention comprises no more than three cell penetrating peptides, particularly preferably the complex for use according to the present invention comprises no more than two cell penetrating peptides and most preferably the complex for use according to the present invention comprises one single cell penetrating peptide.
  • the complex for use according to the present invention comprises as component b) at least one antigen or antigenic epitope.
  • an “antigen” is any structural substance which serves as a target for the receptors of an adaptive immune response, in particular as a target for antibodies, T cell receptors, and/or B cell receptors.
  • An “epitope”, also known as “antigenic determinant”, is the part (or fragment) of an antigen that is recognized by the immune system, in particular by antibodies, T cell receptors, and/or B cell receptors.
  • one antigen has at least one epitope, i.e. a single antigen has one or more epitopes.
  • epitope is mainly used to designate T cell epitopes, which are presented on the surface of an antigen-presenting cell, where they are bound to Major Histocompatibility Complex (MHC).
  • MHC Major Histocompatibility Complex
  • T cell epitopes presented by MHC class I molecules are typically, but not exclusively, peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, generally, but not exclusively, between 12 and 25 amino acids in length.
  • the at least one antigen or antigenic epitope is selected from the group consisting of: (i) a peptide, a polypeptide, or a protein, (ii) a polysaccharide, (iii) a lipid, (iv) a lipoprotein or a lipopeptide, (v) a glycolipid, (vi) a nucleic acid, and (vii) a small molecule drug or a toxin.
  • the at least one antigen or antigenic epitope may be a peptide, a protein, a polysaccharide, a lipid, a combination thereof including lipoproteins and glycolipids, a nucleic acid (e.g. DNA, siRNA, shRNA, antisense oligonucleotides, decoy DNA, plasmid), or a small molecule drug (e.g. cyclosporine A, paclitaxel, doxorubicin, methotrexate, 5-aminolevulinic acid), or any combination thereof in particular if more than one antigen or antigenic epitope is comprised by the inventive complex.
  • a nucleic acid e.g. DNA, siRNA, shRNA, antisense oligonucleotides, decoy DNA, plasmid
  • a small molecule drug e.g. cyclosporine A, paclitaxel, doxorubicin, methotrexate, 5-aminolevul
  • the at least one antigen or antigenic epitope can comprise for example at least one, i.e. one or more, peptides, polypeptides or proteins linked together and/or at least one, i.e. one or more, nucleic acids, e.g. where each one encodes one peptide or polypeptide.
  • the at least one antigen or antigenic epitope can be a combination of a protein, a lipid, and/or a polysaccharide including lipoproteins and glycolipids.
  • the complex for use according to the present invention comprises more than one antigen or antigenic epitope
  • it can comprise more than one peptide, polypeptide, or protein, more than one polysaccharide, more than one lipid, more than one lipoprotein, more than one glycolipid, more than one nucleic acid, more than one small molecule drug or toxin, or a combination thereof.
  • the complex for use according to the invention comprises at least one antigen or antigenic epitope comprising one or more epitope(s) from a cancer/tumor-associated antigen, a cancer/tumor-specific antigen, and/or an antigenic protein from a pathogen, including viral, bacterial, fungal, protozoal and multicellular parasitic antigenic protein.
  • a cancer/tumor-associated antigen e.g., a cancer/tumor-specific antigen
  • an antigenic protein from a pathogen including viral, bacterial, fungal, protozoal and multicellular parasitic antigenic protein.
  • the at least one antigen or antigenic epitope comprises or consists of (i) at least one pathogen epitope and/or (ii) at least one cancer/tumor epitope, in particular at least one tumor epitope.
  • the at least one antigen or antigenic epitope comprises or consists of at least one cancer/tumor epitope, in particular at least one tumor epitope.
  • the complex for use according to the present invention comprises only such antigen(s) or antigenic epitope(s), which are cancer/tumor-associated antigen(s), cancer/tumor-specific antigen(s) and/or cancer/tumor epitope(s); in particular, which are tumor-associated antigen(s), tumor-specific antigen(s), and/or tumor epitope(s).
  • cancer epitope means an epitope from a cancer-associated antigen or from a cancer-specific antigen.
  • tumor epitope means an epitope from a tumor-associated antigen or from a tumor-specific antigen.
  • Such epitopes are typically specific (or associated) for a certain kind of cancer/tumor.
  • cancer/tumor-associated (also cancer/tumor-related) antigens are antigens, which are expressed by both, cancer/tumor cells and normal cells. Accordingly, those antigens are normally present since birth (or even before). Accordingly, there is a chance that the immune system developed self-tolerance to those antigens.
  • Cancer/tumor-specific antigens are antigens, which are expressed specifically by cancer/tumor cells, but not by normal cells. Cancer/tumor-specific antigens include in particular neoantigens. In general neoantigens are antigens, which were not present before and are, thus, “new” to the immune system. Neoantigens are typically due to somatic mutations. In the context of cancer/tumors, cancer/tumor-specific neoantigens were typically not present before the cancer/tumor developed and cancer/tumor-specific neoantigens are usually encoded by somatic gene mutations in the cancerous cells/tumor cells.
  • cancer/tumor-specific antigens in particular neoantigens, are identified in a subject diagnosed with colorectal cancer by methods known to the skilled person, e.g., cancer genome sequencing. After identification, the respective cancer/tumor-specific neoantigens and/or cancer/tumor-specific neoantigenic epitopes are used in a complex for use according to the present invention.
  • a complex for use according to the present invention comprises one or more cancer/tumor-associated epitopes and/or one or more cancer/tumor-associated antigens (but preferably no cancer/tumor-specific epitopes). It is also preferred that a complex for use according to the present invention comprises one or more cancer/tumor-specific epitopes and/or one or more cancer/tumor-specific antigens (but preferably no cancer/tumor-associated epitopes).
  • a complex for use according to the present invention may also preferably comprise both, (i) one or more cancer/tumor-associated epitopes and/or one or more cancer/tumor-associated antigens and (ii) one or more cancer/tumor-specific epitopes and/or one or more cancer/tumor-specific antigens.
  • the cancer/tumor with which the antigens or antigenic epitopes are associated or for which the antigens or antigenic epitopes are specific is colorectal cancer as described herein.
  • the antigens are preferably CRC-associated or CRC-specific antigens and the epitopes are preferably CRC-associated or CRC-specific epitopes.
  • Suitable cancer/tumor epitopes can be retrieved for example from cancer/tumor epitope databases, e.g. from van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B.
  • Peptide database T cell-defined tumor antigens. Cancer Immun 2013; URL: http://www.cancerimmunity.org/peptide/, wherein human tumor antigens recognized by CD4+ or CD8+ T cells are classified into four major groups on the basis of their expression pattern, or from the database “Tantigen” (TANTIGEN version 1.0, Dec.
  • cancer/tumor epitopes include e.g. TRP2-derived epitopes, glycoprotein 100 (gp100) melanoma antigen-derived epitopes, glycoprotein 70 (gp70) antigen-derived epitopes, survivin epitopes, IEa epitopes, IL13r ⁇ 2, Epha2 (ephrin type-A receptor 2), immunogenic fragments thereof, and fusions of such antigens and/or fragments.
  • cancer/tumor epitopes include epitopes of neoantigens, such as, for example, a neoantigen from MC-38 tumor cell line as described by Yadav et al. Nature. 2014 Nov. 27; 515(7528):572-6.
  • neoantigens are antigens, which are entirely absent from the normal human genome.
  • neoantigens are of relevance to tumor control, as the quality of the T cell pool that is available for these antigens is not affected by central T cell tolerance.
  • neoantigens may be based on individual tumor genomes. Potential neoantigens may be predicted by methods known to the skilled person, such as cancer genome sequencing or deep-sequencing technologies identifying mutations within the protein-coding part of the (cancer) genome.
  • cancer/tumor-associated, in particular tumor-related, or tissue-specific antigens useful in a complex for use according to the present invention include, but are not limited to, the following antigens: Her-2/neu, SPAS-1, TRP-2, tyrosinase, Melan A/Mart-1, gplOO, BAGE, GAGE, GM2 ganglioside, kinesin 2, TATA element modulatory factor 1, tumor protein D52, MAGE D, ING2, HIP-55, TGF-1 anti-apoptotic factor, HOM-Mel-40/SSX2, epithelial antigen (LEA 135), DF31MUC1 antigen (Apostolopoulos et al., 1996 Immunol. Cell.
  • EGP40 epithelial glycoprotein 40
  • SCC squamous cell carcinoma antigen
  • cathepsin E Mota et al., 1997, Am. J Pathol. 150: 1223-1229
  • tyrosinase in melanoma Fishman et al., 1997 Cancer 79: 1461-1464
  • PCNA cell nuclear antigen
  • Vaccines (2002)1:49-63 CT9, CT10, Cyp-B, Dek-cain, DAM-6 (MAGE-B2), DAM-10 (MAGE-B1), EphA2 (Zantek et al., Cell Growth Differ. (1999) 10:629-38; Carles-Kinch et al., Cancer Res. (2002) 62:2840-7), EphA4 (Cheng at al., 2002, Cytokine Growth Factor Rev. 13:75-85), tumor associated Thomsen-Friedenreich antigen (Dahlenborg et al., 1997, Int.
  • cancer/tumor-associated, in particular tumor-related, or tissue-specific antigen useful in a complex for use according to the present invention is the antigen ASCL2 (Achaete-scute homolog 2).
  • ASCL2 Achaete-scute homolog 2
  • Numerous other cancer antigens are well known in the art.
  • the cancer/tumor antigen or the cancer/tumor epitope is a recombinant cancer/tumor antigen or a recombinant cancer/tumor epitope.
  • a recombinant cancer/tumor antigen or a recombinant cancer/tumor epitope may be designed by introducing mutations that change (add, delete or substitute) particular amino acids in the overall amino acid sequence of the native cancer/tumor antigen or the native cancer/tumor epitope.
  • the introduction of mutations does not alter the cancer/tumor antigen or the cancer/tumor epitope so much that it cannot be universally applied across a mammalian subject, and preferably a human or dog subject, but changes it enough that the resulting amino acid sequence breaks tolerance or is considered a foreign antigen in order to generate an immune response.
  • Another manner may be creating a consensus recombinant cancer/tumor antigen or cancer/tumor epitope that has at least 85% and up to 99% amino acid sequence identity to its' corresponding native cancer/tumor antigen or native cancer/tumor epitope; preferably at least 90% and up to 98% sequence identity; more preferably at least 93% and up to 98% sequence identity; or even more preferably at least 95% and up to 98% sequence identity.
  • the recombinant cancer/tumor antigen or the recombinant cancer/tumor epitope has 95%, 96%, 97%, 98%, or 99% amino acid sequence identity to its' corresponding native cancer/tumor antigen or cancer/tumor epitope.
  • the native cancer/tumor antigen is the antigen normally associated with the particular cancer or cancer tumor.
  • the consensus sequence of the cancer/tumor antigen can be across mammalian species or within subtypes of a species or across viral strains or serotypes. Some cancer/tumor antigen do not vary greatly from the wild type amino acid sequence of the cancer/tumor antigen.
  • the aforementioned approaches can be combined so that the final recombinant cancer/tumor antigen or cancer/tumor epitope has a percent similarity to native cancer antigen amino acid sequence as discussed above.
  • the amino acid sequence of an epitope of a cancer/tumor antigen as described herein is not mutated and, thus, identical to the reference epitope sequence.
  • pathogen epitope means an epitope from an antigenic protein, an antigenic polysaccharide, an antigenic lipid, an antigenic lipoprotein or an antigenic glycolipid from a pathogen including viruses, bacteria, fungi, protozoa and multicellular parasites.
  • Antigenic proteins, polysaccharides, lipids, lipoproteins or glycolipids from pathogens include, herewith, proteins, polysaccharides, lipids, lipoproteins and glycolipids, respectively, from pathogens responsible of diseases which can be a target for vaccination including, for instance, Amoebiasis, Anthrax, Buruli Ulcer ( Mycobacterium ulcerans ), Caliciviruses associated diarrhoea, Campylobacter diarrhoea, Cervical Cancer (Human papillomavirus), Chlamydia trachomatis associated genital diseases, Cholera, Crimean-Congo haemorrhagic fever, Dengue Fever, Diptheria, Ebola haemorrhagic fever, Enterotoxigenic Escherichia coli (ETEC) diarrhoea, Gastric Cancer ( Helicobacter pylori ), Gonorrhea, Group A Streptococcus associated diseases, Group
  • the at least one antigen or antigenic epitope will be presented at the cell surface in an MHC class I and/or MHC class II context and/or in a CD1 context, whereby presentation at the cell surface in an MHC class I and/or MHC class II context is preferred.
  • the phrase “epitope presentation in the MHC class I context” refers in particular to a CD8 + epitope lying in the groove of a MHC class I molecule at the surface of a cell.
  • the phrase “epitope presentation in the MHC class II context” refers in particular to a CD4 + epitope lying in the groove of a MHC class II molecule at the surface of a cell.
  • the phrase “epitope presentation in the CD1 context” refers in particular to a lipidic epitope lying in the groove of a cluster of differentiation 1 molecule at the surface of a cell.
  • the complex for use according to the invention comprises a cell penetrating peptide and at least one antigen or antigenic epitope, and allows the transport and presentation of said epitopes at the cell surface of antigen presenting cells in an MHC class I and MHC class II context, and is, thus, useful in vaccination and immunotherapy.
  • the complex for use according to the present invention comprises at least one antigen or antigenic epitope, which is at least one CD4 + epitope and/or at least one CD8 + epitope.
  • CD4 + epitope or “CD4 + -restricted epitope”, as used herein, designate an epitope recognized by a CD4 + T cell, said epitope in particular consisting of an antigen fragment lying in the groove of a MHC class II molecule.
  • a single CD4 + epitope comprised in the complex for use according to the present invention preferably consists of about 12-25 amino acids. It can also consist of, for example, about 8-25 amino acids or about 6-100 amino acids.
  • CD8 + epitope or “CD8 + -restricted epitope”, as used herein, designate an epitope recognized by a CD8 + T cell, said epitope in particular consisting of an antigen fragment lying in the groove of a MHC class I molecule.
  • a single CD8 + epitope comprised in the complex for use according to the present invention preferably consists of about 8-11 amino acids. It can also consist of, for example, about 8-15 amino acids or about 6-100 amino acids.
  • the at least one antigen can comprise or the at least one antigenic epitope can consist of a CD4 + epitope and/or a CD8 + epitope corresponding to antigenic determinant(s) of a cancer/tumor-associated antigen, a cancer/tumor-specific antigen, or an antigenic protein from a pathogen. More preferably, the at least one antigen can comprise or the at least one antigenic epitope can consist of a CD4 + epitope and/or a CD8 + epitope corresponding to antigenic determinant(s) of a cancer/tumor-associated antigen or a cancer/tumor-specific antigen.
  • the at least one antigen can comprise or the at least one antigenic epitope can consist of a CD4 + epitope and/or a CD8 + epitope corresponding to antigenic determinant(s) of a tumor-associated antigen or a tumor-specific antigen.
  • the complex for use according to the present invention comprises at least two antigens or antigenic epitopes, wherein at least one antigen or antigenic epitope comprises or consists a CD4 + epitope and at least one antigen or antigenic epitope comprises or consists a CD8 + epitope.
  • a complex for use according to the present invention comprising at least two antigens or antigenic epitopes, wherein at least one antigen or antigenic epitope comprises or consists of a CD4 + epitope and at least one antigen or antigenic epitope comprises or consists a CD8 + epitope, provides an integrated immune response allowing simultaneous priming of CTLs and T h cells and is thus preferable to immunity against only one CD8 + epitope or only one CD4 + epitope.
  • the complex for use according to the present invention may preferably comprise an Ealpha-CD4 + epitope and a gp100-CD8 + epitope.
  • the complex for use according to the present invention comprises at least two antigens or antigenic epitopes, wherein the at least two antigens or antigenic epitopes comprise or consist of at least two, e.g. 2, 3, 4, 5, 6, 7, 8, 9, or more, CD4 + epitopes and/or at least two, e.g. 2, 3, 4, 5, 6, 7, 8, 9, or more, CD8 + epitopes.
  • the at least two antigens or antigenic epitopes are preferably different antigens or antigenic epitopes, more preferably the at least two antigens or antigenic epitopes are different from each other but relating to the same kind of tumor.
  • a multi-antigenic vaccine will (i) avoid outgrowth of antigen-loss variants, (ii) target different tumor cells within a heterogeneous tumor mass and (iii) circumvent patient-to-patient tumor variability.
  • the complex for use according to the present invention particularly preferably comprises at least four antigens or antigenic epitopes, in particular with at least two CD8 + epitopes and at least two CD4 + epitopes.
  • Such a complex for use according to the present invention induces multi-epitopic CD8 CTLs and CD4 T h cells to function synergistically to counter tumor cells and promote efficient anti-tumor immunity. T h cells are also involved in the maintenance of long-lasting cellular immunity that was monitored after vaccination.
  • Such a complex for use according to the present invention induces polyclonal, multi-epitopic immune responses and poly-functional CD8 + and CD4 + T cells, and thus efficacious anti-tumor activity.
  • the complex for use according to the present invention comprises at least two antigens or antigenic epitopes, more preferably the complex for use according to the present invention comprises at least three antigens or antigenic epitopes, even more preferably the complex for use according to the present invention comprises at least four antigens or antigenic epitopes, particularly preferably the complex for use according to the present invention comprises at least five antigens or antigenic epitopes and most preferably the complex for use according to the present invention comprises at least six antigens or antigenic epitopes.
  • the antigens or antigenic epitopes comprised by the complex for use according to the present invention may be the same or different, preferably the antigens or antigenic epitopes comprised by the complex for use according to the present invention are different from each other.
  • the complex for use according to the present invention comprises at least one CD4 + epitope and at least one CD8 + epitope.
  • the complex for use according to the present invention comprises more than one CD4 + epitope, e.g. two or more CD4 + epitopes from the same antigen or from different antigens, and preferably no CD8 + epitope. It is also preferred that the complex for use according to the present invention comprises more than one CD8 + epitope, e.g. two or more CD8 + epitopes from the same antigen or from different antigens, and preferably no CD4 + epitope. Most preferably, however, the complex for use according to the present invention comprises (i) at least one CD4 + epitope, e.g.
  • CD4 + epitopes from the same antigen or from different antigens
  • CD8 + epitope e.g. two or more CD8 + epitopes from the same antigen or from different antigens.
  • the complex for use according to the present invention may preferably comprise a gp100-CD8 + epitope, an Ealpha-CD4 + epitope, and a further CD4 + epitope and a further CD8 + epitope.
  • the complex for use according to the present invention may comprise a polypeptide or protein comprising a gp100-CD8 + epitope and an Ealpha-CD4 + epitope.
  • such a polypeptide or protein comprised by the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 14 or sequence variants thereof as defined above:
  • the complex for use according to the present invention may also comprise a gp70-CD8 + epitope and/or a gp70-CD4 + epitope.
  • the complex for use according to the present invention may comprise a polypeptide or protein comprising a gp70-CD8 + epitope and/or a gp70-CD4 + epitope.
  • such a polypeptide or protein comprised by the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 43 or sequence variants thereof as defined above:
  • the complex for use according to the present invention may preferably comprise at least one survivin epitope, such as a survivin CD8 + epitope and/or a survivin CD4 + epitope. More preferably, the complex for use according to the present invention may comprise a polypeptide or protein comprising a survivin CD8 + epitope and/or a survivin CD4 + epitope. More preferably, the complex for use according to the present invention may comprise a polypeptide or protein comprising more than one survivin CD8 + epitope and/or more than one survivin CD4 + epitope, such as two different survivin CD8 + epitopes. For example, such a polypeptide or protein comprised by the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 44 or sequence variants thereof as defined above:
  • the complex for use according to the present invention may preferably comprise an epitope from a neoantigen.
  • the complex for use according to the present invention may comprise a polypeptide or protein comprising an epitope from a neoantigen, such as the neoantigen from MC-38 tumor cell line identified by Yadav et al. Nature. 2014 Nov. 27; 515(7528):572-6.
  • a polypeptide or protein comprised by the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 42 or sequence variants thereof as defined above:
  • the complex for use according to the present invention may preferably comprise more than one, e.g. two or three, epitopes from neoantigens.
  • the complex for use according to the present invention may comprise a polypeptide or protein comprising more than one, e.g. two or three, epitopes from neoantigens, such as the neoantigens from MC-38 tumor cell line identified by Yadav et al. Nature. 2014 Nov. 27; 515(7528):572-6.
  • a polypeptide or protein comprised by the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 63 or sequence variants thereof as defined above:
  • the at least one antigen or antigenic epitope comprised by the complex for use according to the present invention is a peptide, polypeptide, or a protein.
  • antigen or antigenic epitope of peptidic, polypeptidic, or proteic nature useful in the invention include cancer/tumor antigens or antigenic epitopes thereof, allergy antigens or antigenic epitopes thereof, auto-immune self-antigens or antigenic epitopes thereof, pathogenic antigens or antigenic epitopes thereof, and antigens or antigenic epitopes thereof from viruses, preferably from cytomegalovirus (CMV), orthopox variola virus, orthopox alastrim virus, parapox ovis virus, molluscum contagiosum virus, herpes simplex virus 1, herpes simplex virus 2, herpes B virus, varicella zoster virus, pseudorabies virus, human cytomegaly virus, human herpes virus 6, human herpes virus 7,
  • CMV
  • human immunodeficiency virus type 1 or human immunodeficiency virus type 2 influenza virus, Lassa virus, lymphocytic choriomeningitis virus, Tacaribe virus, Junin virus, Machupo virus, Borna disease virus, Bunyamwera virus, California encephalitis virus, Rift Valley fever virus, sand fly fever virus, Toscana virus, Crimean-Congo haemorrhagic fever virus, Hazara virus, Khasan virus, Hantaan virus, Seoul virus, Prospect Hill virus, Puumala virus, Dobrava Belgrade virus, Tula virus, sinari virus, Lake Victoria Marburg virus, Zaire Ebola virus, Sudan Ebola virus, Ivory Coast Ebola virus, influenza virus A, influenza virus B, influenza viruses C, parainfluenza virus, malaria parasite ( Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, Plasmodium knowlesi ), Marburg virus, meas
  • epitopes as well as variants of antigens as defined above exhibit a sequence homology or identity of about 10%, in particular at least 10%, about 20%, in particular at least 20%, about 30%, in particular at least 30%, about 40%, in particular at least 40%, about 50%, in particular at least 50%, about 60%, in particular at least 60%, about 70%, in particular at least 70%, about 80%, in particular at least 80%, about 90% in particular at least 90%, at least 95% or at least 98% with one of the antigens or antigen sequences as shown or described above.
  • epitopes and variants similarly applies as defined.
  • antigens or antigenic epitopes in the category of peptide, polypeptide or protein include a combination of multiple glioma epitopes such as those described in Novellino et al. (2005, Cancer Immunol Immunother, 54(3):187-207), Vigneron et al. (2013 , Cancer Immun. 13:15).
  • a single complex for use according to the present invention may also comprise only a subset, i.e. one or more of all of said glioma epitopes.
  • different complexes according to the present invention comprise different subsets of all of said glioma epitopes, so that for example a vaccine according to the present invention comprising such different complexes according to the present invention comprises all of said glioma epitopes but distributed in the different complexes.
  • a complex for use according to the invention may also comprise at least one antigen or antigenic epitope, wherein said antigen or antigenic epitope is a polysaccharide, a lipid, a lipoprotein, and/or a glycolipid, in particular a polysaccharidic, lipidic, lipoproteic, and/or glycolipidic epitope, which can be, for example, pathogen epitopes as defined herewith.
  • said antigen or antigenic epitope is a polysaccharide, a lipid, a lipoprotein, and/or a glycolipid, in particular a polysaccharidic, lipidic, lipoproteic, and/or glycolipidic epitope, which can be, for example, pathogen epitopes as defined herewith.
  • the complex for use according to the invention may comprise at least one antigen or antigenic epitope, wherein said antigen or antigenic epitope is polysaccharidic, lipidic, lipoproteic, and/or glycolipidic, including viral, bacterial, fungal, protozoal and multicellular parasitic antigens or antigenic epitopes.
  • said epitopes will be presented at the cell surface in an MHC class I and/or MHC class II context.
  • said lipidic epitopes will be presented at the cell surface in a CD1 (cluster of differentiation 1) context.
  • the complex for use according to the present invention may also comprise at least one antigen or antigenic epitope, wherein said antigen or antigenic epitope is a small molecule drug or toxin.
  • cargo molecules within the category of small molecule drugs or toxins useful in the invention include cyclosporine A, paclitaxel, doxorubicin, methotrexate, 5-aminolevulinic acid, diphtheria toxin, sunitinib and those molecules reviewed in De wit Amer (2010, Neuro Oncol, 12(3):304-16).
  • the complex for use according to the present invention comprises at least one antigen or antigenic epitope, preferably the complex for use according to the present invention comprises more than one antigen or antigenic epitope, in particular 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens or antigenic epitopes, more preferably the complex for use according to the present invention comprises (at least) two or three antigens or antigenic epitopes, even more preferably the complex for use according to the present invention comprises (at least) four or five antigens or antigenic epitopes.
  • antigen or antigenic epitope is comprised by the complex for use according to the present invention it is understood that said antigen or antigenic epitope is in particular also covalently linked in the complex for use according to the present invention, e.g. to another antigen or antigenic epitope and/or to a component a), i.e. a cell penetrating peptide, and/or to a component c), i.e. a TLR peptide agonist.
  • the various antigens or antigenic epitopes comprised by the complex for use according to the present invention may be the same or different.
  • the various antigens or antigenic epitopes comprised by the complex for use according to the present invention are different from each other, thus providing a multi-antigenic and/or multi-epitopic complex.
  • the more than one antigen or antigenic epitope in particular 2, 3, 4, 5, 6, 7, 8, 9, 10 or more antigens or antigenic epitopes, are positioned consecutively in the complex for use according to the present invention.
  • all antigens and/or antigenic epitopes comprised by the complex are positioned in a stretch, which is neither interrupted by component a), i.e. a cell penetrating peptide, nor by component c), i.e. a TLR peptide agonist.
  • component a) and component c) are positioned in the complex for example before or after such a stretch of all antigens and/or antigenic epitopes.
  • the antigens and/or antigenic epitopes positioned consecutively in such a way may be linked to each other for example by a spacer or linker as described below, which is neither component a), i.e. a cell penetrating peptide, nor component c), i.e. a TLR peptide agonist.
  • the complex for use according to the present invention comprises one or more epitopes of an antigen.
  • the complex preferably comprises one or more epitopes of one or more antigens.
  • the complex may comprise one or more epitopes of a first antigen and one or more epitopes of a second antigen; or the complex may comprise one or more epitopes of a first antigen, one or more epitopes of a second antigen, and one or more epitopes of a third antigen; or the complex may comprise one or more epitopes of a first antigen, one or more epitopes of a second antigen, one or more epitopes of a third antigen, and one or more epitopes of a fourth antigen; and so on.
  • the complex comprises more than one epitope of one or more antigens; more preferably the antigenic epitopes of the same antigen are positioned consecutively (or overlapping) in the complex for use according to the present invention.
  • all antigenic epitopes of the same antigen comprised by the complex are positioned in a stretch, which is neither interrupted by component a), i.e. a cell penetrating peptide, nor by component c), i.e. a TLR peptide agonist, nor by any other antigenic epitopes (i.e. epitopes from another antigen).
  • the various antigens and/or antigenic epitopes may also be positioned in any other way in the complex for use according to the present invention, for example with component a) and/or component c) positioned in between two or more antigens and/or antigenic epitopes, i.e. with one or more antigens and/or antigenic epitopes positioned between component a) and component c) (or vice versa) and, optionally, one or more antigens and/or antigenic epitopes positioned at the respective other end of component a) and/or component c).
  • a number of different antigens or antigenic epitopes relating to colorectal cancer may be advantageously comprised by a single complex for use according to the present invention.
  • a number of different antigens or antigenic epitopes relating to colorectal cancer may be distributed to subsets of different antigens or antigenic epitopes, in particular subsets complementing each other in the context of colorectal cancer which are comprised by different complexes according to the present invention, whereby such different complexes comprising different subsets may advantageously be administered simultaneously, e.g. in a single vaccine, to a subject in need thereof.
  • the complex for use according to the present invention comprises at least one tumor epitope, which is an epitope of an antigen selected from the group consisting of EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2.
  • an antigen selected from the group consisting of EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2.
  • the complex for use according to the present invention comprises at least one tumor epitope, which is an epitope of an antigen selected from the group consisting of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2.
  • an antigen selected from the group consisting of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2.
  • an antigen selected from the group consisting of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CE
  • the complex for use according to the present invention comprises at least one tumor antigen selected from the group consisting of EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2, or a fragment thereof, or a sequence variant of a tumor antigen or a sequence variant of a fragment thereof.
  • the tumor antigen selected from the group consisting of EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2, or a fragment thereof, or a sequence variant of a tumor antigen or a sequence variant of a fragment thereof.
  • the complex for use according to the present invention comprises at least one tumor antigen selected from the group consisting of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2, or a fragment thereof, or a sequence variant of a tumor antigen or a sequence variant of a fragment thereof.
  • tumor antigen selected from the group consisting of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART and IL13Ralpha2, or a fragment thereof, or a sequence variant of a tumor antigen or a sequence variant of a fragment thereof.
  • a “fragment” of an antigen comprises at least 10 consecutive amino acids of the antigen, preferably at least 15 consecutive amino acids of the antigen, more preferably at least 20 consecutive amino acids of the antigen, even more preferably at least 25 consecutive amino acids of the antigen and most preferably at least 30 consecutive amino acids of the antigen.
  • a “sequence variant” is as defined above, namely a sequence variant has an (amino acid) sequence which is at least 70%, preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% identical to the reference sequence.
  • a “functional” sequence variant means in the context of an antigen/antigen fragment/epitope, that the function of the epitope(s), e.g. comprised by the antigen (fragment), is not impaired or abolished.
  • the amino acid sequence of the epitope(s), e.g. comprised by the cancer/tumor antigen (fragment) as described herein is not mutated and, thus, identical to the reference epitope sequence.
  • cancer/tumor epitopes of those antigens are known from the literature or can be identified by using cancer/tumor epitope databases, e.g. from van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B.
  • Peptide database T cell-defined tumor antigens. Cancer Immun 2013; URL: http://www.cancerimmunity.org/peptide/, wherein human tumor antigens recognized by CD4 + or CD8 + T cells are classified into four major groups on the basis of their expression pattern, or from the database “Tantigen” (TANTIGEN version 1.0, Dec. 1, 2009; developed by Bioinformatics Core at Cancer Vaccine Center, Dana-Farber Cancer Institute; URL: http://cvc.dfci.harvard.edu/tadb/).
  • Ep-Cam is a glycoprotein mediating cellular adhesion.
  • the amino acid sequence of EpCAM is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 47 or a fragment or a variant thereof as described herein.
  • a preferred EpCAM epitope which is preferably comprised by the complex for use according to the present invention, includes the following epitope (the epitope sequence shown in the following is a fragment of the above EpCAM sequence and is, thus, shown in the above EpCAM sequence underlined; the following epitope sequence may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 48 or a fragment or a variant thereof as described herein.
  • Her-2 belongs to the EGFR (epidermal growth factor receptor) family. Many HLA-A epitopes are known to the skilled person.
  • the amino acid sequence of HER2 is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 70 or a fragment or a variant thereof as described herein.
  • suitable cancer/tumor epitopes of Her-2 are known from the literature or can be identified by using cancer/tumor epitope databases, e.g. from van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B.
  • Peptide database T cell-defined tumor antigens.
  • Cancer Immun 2013 http://www.cancerimmunity.org/peptide/, wherein human tumor antigens recognized by CD4+ or CD8+ T cells are classified into four major groups on the basis of their expression pattern, or from the database “Tantigen” (TANTIGEN version 1.0, Dec. 1, 2009; developed by Bioinformatics Core at Cancer Vaccine Center, Dana-Farber Cancer Institute; URL: http://cvc.dfci.harvard.edu/tadb/).
  • MUC-1 is a human epithelial mucin, acting on cell adhesion.
  • the amino acid sequence of MUC-1 is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 49 or a fragment or a variant thereof as described herein.
  • MUC-1 epitopes which are preferably comprised by the complex for use according to the present invention, include the following epitopes (the epitope sequences shown in the following are fragments of the above MUC-1 sequence and are, thus, shown in the above MUC-1 sequence underlined; each of the following epitope sequences may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 50 and/or an amino acid sequence according to SEQ ID NO: 51.
  • TOMM34 is involved in the import of precursor proteins into mitochondria. Many epitopes thereof are known to the skilled person.
  • RNF43 is a RING-type E3 ubiquitin ligase and is predicted to contain a transmembrane domain, a protease-associated domain, an ectodomain, and a cytoplasmic RING domain. RNF43 is thought to negatively regulate Wnt signaling, and expression of RNF43 results in an increase in ubiquitination of frizzled receptors, an alteration in their subcellular distribution, resulting in reduced surface levels of these receptors. Many epitopes thereof are known to the skilled person.
  • KOC1 also known as insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is an mRNA binding protein. No expression data are however available.
  • VEGF Vascular Endothelial Growth Factor
  • VAGFR Vascular Endothelial Growth Factor Receptor
  • VEGF Vascular endothelial growth factor
  • VGF vascular permeability factor
  • Human chorionic gonadotropin is a hormone produced by the embryo following implantation. Some cancerous tumors produce this hormone; therefore, elevated levels measured when the patient is not pregnant can lead to a cancer diagnosis.
  • hCG is heterodimeric with an a (alpha) subunit identical to that of luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and ⁇ (beta) subunit that is unique to hCG.
  • LH luteinizing hormone
  • FSH follicle-stimulating hormone
  • TSH thyroid-stimulating hormone
  • ⁇ (beta) subunit that is unique to hCG.
  • the ⁇ -subunit of hCG gonadotropin (beta-hCG) contains 145 amino acids and is encoded by six highly homologous genes.
  • Survivin also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5
  • BIRC5 baculoviral inhibitor of apoptosis repeat-containing 5
  • the survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death.
  • the amino acid sequence of survivin is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 52 or a fragment or a variant thereof as described herein.
  • a preferred survivin epitope which is preferably comprised by the complex for use according to the present invention, includes the following epitope (the epitope sequence shown in the following is a fragment of the above survivin sequence and is, thus, shown in the above survivin sequence underlined; the following epitope sequence may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 53.
  • the complex for use according to the present invention comprises an epitope of survivin. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 52, or a fragment thereof having a length of at least 10 amino acids (preferably at least 15 amino acids, more preferably at least 20 amino acids, even more preferably at least 25 amino acids and most preferably at least 30 amino acids), or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity). Even more preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 53.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 95 or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • CEA Carcina-Embryonic Antigen
  • CEA is an intracellular adhesion glycoprotein.
  • CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Therefore, CEA is usually present only at very low levels in the blood of healthy adults.
  • the amino acid sequence of CEA is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 54 or a fragment or a variant thereof as described herein.
  • CEA epitopes which are preferably comprised by the complex for use according to the present invention, include the following epitopes (the epitope sequences shown in the following are fragments of the above CEA sequence and are, thus, shown in the above CEA sequence underlined; each of the following epitope sequences may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 55 and/or an amino acid sequence according to SEQ ID NO: 56.
  • the complex for use according to the present invention comprises an epitope of CEA. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 54, or a fragment thereof having a length of at least 10 amino acids (preferably at least 15 amino acids, more preferably at least 20 amino acids, even more preferably at least 25 amino acids and most preferably at least 30 amino acids), or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 55 and/or a peptide having an amino acid sequence according to SEQ ID NO: 56.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 96 or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • TGF ⁇ R2 Transforming Growth Factor Beta Receptor 2 (TGF ⁇ R2)
  • TGF ⁇ receptors are single pass serine/threonine kinase receptors. They exist in several different isoforms.
  • TGF ⁇ R2 is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation.
  • P53 is a tumor suppressor protein having a role in preventing genome mutation.
  • P53 has many mechanisms of anticancer function and plays a role in apoptosis, genomic stability, and inhibition of angiogenesis. In its anti-cancer role, p53 works through several mechanisms: it an activate DNA repair proteins when DNA has sustained damage; it can arrest growth by holding the cell cycle at the G1/S regulation point on DNA damage recognition; and it can initiate apoptosis.
  • KRas also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog and KRAS, performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers.
  • the KRAS protein is a GTPase and is an early player in many signal transduction pathways.
  • KRAS is usually tethered to cell membranes because of the presence of an isoprene group on its C-terminus.
  • the amino acid sequence of KRas is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 57 or a fragment or a variant thereof as described herein.
  • a preferred Kirsten Ras epitope which is preferably comprised by the complex for use according to the present invention, includes the following epitope (the epitope sequence shown in the following is a fragment of the above Kirsten Ras sequence and is, thus, shown in the above Kirsten Ras sequence underlined; the following epitope sequence may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 58.
  • OGT O-Linked N-Acetylglucosamine (GlcNAc) Transferase, O-GlcNAc transferase, OGTase, O-linked N-acetylglucosaminyltransferase, uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase, protein O-linked beta-N-acetylglucosamine transferase) is an enzyme with system name UDP-N-acetyl-D-glucosamine:protein-O-beta-N-acetyl-D-glucosaminyl transferase) is an enzyme with system name “UDP-N-acetyl-D-glucosamine:protein-O-beta-N-acetyl-D-glucosaminyl transferase”.
  • OGT catalyzes the addition of a single N-acetylglucosamine in O-glycosidic linkage to serine or threonine residues of intracellular proteins.
  • OGT is a part of a host of biological functions within the human body.
  • OGT is involved in the resistance of insulin in muscle cells and adipocytes by inhibiting the Threonine 308 phosphorylation of AKT1, increasing the rate of IRS1 phosphorylation (at Serine 307 and Serine 632/635), reducing insulin signaling, and glycosylating components of insulin signals. Additionally, OGT catalyzes intracellular glycosylation of serine and threonine residues with the addition of N-acetylglucosamine.
  • OGT alleles are vital for embryogenesis, and that OGT is necessary for intracellular glycosylation and embryonic stem cell vitality.
  • OGT also catalyzes the posttranslational modification that modifies transcription factors and RNA polymerase II, however the specific function of this modification is mostly unknown.
  • GASPS Caspase 5
  • Caspase 5 is an enzyme that proteolytically cleaves other proteins at an aspartic acid residue, and belongs to a family of cysteine proteases called caspases. It is an inflammatory caspase, along with caspase 1, caspase 4 and the murine caspase 4 homolog caspase 11, and has a role in the immune system.
  • COA-1 Colorectal Tumor-Associated Antigen-1
  • COA-1 was identified in 2003 by Maccalli et al. (Maccalli, C., et al., Identification of a colorectal tumor - associated antigen ( COA -1) recognized by CD 4(+) T lymphocytes . Cancer Res, 2003. 63(20): p. 6735-43) as strongly expressed by colorectal and melanoma cells (no data available). Its mutation may interfere with the differential recognition of tumor and normal cells.
  • the complex for use according to the present invention preferably comprises an antigen of the MAGE-family (a “MAGE” antigen) or an epitope thereof.
  • MAGE-A3 and MAGE-D4 are preferred, and MAGE-A3 is particularly preferred.
  • the normal function of MAGE-A3 in healthy cells is unknown.
  • MAGE-A3 is a tumor-specific protein, and has been identified on many tumors.
  • the amino acid sequence of MAGE-A3 is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 59.
  • a preferred MAGE-A3 epitope which is preferably comprised by the complex for use according to the present invention, includes the following epitope (the epitope sequence shown in the following is a fragment of the above MAGE-A3 sequence and is, thus, shown in the above MAGE-A3 sequence underlined; the following epitope sequence may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 60.
  • the complex for use according to the present invention preferably comprises an antigen of the SART-family (a “SART” antigen) or an epitope thereof; the complex for use according to the present invention more preferably comprises SART-3 or an epitope thereof.
  • SART antigen of the SART-family
  • Squamous cell carcinoma antigen recognized by T-cells 3 possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients.
  • SART-3 is thought to be involved in the regulation of mRNA splicing.
  • IL13Ralpha2 binds interleukin 13 (IL-13) with very high affinity (and can therefore sequester it) but does not allow IL-4 binding. It acts as a negative regulator of both IL-13 and IL-4, however the mechanism of this is still undetermined.
  • the amino acid sequence of IL13Ralpha2 is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 61 or a fragment or a variant thereof as described herein.
  • a preferred IL13Ralpha2 epitope which is preferably comprised by the complex for use according to the present invention, includes the following epitope (the epitope sequence shown in the following is a fragment of the above IL13Ralpha2 sequence and is, thus, shown in the above IL13Ralpha2 sequence underlined; the following epitope sequence may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 62.
  • ASCL2 is a basic helix-loop-helix transcription factor essential for the maintenance of proliferating trophoblasts during placental development. ASCL2 was found to be a putative regulator of proliferation that is overexpressed in intestinal neoplasia.
  • the amino acid sequence of ASCL2 is shown in the following:
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 92 or a fragment or a variant thereof as described herein.
  • ASCL2 epitopes which are preferably comprised by the complex for use according to the present invention, include the following epitopes (the epitope sequences shown in the following are fragments of the above ASCL2 sequence and are, thus, shown in the above ASCL2 sequence underlined; each of the following epitope sequences may refer to one epitope or more than one (overlapping) epitopes):
  • a preferred complex for use according to the present invention comprises an amino acid sequence according to SEQ ID NO: 93 and/or an amino acid sequence according to SEQ ID NO: 94.
  • the complex for use according to the present invention comprises an epitope of ASCL2. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 92, or a fragment thereof having a length of at least 10 amino acids (preferably at least 15 amino acids, more preferably at least 20 amino acids, even more preferably at least 25 amino acids and most preferably at least 30 amino acids), or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 93 and/or a peptide having an amino acid sequence according to SEQ ID NO: 94.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 97 or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • the complex for use according to the present invention comprises at least one tumor epitope, which is an epitope of an antigen selected from the group consisting of EpCAM, MUC-1, survivin, CEA, KRas, MAGE-A3 and IL13Ralpha2, such as an epitope according to any of SEQ ID NOs 48, 50, 51, 53, 55, 56, 58, 60 and 62;
  • the complex for use according to the present invention comprises at least one tumor epitope, which is an epitope of an antigen selected from the group consisting of EpCAM, MUC-1, survivin, CEA, KRas, MAGE-A3, IL13Ralpha2, and ASCL2, such as an epitope according to any of SEQ ID NOs 48, 50, 51, 53, 55, 56, 58, 60, 62, 93 and 94; more preferably the at least one tumor epitope is an epitope of an antigen selected from the group consisting of EpCAM, MUC-1, survivin, CE
  • the complex for use according to the present invention comprises
  • the complex for use according to the present invention comprises
  • cancer/tumor epitope databases e.g. from van der Bruggen P, Stroobant V, Vigneron N, Van den Eynde B.
  • Peptide database T cell-defined tumor antigens. Cancer Immun 2013; URL: http://www.cancerimmunity.org/peptide/, or from the database “Tantigen” (TANTIGEN version 1.0, Dec. 1, 2009; developed by Bioinformatics Core at Cancer Vaccine Center, Dana-Farber Cancer Institute; URL: http://cvc.dfci.harvard.edu/tadb/).
  • a “sequence variant” is as defined above, namely a sequence variant has an (amino acid) sequence which is at least 70%, at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% identical to the reference sequence.
  • a “functional” sequence variant means in the context of an epitope, that the function as an epitope is not impaired or abolished.
  • the amino acid sequence of an epitope of a cancer/tumor antigen as described herein is not mutated and, thus, identical to the reference epitope sequence.
  • the complex for use according to the present invention comprises
  • the complex for use according to the present invention comprises
  • a “fragment” of an antigen comprises at least 10 consecutive amino acids of the antigen, preferably at least 15 consecutive amino acids of the antigen, more preferably at least 20 consecutive amino acids of the antigen, even more preferably at least 25 consecutive amino acids of the antigen and most preferably at least 30 consecutive amino acids of the antigen.
  • a fragment of EpCAM comprises at least 10 consecutive amino acids of EpCAM (SEQ ID NO: 47), preferably at least 15 consecutive amino acids of EpCAM (SEQ ID NO: 47), more preferably at least 20 consecutive amino acids of EpCAM (SEQ ID NO: 47), even more preferably at least 25 consecutive amino acids of EpCAM (SEQ ID NO: 47) and most preferably at least 30 consecutive amino acids of EpCAM (SEQ ID NO: 47);
  • a fragment of MUC-1 comprises at least 10 consecutive amino acids of MUC-1 (SEQ ID NO: 49), preferably at least 15 consecutive amino acids of MUC-1 (SEQ ID NO: 49), more preferably at least 20 consecutive amino acids of MUC-1 (SEQ ID NO: 49), even more preferably at least 25 consecutive amino acids of MUC-1 (SEQ ID NO: 49) and most preferably at least 30 consecutive amino acids of MUC-1 (SEQ ID NO: 49);
  • a fragment of survivin comprises at least 10 consecutive amino acids of survivin (SEQ ID NO: 52), preferably at least 15 consecutive amino acids
  • a fragment of ASCL2 comprises at least 10 consecutive amino acids of ASCL2 (SEQ ID NO: 92), preferably at least 15 consecutive amino acids of ASCL2 (SEQ ID NO: 92), more preferably at least 20 consecutive amino acids of ASCL2 (SEQ ID NO: 92), even more preferably at least 25 consecutive amino acids of ASCL2 (SEQ ID NO: 92) and most preferably at least 30 consecutive amino acids of ASCL2 (SEQ ID NO: 92).
  • a functional sequence variant of such a fragment has an (amino acid) sequence, which is at least 70%, at least 75%, preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% identical to the reference sequence, and the epitope function of at least one, preferably all, epitope(s) comprised by the fragment is maintained.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of EpCAM, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, CEA, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, EpCAM, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, CEA, TGF ⁇ R2, p53, KRas, OGT, GASPS, COA-1, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • CEA one or more epitopes of CEA (such as the epitope according to SEQ ID NO: 55 and/or the epitope according to SEQ ID NO: 56) or functional sequence variants thereof.
  • Such a complex does preferably not comprise any epitope of HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, EpCAM, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • the complex comprises in N- to C-terminal direction:
  • Such a complex does preferably not comprise any epitope of HER-2, EpCAM, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2
  • the complex comprises in N- to C-terminal direction:
  • Such a complex does preferably not comprise any further antigen or further epitopes of antigens other than CEA, survivin and ASCL2, more preferably such a complex does not comprise any other (tumor) epitope.
  • the C-terminus of (i) the peptide having an amino acid sequence according to SEQ ID NO: 54 or the fragment or variant thereof is directly linked to the N-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 52 or the fragment or variant thereof; and the C-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 52 or the fragment or variant thereof is directly linked to the N-terminus of (iii) the peptide having an amino acid sequence according to SEQ ID NO: 92 or the fragment or variant thereof.
  • the complex comprises in N- to C-terminal direction:
  • Such a complex does preferably not comprise any further antigen or further epitopes of antigens other than CEA, survivin and ASCL2, more preferably such a complex does not comprise any other (tumor) epitope.
  • the C-terminus of (i) the peptide having an amino acid sequence according to SEQ ID NO: 96 or the variant thereof is directly linked to the N-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 95 or the variant thereof; and the C-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 95 or the variant thereof is directly linked to the N-terminus of (iii) the peptide having an amino acid sequence according to SEQ ID NO: 97 or the variant thereof.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 98 or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • a complex does preferably not comprise any further antigen or further epitopes of antigens other than CEA, survivin and ASCL2, more preferably such a complex does not comprise any other (tumor) epitope.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, CEA, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, EpCAM, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, EpCAM, CEA, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of ASCL2, HER-2, EpCAM, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, GASPS, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, CEA, TGF ⁇ R2, p53, KRas, OGT, GASPS, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2. More preferably, such a complex does not comprise any epitope of ASCL2, EpCAM, HER-2, MUC-1, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TGF ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • such a complex comprises
  • Such a complex does preferably not comprise any epitope of EpCAM, HER-2, MUC-1, CEA, TOMM34, RNF 43, KOC1, VEGFR, ⁇ hCG, survivin, TG ⁇ R2, p53, KRas, OGT, CASP5, COA-1, MAGE, SART or IL13Ralpha2.
  • the TLR peptide agonist allows an increased targeting of the vaccine towards dendritic cells along with self-adjuvancity.
  • Physical linkage of a TLR peptide agonist to the CPP and the at least one antigen or antigenic epitope according to the present invention in the complex for use according to the present invention provides an enhanced immune response by simultaneous stimulation of antigen presenting cells, in particular dendritic cells, that internalize, metabolize and display antigen(s).
  • a “TLR peptide agonist” is an agonist of a Toll-like receptor (TLR), i.e. it binds to a TLR and activates the TLR, in particular to produce a biological response.
  • TLR peptide agonist is a peptide, a polypeptide or a protein as defined above.
  • the TLR peptide agonist comprises from 10 to 150 amino acids, more preferably from 15 to 130 amino acids, even more preferably from 20 to 120 amino acids, particularly preferably from 25 to 110 amino acids, and most preferably from 30 to 100 amino acids.
  • TLRs Toll like receptors
  • LRRs leucine-rich repeats
  • Toll like receptors include TLRs1-10. Compounds capable of activating TLR receptors and modifications and derivatives thereof are well documented in the art.
  • TLR1 may be activated by bacterial lipoproteins and acetylated forms thereof
  • TLR2 may in addition be activated by Gram positive bacterial glycolipids, LPS, LP A, LTA, fimbriae, outer membrane proteins, heat shock proteins from bacteria or from the host, and Mycobacterial lipoarabinomannans.
  • TLR3 may be activated by dsRNA, in particular of viral origin, or by the chemical compound poly(LC).
  • TLR4 may be activated by Gram negative LPS, LTA, Heat shock proteins from the host or from bacterial origin, viral coat or envelope proteins, taxol or derivatives thereof, hyaluronan containing oligosaccharides and fibronectins.
  • TLR5 may be activated with bacterial flagellae or flagellin.
  • TLR6 may be activated by mycobacterial lipoproteins and group B streptococcus heat labile soluble factor (GBS-F) or staphylococcus modulins.
  • TLR7 may be activated by imidazoquinolines.
  • TLR9 may be activated by unmethylated CpG DNA or chromatin—lgG complexes.
  • the TLR peptide agonist comprised by the complex for use according to the present invention is an agonist of TLR1, 2, 4, 5, 6, and/or 10.
  • TLRs are expressed either on the cell surface (TLR1, 2, 4, 5, 6, and 10) or on membranes of intracellular organelles, such as endosomes (TLR3, 4, 7, 8, and 9).
  • the natural ligands for the endosomal receptors turned out to be nucleic acid-based molecules (except for TLR4).
  • the cell surface-expressed TLR1, 2, 4, 5, 6, and 10 recognize molecular patterns of extracellular microbes (Monie, T. P., Bryant, C. E., et al. 2009: Activating immunity: Lessons from the TLRs and NLRs. Trends Biochem. Sci. 34(11), 553-561).
  • TLRs are expressed on several cell types but virtually all TLRs are expressed on DCs allowing these specialized cells to sense all possible pathogens and danger signals.
  • the TLR peptide agonist comprised by the complex for use according to the present invention is more preferably a peptide agonist of TLR2, TLR4 and/or TLR5.
  • the TLR peptide agonist is a TLR2 peptide agonist and/or a TLR4 peptide agonist.
  • the TLR peptide agonist is a TLR4 peptide agonist.
  • the TLR peptide agonist is one TLR peptide agonist, which is both, a TLR2 and a TLR4 agonist.
  • TLR2 can detect a wide variety of ligands derived from bacteria, viruses, parasites, and fungi.
  • the ligand specificity is often determined by the interaction of TLR2 with other TLRs, such as TLR1, 6, or 10, or non-TLR molecules, such as dectin-1, CD14, or CD36.
  • TLR1 TLR1, 6, or 10
  • non-TLR molecules such as dectin-1, CD14, or CD36.
  • TLR2 can identify triacyl lipoproteins or lipopeptides from (myco)bacterial origin, such as Pam3CSK4 and peptidoglycan (PGA; Gay, N.)., and Gangloff, M. (2007): Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem.
  • TLR2 interacts with a broad and structurally diverse range of ligands, including molecules expressed by microbes and fungi.
  • Multiple TLR2 agonists have been identified, including natural and synthetic lipopeptides (e.g. Mycoplasma fermentas macrophage-activating lipopeptide (MALP-2)), peptidoglycans (PG such as those from S. aureus ), lipopolysaccharides from various bacterial strains (LPS), polysaccharides (e.g. zymosan), glycosylphosphatidyl-inositol-anchored structures from gram positive bacteria (e.g.
  • lipopeptides e.g. Mycoplasma fermentas macrophage-activating lipopeptide (MALP-2)
  • PG peptidoglycans
  • LPS lipopolysaccharides from various bacterial strains
  • polysaccharides e.g. zymosan
  • LTA lipoteichoic acid
  • lipo-arabinomannan from mycobacteria and lipomannas from M. tuberculosis .
  • Certain viral determinants may also trigger via TLR2 (Barbalat R, Lau L, Locksley R M, Barton G M. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol. 2009: 10(11):1200-7).
  • Bacterial lipopeptides are structural components of cell walls. They consist of an acylated s-glycerylcysteine moiety to which a peptide can be conjugated via the cysteine residue.
  • TLR2 agonists which are bacterial lipopeptides, include MALP-2 and it's synthetic analogue di-palmitoyl-S-glyceryl cysteine (Pam 2 Cys) or tri-palmitoyl-S-glyceryl cysteine (Pam 3 Cys).
  • TLR4 Monophosphoryl Lipid A from Salmonella minnesota R595 (MPLA), lipopolysaccharides (LPS), mannans ( Candida albicans ), glycoinositolphospholipids ( Trypanosoma ), viral envelope proteins (RSV and MMTV) and endogenous antigens including fibrinogen and heat-shock proteins.
  • MPLA Salmonella minnesota R595
  • LPS lipopolysaccharides
  • mannans Candida albicans
  • GMV glycoinositolphospholipids
  • RSV and MMTV viral envelope proteins
  • endogenous antigens including fibrinogen and heat-shock proteins.
  • Such agonists of TLR4 are for example described in Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. Feb. 24; 2006: 124(4):783-801 or in Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Bio
  • LPS which is found in the outer membrane of gram negative bacteria, is the most widely studied of the TLR4 ligands. Suitable LPS-derived TLR4 agonist peptides are described for example in WO 2013/120073 (A1).
  • TLR5 is triggered by a region of the flagellin molecule expressed by nearly all motile bacteria.
  • flagellin, or peptides or proteins derived from flagellin and/or variants or fragments of flagellin are also suitable as TLR peptide agonists comprised by the complex for use according to the present invention.
  • TLR peptide agonists thus include the TLR2 lipopeptide agonists MALP-2, Pam 2 Cys and Pam 3 Cys or modifications thereof, different forms of the TLR4 agonist LPS, e.g. N. meningitidis wild-type L3-LPS and mutant penta-acylated LpxL1-LPS, and the TLR5 agonist flagellin.
  • the TLR peptide agonist comprised by the complex for use according to the present invention is neither a lipopeptide nor a lipoprotein, neither a glycopeptide nor a glycoprotein, more preferably, the TLR peptide agonist comprised by the complex for use according to the present invention is a classical peptide, polypeptide or protein as defined herein.
  • a preferred TLR2 peptide agonist is annexin II or an immunomodulatory fragment thereof, which is described in detail in WO 2012/048190 A1 and U.S. patent application Ser. No. 13/033,1546, in particular a TLR2 peptide agonist comprising an amino acid sequence according to SEQ ID NO: 4 or SEQ ID NO: 7 of WO 2012/048190 A1 or fragments or variants thereof are preferred.
  • TLR2 peptide agonist comprising or consisting of an amino acid sequence according to SEQ ID NO: 15 or a sequence variant thereof as described above is particularly preferred as component c), i.e. as the at least one TLR peptide agonist, comprised by the complex for use according to the present invention.
  • TLR2 peptide agonist Anaxa SEQ ID NO: 15 STVHEILCKLSLEGDHSTPPSAYGSVKPYTNFDAE
  • a particularly preferred functional sequence variant of the TLR peptide agonist according to SEQ ID NO: 15 is the TLR peptide agonist according to SEQ ID NO: 71:
  • a TLR2 peptide agonist comprising or consisting of an amino acid sequence according to SEQ ID NO: 71 or a sequence variant thereof as described above is particularly preferred as component c), i.e. as the at least one TLR peptide agonist, comprised by the complex.
  • the TLR peptide agonist in the complex most preferably comprises or consists of a peptide having an amino acid sequence according to SEQ ID NO: 71, or a functional sequence variant thereof having at least 70% sequence identity (preferably at least 75%, more preferably at least 80%, even preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95%, most preferably at least 99% sequence identity).
  • TLR peptides agonists are particularly preferred, which in particular correspond to motifs that bind to TLR4, in particular (i) peptides mimicking the natural LPS ligand (RS01: Gln-Glu-Ile-Asn-Ser-Ser-Tyr and RS09: Ala-Pro-Pro-His-Ala-Leu-Ser) and (ii) Fibronectin derived peptides.
  • the cellular glycoprotein Fibronectin (FN) has multiple isoforms generated from a single gene by alternative splicing of three exons. One of these isoforms is the extra domain A (EDA), which interacts with TLR4.
  • TLR peptide agonists comprise a fibronectin EDA domain or a fragment or variant thereof.
  • suitable fibronectin EDA domains or a fragments or variants thereof are disclosed in EP 1 913 954 B1, EP 2 476 440 A1, US 2009/0220532 A1, and WO 2011/101332 A1.
  • a TLR4 peptide agonist comprising or consisting of an amino acid sequence according to SEQ ID NO: 45 or a sequence variant thereof as described above is particularly preferred as component c), i.e. as the at least one TLR peptide agonist, comprised by the complex for use according to the present invention.
  • TLR4 peptide agonist EDA SEQ ID NO: 45 NIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIRELFPAP DGEDDTAELQGLRPGSEYTVSVVALHDDMESQPLIGIQST
  • high-mobility group box 1 protein HMGB1
  • peptide fragments thereof are assumed to be TLR4 agonists.
  • TLR4 agonists such as TLR4 agonists.
  • TLR4 agonist comprising or consisting of an amino acid sequence according to SEQ ID NO: 15 or 71 or a functional sequence variant thereof is particularly preferred as component c), i.e. as the at least one TLR peptide agonist, comprised by the complex.
  • the complex for use according to the present invention comprises at least one TLR peptide agonist, preferably the complex for use according to the present invention comprises more than one TLR peptide agonist, in particular 2, 3, 4, 5, 6, 7, 8, 9, 10 or more TLR peptide agonists, more preferably the complex for use according to the present invention comprises (at least) two or three TLR peptide agonists, even more preferably the complex for use according to the present invention comprises (at least) four or five TLR peptide agonists. If more than one TLR peptide agonist is comprised by the complex for use according to the present invention it is understood that said TLR peptide agonist is in particular also covalently linked in the complex for use according to the present invention, e.g. to another TLR peptide agonist and/or to a component a), i.e. a cell penetrating peptide, and/or to a component b), i.e. an antigen or antigenic epitope.
  • the complex for use according to the present invention comprises one single TLR peptide agonist.
  • the complex for use according to the present invention comprises one single TLR peptide agonist and no further component having TLR agonist properties except the one single TLR peptide agonist as described.
  • the various TLR peptide agonists comprised by the complex for use according to the present invention may be the same or different.
  • the various TLR peptide agonists comprised by the complex for use according to the present invention are different from each other.
  • the more than one antigen or antigenic epitope in particular 2, 3, 4, 5, 6, 7, 8, 9, 10 antigens or antigenic epitopes, or more TLR peptide agonists, in particular 2, 3, 4, 5, 6, 7, 8, 9, 10 TLR agonists, are positioned consecutively in the complex for use according to the present invention.
  • all TLR peptide agonists comprised by the complex are positioned in a stretch, which is neither interrupted by component a), i.e. a cell penetrating peptide, nor by component b), i.e. at least one antigen or antigenic epitope.
  • component a) and component b) are positioned in the complex for example before or after such a stretch of all TLR peptide agonists.
  • the TLR peptide agonists positioned consecutively in such a way may be linked to each other for example by a spacer or linker as described below, which is neither component a), i.e. a cell penetrating peptide, nor component h), i.e. at least one antigen or antigenic epitope.
  • the various TLR peptide agonists may also be positioned in any other way in the complex for use according to the present invention, for example with component a) and/or component b) positioned in between two or more TLR peptide agonists, i.e. with one or more TLR peptide agonist positioned between component a) and component b) (or vice versa) and, optionally, one or more TLR peptide agonists positioned at the respective other end of component a) and/or component b).
  • TLR peptide agonists activating the same or different TLR receptors may be advantageously comprised by a single complex for use according to the present invention.
  • a number of different TLR peptide agonists activating the same or different TLR receptors may be distributed to subsets of different TLR peptide agonists activating the same or different TLR receptors, which are comprised by different complexes according to the present invention, whereby such different complexes comprising different subsets may advantageously be administered simultaneously, e.g. in a single vaccine, to a subject in need thereof.
  • components a), b) and c) are covalently linked, i.e. the linkage between two out of the three components a), b), and c) of the complex for use according to the present invention is a covalent linkage.
  • two out of the three components a), b), and c) of the complex for use according to the present invention are covalently linked to each other (i.e. the “first” and the “second” component), and the third component out of the three components a), b), and c) is covalently linked either to the first component out of the three components a), b), and c) or to the second component out of the three components a), b), and c).
  • a linear molecule is formed.
  • each of the three components a), b), and c) is covalently linked to both of the other components out of the three components a), b), and c).
  • a “covalent linkage” refers to a chemical bond that involves the sharing of electron pairs between atoms.
  • a “covalent linkage” in particular involves a stable balance of attractive and repulsive forces between atoms when they share electrons. For many molecules, the sharing of electrons allows each atom to attain the equivalent of a full outer shell, corresponding to a stable electronic configuration.
  • Covalent bonding includes many kinds of interactions, including for example ⁇ -bonding, ⁇ -bonding, metal-to-metal bonding, agostic interactions, and three-center two-electron bonds. Accordingly, the complex for use according to the present invention may also be referred to as “compound”, in particular it may be referred to as “molecule”.
  • components a), b), and c) are covalently linked by chemical coupling in any suitable manner known in the art, such as cross-linking methods.
  • any suitable manner known in the art such as cross-linking methods.
  • many known chemical cross-linking methods are non-specific, i.e., they do not direct the point of coupling to any particular site on the components a), b), and c).
  • the use of non-specific cross-linking agents may attack functional sites or sterically block active sites, rendering the fused components of the complex for use according to the present invention biologically inactive. It is referred to the knowledge of the skilled artisan to block potentially reactive groups by using appropriate protecting groups.
  • Coupling specificity can be increased by direct chemical coupling to a functional group found only once or a few times in components a), b), and/or c), which functional group is to be cross-linked to the another of the components a), b), and c).
  • the cystein thiol group may be used, if just one cystein residue is present in a certain component a), b), or c) of complex for use according to the present invention.
  • a cross-linking reagent specific for primary amines will be selective for the amino terminus of the respective component.
  • cross-linking may also be carried out via the side chain of a glutamic acid residue placed at the N-terminus of the peptide such that a amide bond can be generated through its side-chain. Therefore, it may be advantageous to link a glutamic acid residue to the N-terminus of a certain component a), b), or c).
  • a cysteine residue is to be introduced into a certain component a), b), or c
  • introduction at or near its N- or C-terminus is preferred.
  • Conventional methods are available for such amino acid sequence alterations based on modifications of certain component a), b), or c) by either adding one or more additional amino acids, e.g.
  • cystein residue to the translocation sequence or by substituting at least one residue of the translocation sequence(s) being comprised in the respective component.
  • a cystein side chain is used for coupling purposes, a certain component a), b), or c) has preferably one cystein residue.
  • Any second cystein residue should preferably be avoided and can, optionally, be replaced when they occur in the respective component comprised by the complex for use according to the present invention.
  • a cysteine residue is replaced in the original sequence of a certain component a), b), or c), it is typically desirable to minimize resulting changes in the peptide folding of the respective component. Changes in folding are minimized when the replacement is chemically and sterically similar to cysteine. Therefore, serine is preferred as a replacement for cystein.
  • Coupling of two out of the three components a), b), and c) can be accomplished via a coupling or conjugating agent including standard peptide synthesis coupling reagents such as HOBt, HBTU, DICI, TBTU.
  • a coupling or conjugating agent including standard peptide synthesis coupling reagents such as HOBt, HBTU, DICI, TBTU.
  • reagents for example, N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) or N,N′-(1,3-phenylene)bismaleimide; N,N′-ethylene-bis-(iodoacetamide) or other such reagent having 6 to 11 carbon methylene bridges; and 1,5-difluoro-2,4-dinitrobenzene.
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • N,N′-(1,3-phenylene)bismaleimide N,N′-ethylene-bis-(iodoacetamide) or other such reagent having 6 to 11 carbon methylene bridges
  • 1,5-difluoro-2,4-dinitrobenzene 1,5-difluoro-2,4-dinitrobenzene.
  • cross-linking agents useful for this purpose include: p,p′-difluoro-m,m′-dinitrodiphenylsulfone; dimethyl adipimidate; phenol-1,4-disulfonylchloride; hexamethylenediisocyanate or diisothiocyanate, or azophenyl-p-diisocyanate; glutaraldehyde and disdiazobenzidine.
  • Cross-linking agents may be homobifunctional, i.e., having two functional groups that undergo the same reaction.
  • a preferred homobifunctional cross-linking agent is bismaleimidohexane (BMH).
  • BMH contains two maleimide functional groups, which react specifically with sulfhydryl-containing compounds under mild conditions (pH 6.5-7.7).
  • the two maleimide groups are connected by a hydrocarbon chain. Therefore, BMH is useful for irreversible cross-linking of proteins (or polypeptides) that contain cysteine residues.
  • Cross-linking agents may also be heterobifunctional. Heterobifunctional cross-linking agents have two different functional groups, for example an amine-reactive group and a thiol-reactive group, that will cross-link two proteins having free amines and thiols, respectively.
  • heterobifunctional cross-linking agents are Succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC), m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), and succinimide 4-(p-maleimidophenyhbutyrate (SMPB), an extended chain analog of MBS.
  • SMCC Succinimidyl-4-(N-maleimidomethyl)-cyclohexane-1-carboxylate
  • MBS m-maleimidobenzoyl-N-hydroxysuccinimide ester
  • SMPB succinimide 4-(p-maleimidophenyhbutyrate
  • cross-linking agents often have low solubility in water, a hydrophilic moiety, such as a sulfonate group, may be added to the cross-linking agent to improve its water solubility.
  • Sulfo-MBS and sulfo-SMCC are examples of cross-linking agents modified for water solubility.
  • Many cross-linking agents yield a conjugate that is essentially non-cleavable under cellular conditions. Therefore, some cross-linking agents contain a covalent bond, such as a disulfide, that is cleavable under cellular conditions.
  • cleavable cross-linkers For example, Traut's reagent, dithiobis (succinimidylpropionate) (DSP), and N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) are well-known cleavable cross-linkers.
  • DSP dithiobis
  • SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
  • cleavable cross-linking agent permits the cell penetrating peptide, the at least one antigen or antigenic epitope and the at least one TLR peptide agonist comprised by the complex for use according to the present invention to separate from each other after delivery into the target cell.
  • direct disulfide linkage may also be useful.
  • Chemical cross-linking may also include the use of spacer arms.
  • Spacer arms provide intramolecular flexibility or adjust intramolecular distances between conjugated moieties and thereby may help preserve biological activity.
  • a spacer arm may be in the form of a protein (or polypeptide) moiety that includes spacer amino acids, e.g. proline.
  • a spacer arm may be part of the cross-linking agent, such as in “long-chain SPDP” (Pierce Chem. Co., Rockford, Ill., cat. No. 21651 H). Numerous cross-linking agents, including the ones discussed above, are commercially available. Detailed instructions for their use are readily available from the commercial suppliers.
  • Cross-linking agents for peptide or protein crosslinking include for example (i) amine-to-amine crosslinkers, e.g. homobifunctional amine-specific protein crosslinking reagents based on NHS-ester and imidoester reactive groups for selective conjugation of primary amines; available in short, long, cleavable, irreversible, membrane permeable, and cell surface varieties; (ii) sulfhydryl-to-carbohydrate crosslinkers, e.g.
  • crosslinking reagents based on maleimide and hydrazide reactive groups for conjugation and formation of covalent cross' inks (iii) sulfhydryl-to-sulfhydryl crosslinkers, e.g. homobifunctional sulfhydryl-specific crosslinking reagents based on maleimide or pyridyldithiol reactive groups for selective covalent conjugation of protein and peptide thiols (reduced cysteines) to form stable thioether bonds; (iv) photoreactive crosslinkers, e.g.
  • amine-to-sulfhydryl crosslinkers e.g. heterobifunctional protein crosslinking reagents for conjugation between primary amine (lysine) and sulfhydryl (cysteine) groups of proteins and other molecules; available with different lengths and types of spacer arms; and (vi) amine-to-amine crosslinkers, e.g. carboxyl-to-amine crosslinkers, e.g.
  • Carbodiimide crosslinking reagents DCC and EDC (EDAC), for conjugating carboxyl groups (glutamate, aspartate, C-termini) to primary amines (lysine, N-termini) and also N-hydroxysuccinimide (NHS) for stable activation of carboxylates for amine-conjugation.
  • carboxyl groups glutamate, aspartate, C-termini
  • primary amines lysine, N-termini
  • NHS N-hydroxysuccinimide
  • crosslinkers in general which can be used in the complex for use according to the present invention, include N-( ⁇ -Maleimidoacetoxy)-succinimide ester, N-5-Azido-2-nitrobenzyloxy-succinimide, 1,4-Bis-Maleimidobutane, 1,4-Bis-Maleimmidyl-2,3-dihydroxy-butane, Bis-Maleimidohexane, Bis-Maleimidoethane, N-( ⁇ -Maleimidopropionic acid)hydrazide*TFA, N-( ⁇ -Maleimidopropyloxy)succinimide ester, 1,8-Bis-Maleimidodiethylene-glycol, 1,11-Bis-Maleimidotriethyleneglycol, Bis (Sulfosuccinimidyl)suberate, MS (sulfosuccinimidyl)glutarate-d0, Bis (s
  • the linkage between two out of the three components a), b), and c) of the complex for use according to the present invention may be directly or indirectly, i.e. two components directly adjoin or they may be linked by an additional component of the complex, e.g. a spacer or a linker.
  • a direct linkage may be realized preferably by an amide bridge, if the components to be linked have reactive amino or carboxy groups. More specifically, if the components to be linked are peptides, polypeptides or proteins, a peptide bond is preferred. Such a peptide bond may be formed using a chemical synthesis involving both components (an N-terminal end of one component and the C-terminal end of the other component) to be linked, or may be formed directly via a protein synthesis of the entire peptide sequence of both components, wherein both (protein or peptide) components are preferably synthesized in one step. Such protein synthesis methods include e.g., without being limited thereto, liquid phase peptide synthesis methods or solid peptide synthesis methods, e.g.
  • solid peptide synthesis methods according to Merrifield, t-Boc solid-phase peptide synthesis, Fmoc solid-phase peptide synthesis, BOP (Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate) based solid-phase peptide synthesis, etc.
  • BOP Benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate
  • ester or ether linkages are preferred.
  • a linkage may occur via the side chains, e.g. by a disulfide bridge.
  • Further components of other chemical nature e.g. the at least one antigen or antigenic epitope if it is not of peptidic nature, may be likewise attached to the components of peptidic nature, e.g. the cell penetrating peptide, the at least one TLR peptide agonist, and the at least one antigen or antigenic epitope if it is of peptidic nature.
  • the linkage via a side chain will preferably be based on side chain amino, thiol or hydroxyl groups, e.g.
  • a linkage of a peptidic main chain with a peptidic side chain of another component may also be via an isopeptide bond.
  • An isopeptide bond is an amide bond that is not present on the main chain of a protein. The bond forms between the carboxyl terminus of one peptide or protein and the amino group of a lysine residue on another (target) peptide or protein.
  • the complex for use according to the present invention may optionally comprise a spacer or linker, which are non-immunologic moieties, which are preferably cleavable, and which link component a) and b) and/or component a) and c), and/or component b) and c), and/or link consecutive antigens or antigenic epitopes, and/or link consecutive TLR peptide agonists, and/or link consecutive cell penetrating peptides, and/or which can be placed at the C-terminal part of components b) and/or c).
  • a spacer or linker which are non-immunologic moieties, which are preferably cleavable, and which link component a) and b) and/or component a) and c), and/or component b) and c), and/or link consecutive antigens or antigenic epitopes, and/or link consecutive TLR peptide agonists, and/or link consecutive cell penetrating peptides
  • a linker or spacer may preferably provide further functionalities in addition to linking of the components, and preferably being cleavable, more preferably naturally cleavable inside the target cell, e.g. by enzymatic cleavage.
  • further functionalities do in particular not include any immunological functionalities.
  • Examples of further functionalities, in particular regarding linkers in fusion proteins, can be found in Chen X. et al., 2013: Fusion Protein Linkers: Property, Design and Functionality. Adv Drug Deliv Rev. 65(10): 1357-1369, wherein for example also in vivo cleavable linkers are disclosed.
  • linkers e.g. flexible linkers and rigid linkers, and linker designing tools and databases, which can be useful in the complex for use according to the present invention or to design a linker to be used in the complex for use according to the present invention.
  • Said spacer may be peptidic or non-peptidic, preferably the spacer is peptidic.
  • a peptidic spacer consists of about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, more preferably of about 1, 2, 3, 4, or 5 amino acids.
  • the amino acid sequence of the peptidic spacer may be identical to that of the N-terminal or C-terminal flanking region of any of the components a), b), or c).
  • a peptidic spacer can consist of non-natural amino acid sequences such as an amino acid sequence resulting from conservative amino acid substitutions of said natural flanking regions or sequences of known cleavage sites for proteases such as an enterokinase target site (amino acid sequence: DDDK, SEQ ID NO: 16), factor Xa target site (amino acid sequence: IEDGR, SEQ ID NO: 17), thrombin target site (amino acid sequence: LVPRGS, SEQ ID NO: 18), protease TEV target site (amino acid sequence: ENLYFQG, SEQ ID NO: 19), PreScission protease target site (amino acid sequence LEVLFQGP, SEQ ID NO: 20), polycationic amino acids, e.g.
  • the peptidic spacer does not contain any Cys (C) residues.
  • the linker sequence contains at least 20%, more preferably at least 40% and even more preferably at least 50% Gly or ⁇ -alanine residues, e.g. GlyGlyGlyGlyGly (SEQ ID NO: 22), GlyGlyGlyGly (SEQ ID NO: 23), GlyGlyGly, CysGlyGly or GlyGlyCys, etc.
  • Appropriate linker sequences can be easily selected and prepared by a person skilled in the art. They may be composed of D and/or L amino acids. Further examples of a peptidic spacer include the amino acid sequences EQLE (SEQ ID NO: 24) or TEWT (SEQ ID NO: 25) or any conservative substitutions thereof.
  • a non-peptidic spacer can include or may be an ester, a thioester, and a di-sulfide.
  • the complex for use according to the invention may comprise a spacer or linker, in particular a peptidic spacer, placed between component a) and b) and/or between component a) and c), and/or between component b) and c).
  • This peptidic spacer can be chosen by one skilled in the art so that it may be cut by the cell machinery once the complex comprising the cell penetrating peptide and the cargo molecule has been internalized.
  • each of the antigens or antigenic epitopes and/or each of the TLR peptide agonists comprised in the complex of the invention can be either directly linked to each other or linked via spacers or linkers such as, e.g., a peptidic spacer consisting of a few amino acids.
  • the complex for use according to the present invention comprises several antigens or antigenic epitopes or when the complex comprises several TLR peptide agonists
  • some antigens or antigenic epitopes and/or some TLR peptide agonists comprised by the complex of the invention are directly linked to each other and some other antigens or antigenic epitopes and/or some other TLR peptide agonists are linked via spacers or linkers such as a peptidic spacer consisting of a few amino acids.
  • two successive antigens or antigenic epitopes or two successive TLR peptide agonists comprised in the complex of the invention are linked to each other by spacers consisting of the natural flanking regions of said antigens or antigenic epitopes or of said TLR peptide agonists, respectively.
  • the spacer used to link a first antigen/antigenic epitope or a first TLR peptide agonist to a second antigen/antigenic epitope or to a second TLR peptide agonist may consists of up to about 8 amino acids corresponding to up to about 4 amino acids of the N-terminal or C-terminal flanking region of the first antigen/antigenic epitope or the first TLR peptide agonist, followed by up to about 4 amino acids of the N-terminal or C-terminal flanking region of the second antigen/antigenic epitope or the second TLR peptide agonist.
  • the spacer used to link a first antigen/antigenic epitope or a first TLR peptide agonist (“antigen/epitope/TLR peptide agonist 1”) to a second epitope (“antigen/epitope/TLR peptide agonist 2”) consists of about 8 amino acids corresponding to any possible combination ranging from: 0 flanking amino acid of antigen/epitope/TLR peptide agonist 1 and 8 flanking amino acids of antigen/epitope/TLR peptide agonist 2, to 8 flanking amino acids of antigen/epitope/TLR peptide agonist 1 and 0 flanking amino acid of antigen/epitope/TLR peptide agonist 2, i.e.
  • the total of 8 amino acids constituting a spacer linking two consecutive antigen/epitope/TLR peptide agonist is not an absolute value and the spacer could also be composed of a total of, for instance, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 9 amino acids or 10 amino acids.
  • equivalent combinations as mentioned above are also an illustration of the invention in the situation where a spacer has less or more than 8 amino acids.
  • the spacer used to link a first antigen/antigenic epitope or a first TLR peptide agonist (“antigen/epitope/TLR peptide agonist 1”) to a second antigen/antigenic epitope or to a second TLR peptide agonist, respectively, (“antigen/epitope/TLR peptide agonist 2”) consists of e.g. 1, 2, 3, 4, or 5 amino acids. More particularly, said spacer's amino acid sequence can correspond to the 4 amino acids of the N-terminal or C-terminal flanking region of antigen/epitope/TLR peptide agonist 1 or antigen/epitope/TLR peptide agonist 2.
  • a spacer as described above may also be placed at the C-terminal part of the last antigen/epitope/TLR peptide agonist comprised in the complex for use according to the present invention.
  • linkages between two of the three components a), b), and c) are well documented in the literature and can depend on the nature of the at least one antigen or antigenic epitope.
  • linkages between two of the three components a), b), and c) can be achieved via cleavable disulphide linkages through total stepwise solid-phase synthesis or solution-phase or solid-phase fragment coupling, stable amide, thiazolidine, oxime and hydrazine linkage, disulphide linkage, stable thiomaleimide linkage, peptide bond (including peptide bonds between amino acids of a fusion protein), or electrostatic or hydrophobic interactions.
  • the at least one antigen or antigenic epitope comprised by the complex for use according to the present invention as well as any optional spacer or linker comprised by the complex for use according to the present invention are of peptidic nature. More preferably, all components of the complex for use according to the present invention, e.g. the cell penetrating peptide, the at least one antigen or antigenic epitope, which is a peptide, polypeptide or protein, the at least one TLR peptide agonist and any optional peptidic linker or spacer are linked in the complex for use according to the present invention by a peptide bond.
  • the complex for use according to the present invention is thus a peptide, polypeptide or protein, such as a fusion protein, e.g. a recombinant fusion protein.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, or SEQ ID NO: 87; or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, SEQ ID NO: 69, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91;
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, or SEQ ID NO: 69; or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, or SEQ ID NO: 69 is preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is more preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is more preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is more preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, or SEQ ID NO: 87 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90 or SEQ ID NO: 91 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74,
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is even more preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 28, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 28, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is even more preferred.
  • a complex comprising or consisting of an amino acid sequence according to SEQ ID NO: 28, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 or a complex comprising or consisting of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 28, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41 or SEQ ID NO: 69 is particularly preferred.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 72 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 72.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 73 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 73.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 74 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 74.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 75 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 75.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 76 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 76.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 77 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 77.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 78 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 78.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 79 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 79.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 80 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 80.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 81 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 81.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 82 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 82.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 83 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 83.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 84 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 84.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 85 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 85.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 86 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 86.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 87 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 87.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 88 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 88.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 89 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 89.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 90 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 90.
  • the complex for use according to the present invention comprises or consists of an amino acid sequence according to SEQ ID NO: 91 or of an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with SEQ ID NO: 91.
  • the complex for use according to the present invention comprises or consists of a polypeptide having an amino acid sequence according to SEQ ID NO: 89, or a functional sequence variant thereof having at least 50% sequence identity (preferably at least 60%, more preferably at least 70%, more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95% and most preferably at least 98% or 99% sequence identity).
  • SEQ ID NO: 26 MHHHHHHNID RPKGLAFTDV DVDSIKIAWE SPQGQVSRYR VTYSSPEDGI RELFPAPDGEDDTAELQGLR PGSEYTVSVV ALHDDMESQP LIGIQSTKRY KNRVASRKSR AKFKQLLQHY REVAAAKSSE NDRLRLLLKE SLKISQAVHA AHAEINEAGR EVVGVGALKV PRNQDWLGVP RFAKFASFEA QGALANIAVD KANLDVEQLE SIINFEKLTE WTGS SEQ ID NO: 27: MHHHHHHSTV HEILCKLSLE GDHSTPPSAY GSVKPYTNFD AEKRYKNRVA SRKSRAKFKQ LLQHYREVAA AKSSENDRLR LLLKESLKIS QAVHAAHAEI NEAGREVVGV GALKVPRNQD WLGVPRFAKF ASFEAQGALA NIAVDKANLD VEQLESIINF EKL
  • the complex for use according to the present invention comprises (or consists of) the following components:
  • the present invention also provides a complex comprising:
  • Preferred embodiments of such a complex according to the present invention correspond to preferred embodiments of the complex for use according to the present invention as described above.
  • the complex according to the present invention preferably comprises a peptide having an amino acid sequence according to SEQ ID NO: 52, or a fragment thereof having a length of at least 10 amino acids, or a functional sequence variant thereof having at least 70% sequence identity, as described above. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 53. Even more preferably, the complex the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 95 or a functional sequence variant thereof having at least 70% sequence identity, as described above.
  • the complex according to the present invention preferably comprises a peptide having an amino acid sequence according to SEQ ID NO: 54, or a fragment thereof having a length of at least 10 amino acids, or a functional sequence variant thereof having at least 70% sequence identity, as described above. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 55 and/or a peptide having an amino acid sequence according to SEQ ID NO: 56. Even more preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 96 or a functional sequence variant thereof having at least 70% sequence identity, as described above.
  • the complex according to the present invention preferably comprises a peptide having an amino acid sequence according to SEQ ID NO: 92, or a fragment thereof having a length of at least 10 amino acids, or a functional sequence variant thereof having at least 70% sequence identity, as described above. More preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 93 and/or a peptide having an amino acid sequence according to SEQ ID NO: 94. Even more preferably, the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 97 or a functional sequence variant thereof having at least 70% sequence identity, as described above.
  • the complex comprises in N- to C-terminal direction:
  • the complex comprises in N- to C-terminal direction:
  • the C-terminus of (i) the peptide having an amino acid sequence according to SEQ ID NO: 54 or the fragment or variant thereof as described above is directly linked to the N-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 52 or the fragment or variant thereof as described above; and the C-terminus of (ii) the peptide having an amino acid sequence according to SEQ ID NO: 52 or the fragment or variant thereof as described above is directly linked to the N-terminus of (iii) the peptide having an amino acid sequence according to SEQ ID NO: 92 or the fragment or variant thereof as described above.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 96 or a functional sequence variant thereof having at least 70% sequence identity as described above; a peptide having an amino acid sequence according to SEQ ID NO: 95 or a functional sequence variant thereof having at least 70% sequence identity as described above; and a peptide having an amino acid sequence according to SEQ ID NO: 97 or a functional sequence variant thereof having at least 70% sequence identity as described above.
  • the complex comprises a peptide having an amino acid sequence according to SEQ ID NO: 98 or a functional sequence variant thereof having at least 70% sequence identity as described above.
  • the complex is a recombinant polypeptide or a recombinant protein as described above.
  • the cell penetrating peptide of the complex according to the present invention preferably corresponds to the cell penetrating peptide of the complex for use according to the present invention as described above. This applies in particular to preferred embodiments of the cell penetrating peptide.
  • the TLR peptide agonist of the complex according to the present invention preferably corresponds to the TLR peptide agonist of the complex for use according to the present invention as described above. This applies in particular to preferred embodiments of the TSR peptide agonist.
  • the complex according to the present invention comprises preferably in N- to C-terminal direction, the following components, as described above:
  • the complex comprises or consists of a polypeptide having an amino acid sequence according to SEQ ID NO: 89, or a functional sequence variant thereof having at least 50% sequence (preferably at least 60%, more preferably at least 70%, more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95% and most preferably at least 98% or 99% sequence identity).
  • the complex according to the present invention may be used in the prevention and/or treatment of colorectal cancer as described herein.
  • the components a), b), and c) may be arranged in the complex for use according to the present invention in any way.
  • the more than one cell penetrating peptide may be positioned in a non-consecutive manner, i.e. at least one antigen or antigenic epitope (component b)) and/or at least one TLR peptide agonist (component c)) may interrupt a stretch of consecutively positioned cell penetrating peptides and/or the cell penetrating peptides may be positioned with component b) and/or with component c) in an alternating manner.
  • the more than one antigen or antigenic epitope may be positioned in a non-consecutive manner, i.e. at least one cell penetrating peptide (component a)) and/or at least one TLR peptide agonist (component c)) may interrupt a stretch of consecutively positioned antigens or antigenic epitopes and/or the antigens or antigenic epitopes may be positioned with component a) and/or with component c) in an alternating manner.
  • the more than one TLR peptide agonist may be positioned in a non-consecutive manner, i.e.
  • At least one cell penetrating peptide (component a)) and/or at least one antigen or antigenic epitope (component b)) may interrupt a stretch of consecutively positioned TLR peptide agonists and/or the TLR peptide agonists may be positioned with component a) and/or with component b) in an alternating manner.
  • the more than one cell penetrating peptide is positioned in the complex for use according to the present invention in a consecutive manner and/or the more than one antigen or antigenic epitope is positioned in the complex for use according to the present invention in a consecutive manner and/or the more than one TLR peptide agonist is positioned in the complex for use according to the present invention in a consecutive manner.
  • all single units of a certain component i.e. all cell penetrating peptides, all antigens or antigenic epitopes or all TLR peptide agonists, which are comprised by the complex are positioned in a stretch, which is not interrupted by any of the other two components.
  • the other two components are positioned in the complex for example before or after such a stretch of all single units of said certain component.
  • the single units of said certain component positioned consecutively in such a way may be linked to each other for example by a spacer or linker as described herein, which is not of the other two components.
  • each of the components a), b), and c) is positioned in a consecutive manner.
  • each component a), b), and c) typically comprises a single main chain and at least one side chain.
  • main chain also “backbone chain”
  • main chain refers to the main continuous chain of covalently bond atoms in a molecule.
  • main chain typically comprises alpha-carbon atoms and nitrogen atoms of the constituent amino acids linked by the peptide bond.
  • the backbone does not include the side chains.
  • side chain also “pendant chain”
  • side chains refers to a chemical group that is attached to a core part of the molecule called “main chain” or backbone.
  • the side chains typically represent the (main) parts of the constituent amino acids, which are attached to the alpha-carbon atoms of the backbone.
  • the components a), b), and c) may be covalently linked via a linker or spacer as described herein or they may be directly covalently linked.
  • a linker or spacer Independently of whether a spacer or linker is used for covalent linkage or not, there are in principle four options of how two of the three components are linked to each other in the complex for use according to the present invention, namely:
  • all three components a), b), and c) are linked via main-chain/main-chain linkage, thus resulting in particular in a main chain of the complex for use according to the present invention, which comprises the main chain of one or more cell penetrating peptide(s), the main chain of one or more antigen(s) or antigenic epitope(s), and the main chain of one or more TLR peptide agonist(s).
  • the main chain of one or more cell penetrating peptide(s), the main chain of one or more antigen(s) or antigenic epitope(s), and the main chain of one or more TLR peptide agonist(s) constitute the main chain of the complex for use according to the present invention, optionally together with further components, for example linker(s), spacer(s), etc.
  • the following arrangements of the components a), b), and c) are preferred, in particular if the at least one antigen or antigenic epitope is a peptide, polypeptide or protein, whereby said preferred arrangements are shown below in N-terminus ⁇ C-terminus direction of the main chain of the complex and wherein all three components a), b), and c) are linked via main-chain/main-chain linkage and may be optionally linked by a linker, a spacer or another additional component:
  • the at least one antigen or antigenic epitope is positioned C-terminally of the cell penetrating peptide, whereby the cell penetrating peptide and the at least one antigen or antigenic epitope are optionally linked by a further component, e.g. a linker, a spacer, or by the at least one TLR peptide agonist. Accordingly, this corresponds to the arrangements ( ⁇ ), ( ⁇ ), and ( ⁇ ) from the arrangements shown above, i.e. from the above arrangements arrangements ( ⁇ ), ( ⁇ ), and ( ⁇ ) are more preferred.
  • the at least one antigen or antigenic epitope is positioned C-terminally of the cell penetrating peptide, whereby the cell penetrating peptide and the at least one antigen or antigenic epitope are optionally linked by a further component, e.g. a linker, a spacer, but not by the at least one TLR peptide agonist. Accordingly, this corresponds to the arrangements ( ⁇ ) and ( ⁇ ) from the arrangements shown above, i.e. from the above arrangements arrangements ( ⁇ ) and ( ⁇ ) are even more preferred.
  • the complex for use according to the present invention is a recombinant polypeptide or a recombinant protein and the components a) to c) are positioned in N-terminus ⁇ C-terminus direction of the main chain of said complex in the order:
  • component a)-component b)-component c (a) component a)-component b)-component c); or ( ⁇ ) component c)-component a)-component b), wherein the components may be linked by a further component, in particular by a linker or a spacer.
  • the at least one TLR agonist comprises or consists of at least one TLR2 agonist, for example:
  • TLR2 peptide agonist may also be arranged at other positions in the complex, for example:
  • the at least one TLR agonist comprises or consists of at least one TLR4 agonist, for example:
  • TLR4 peptide agonist may also be arranged at other positions in the complex, for example:
  • components a) and b) are linked via main-chain/main-chain linkage, resulting thus in the following arrangements of the components a) and b) in the complex, shown in N-terminus ⁇ C-terminus direction of the main chain of the complex, whereby the components a) and b) may be optionally linked by a further component, e.g. a linker, a spacer etc.:
  • component c) i.e. the at least one TLR peptide agonist
  • component c may then be arranged via main-chain/side-chain linkage, via side-chain/main-chain linkage or via side-chain/side chain linkage to either the cell penetrating peptide (a) or to the antigen/antigenic epitope (b) or, if present, to an additional component like a spacer or linker, which may be, for example, positioned between the cell penetrating peptide (a) and the antigen/antigenic epitope (b).
  • components b) and c) are linked via main-chain/main-chain linkage, resulting thus in the following arrangements of the components b) and c) in the complex, shown in N-terminus ⁇ C-terminus direction of the main chain of the complex, whereby the components b) and c) may be optionally linked by a further component, e.g. a linker, a spacer etc.:
  • component a i.e. the cell penetrating peptide
  • component a may then be arranged via main-chain/side-chain linkage, via side-chain/main-chain linkage or via side-chain/side chain linkage to either the antigen/antigenic epitope (b) or to the TLR peptide agonist (c) or, if present, to an additional component like a spacer or linker, which may be, for example, positioned between the antigen/antigenic epitope (b) and the TLR peptide agonist (c).
  • component a) may be linked—optionally via a spacer or a linker—via side-chain/main-chain linkage to component c), i.e. the side chain the cell penetrating peptide is covalently linked—optionally via a spacer or a linker—to the main chain of the at least one TLR peptide agonist;
  • components a) and c) are linked via main-chain/main-chain linkage, resulting thus in the following arrangements of the components a) and b) in the complex, shown in N-terminus ⁇ C-terminus direction of the main chain of the complex, whereby the components a) and c) may be optionally linked by a further component, e.g. a linker, a spacer etc.:
  • component b i.e. the at least one antigen or antigenic epitope
  • component b may then be arranged via main-chain/side-chain linkage, via side-chain/main-chain linkage or via side-chain/side chain linkage to either the cell penetrating peptide (a) or to the TLR peptide agonist (c) or, if present, to an additional component like a spacer or linker, which may be, for example, positioned between the cell penetrating peptide (a) and the TLR peptide agonist (c).
  • the present invention provides the complex as described above for use in the prevention and/or treatment of colorectal cancer.
  • Colorectal cancer also known as “bowel cancer” is a cancer that comprises colon cancers and rectal cancers (CC). Both individual cancers have many features in common, but the cancer starting point. According to Siegel, R., C. Desantis, and A. Jemal, Colorectal cancer statistics, 2014. CA Cancer J Clin, 2014. 64(2): p. 104-17, in the United States between 2006 and 2010, the incidence by tumor site is slightly more important in the proximal colon (first and middle parts of the colon). With about 19 cases on 100,000 people, it represents 42% of the cases. It is followed by the rectal cancer, with 28% of the cases and the distal colon (bottom part of the colon) with an incidence of 10 cases on 100,000 people.
  • colonal cancer includes (i) cancers of colon, such as cancers of cecum (including cancers the ileocecal valve), appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon (including cancers of sigmoid (flexure)) as well as cancers of overlapping sites of colon; (ii) cancers of rectosigmoid junction, such as cancers of colon and rectum and cancers of rectosigmoid; and (iii) cancers of rectum, such as cancers of rectal ampulla.
  • cancers of colon such as cancers of cecum (including cancers the ileocecal valve), appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon (including cancers of sigmoid (flexure)) as well as cancers of overlapping sites of colon
  • cancers of rectosigmoid junction such as cancers
  • the colorectal cancer is a cancer of colon, such as a cancer of cecum (including cancer the ileocecal valve), cancer of appendix, cancer of ascending colon, cancer of hepatic flexure, cancer of transverse colon, cancer of splenic flexure, cancer of descending colon, cancer of sigmoid colon (including cancers of sigmoid (flexure)) or a combination thereof.
  • a cancer of cecum including cancer the ileocecal valve
  • cancer of appendix cancer of ascending colon
  • cancer of hepatic flexure cancer of transverse colon
  • cancer of splenic flexure cancer of descending colon
  • cancer of sigmoid colon including cancers of sigmoid (flexure)
  • the colorectal cancer is a cancer of rectosigmoid junction, such as (i) a cancer of colon and rectum or (ii) a cancer of rectosigmoid.
  • the colorectal cancer is a cancer of rectum, such as a cancer of rectal ampulla.
  • colorectal cancers include colorectal adenocarcinoma, colorectal stromal tumors, primary colorectal lymphoma, colorectal leiomyosarcoma, colorectal melanoma, colorectal squamous cell carcinoma and colorectal carcinoid tumors, such as, for example, carcinoid tumors of cecum, appendix, ascending colon, transverse colon, descending colon, sigmoid colon and/or rectum.
  • colorectal cancers include colorectal adenocarcinoma, colorectal stromal tumors, primary colorectal lymphoma, colorectal leiomyosarcoma, colorectal melanoma, colorectal squamous cell carcinoma and colorectal carcinoid tumors, such as, for example, carcinoid tumors of cecum, appendix, ascending colon, transverse colon, descending colon, sigmoid colon and/or rectum. More preferably, the colorectal cancer is a colorectal adenocarcinoma or a colorectal carcinoid carcinoma. Even more preferably, the colorectal cancer is a colorectal adenocarcinoma.
  • CRCs More than 95% of CRCs are adenocarcinomas.
  • Colorectal adenocarcinomas typically start from glandular cells that make mucus to lubricate the colon or rectum.
  • CRC typically starts in the innermost layer and can grow through some or all of the other layers. In rare cases, CRC could form in a polyp, which facilitates its growth into the wall of starting region. In advanced stage (stage III and IV), the cancer travels to nearby lymph nodes or to distant parts of the body through blood vessels.
  • the TNM staging system includes the following stages for primary tumors (“T” stages): TX—Primary tumour cannot be assessed, T0—No evidence of primary tumour, Ta—Non-invasive papillary carcinoma, Tis—Carcinoma in situ: intraepithelial or invasion of lamina basement, T1—Tumour invades submucosa, T2—Tumour invades muscularis basement, T3—Tumour invades through the muscularis basement into the horrorectal tissues, T4a—Tumour penetrates to the surface of the visceral peritoneum and T4b—Tumour directly invades or is adherent to other organs or structures; following stages for lymph nodes (“N” stages): NX—Regional lymph nodes cannot be assessed, N0—No regional lymph node metastasis, N1—Metastasis in 1-3 regional lymph nodes with N1a—Metastasis in 1 regional lymph node, N1b—Metastasis in 2-3 regional lymph no
  • Stage 0 T1s, N0, M0; Stage I: T1, N0, M0 or T2, N0, M0; Stage IIA: T3, N0, M0; Stage IIB: T4a, N0, M0; Stage 11C: T4b, N0, M0; Stage IIIA: T1-T2, N1/N1c, M0 or T1, N2a, M0; Stage IIIB: T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0; Stage IIIC: T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, N1-N2, M0; Stage IVA: any T, any N, M1a and Stage IVB: any T, any N, M1b.
  • Stage 0 the cancer has not grown beyond the inner layer of the colon or rectum; in Stage I the cancer has spread from the mucosa to the muscle layer; in Stage II the cancer has spread through the muscle layer to the serosa nearby organs; in Stage III the cancer has spread to nearby lymph node(s) or cancer cells have spread to tissues near the lymph nodes; and in Stage IV the cancer has spread through the blood and lymph nodes to other parts of the body.
  • colorectal cancer includes all numerical stages as described above, and, thus, a preferred stage of colorectal cancer may be selected from the group consisting of Stage 0 (Tis, N0, M0), Stage I (T1, N0, M0 or T2, N0, M0), Stage IIA (T3, N0, M0), Stage IIB (T4a, N0, M0), Stage IIC (T4b, N0, M0), Stage IIIA (T1-T2, N1/N1c, M0 or T1, N2a, M0), Stage IIIB (T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0), Stage IIIC (T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, N1-N2, M0), Stage IVA (any T, any N, M1a) and Stage IVB (any T, any N, M1b
  • the colorectal cancer is selected from the group consisting of Stage I (T1, N0, M0 or T2, N0, M0), Stage HA (T3, N0, M0), Stage IIB (T4a, N0, M0), Stage IIC (T4b, N0, M0), Stage IIIA (T1-T2, N1/N1c, M0 or T1, N2a, M0), Stage IIIB (T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0), Stage 111C (T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, N1-N2, M0), Stage IVA (any T, any N, M1a) and Stage IVB (any T, any N, M1b).
  • Stage IVA any T, any N, M1a
  • Stage IVB any T, any N, M1b
  • the colorectal cancer is selected from the group consisting of Stage IIA (T3, N0, M0), Stage IIB (T4a, N0, M0), Stage IIC (T4b, N0, M0), Stage IIIA (T1-T2, N1/N1c, M0 or T1, N2a, M0), Stage IIIB (T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0), Stage IIIC (T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, N1-N2, M0), Stage IVA (any T, any N, M1a) and Stage IVB (any T, any N, M1b).
  • Stage IIA T3, N0, M0
  • Stage IIB T4a, N0, M0
  • Stage IIC T4b, N0, M0
  • Stage IIIA T1-T2, N1/N1c, M0 or T
  • the colorectal cancer is (i) Stage III colorectal cancer, such as Stage IIIA (T1-T2, N1/N1c, M0 or T1, N2a, M0), Stage IIIB (T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b, M0), or Stage IIIC (T4a, N2a, M0 or T3-T4a, N2b, M0 or T4b, N1-N2, M0), or (ii) Stage IV colorectal cancer, such as Stage IVA (any T, any N, M1a) and Stage IVB (any T, any N, M1b).
  • Stage III colorectal cancer such as Stage IIIA (T1-T2, N1/N1c, M0 or T1, N2a, M0), Stage IIIB (T3-T4a, N1/N1c, M0 or T2-T3, N2a, M0 or T1-T2, N2b,
  • the present invention provides a nucleic acid, in particular a nucleic acid molecule, encoding the complex as described herein, wherein the complex is a polypeptide or a protein, for use in the prevention and/or treatment of colorectal cancer.
  • the present invention provides polynucleotides for use in the prevention and/or treatment of colorectal cancer, said polynucleotides encoding the complex as defined above.
  • the present invention in particular provides a nucleic acid, in particular a nucleic acid molecule, comprising a polynucleotide, wherein the polynucleotide encodes the complex as described herein and wherein the complex is a polypeptide or a protein, for use in the prevention and/or treatment of colorectal cancer.
  • the present invention also provides a nucleic acid, in particular a nucleic acid molecule, encoding the complex according to the present invention as described above, wherein the complex is a polypeptide or a protein.
  • the present invention provides polynucleotides encoding the complex as defined above.
  • the present invention in particular provides a nucleic acid, in particular a nucleic acid molecule, comprising a polynucleotide, wherein the polynucleotide encodes the complex according to the present invention as described herein and wherein the complex is a polypeptide or a protein.
  • a nucleic acid may be used in the prevention and/or treatment of colorectal cancer.
  • Nucleic acids preferably comprise single stranded, double stranded or partially double stranded nucleic acids, preferably selected from genomic DNA, cDNA, RNA, siRNA, antisense DNA, antisense RNA, ribozyme, complimentary RNA/DNA sequences with or without expression elements, a mini-gene, gene fragments, regulatory elements, promoters, and combinations thereof.
  • nucleic acid (molecules) and/or polynucleotides include, e.g., a recombinant polynucleotide, a vector, an oligonucleotide, an RNA molecule such as an rRNA, an mRNA, an miRNA, an siRNA, or a tRNA, or a DNA molecule as described above.
  • the nucleic acid (molecule) is a DNA molecule or an RNA molecule; preferably selected from genomic DNA; cDNA; siRNA; rRNA; mRNA; antisense DNA; antisense RNA; ribozyme; complimentary RNA and/or DNA sequences; RNA and/or DNA sequences with or without expression elements, regulatory elements, and/or promoters; a vector; and combinations thereof.
  • the invention relates to a nucleic acid (for use) according to the present invention, said nucleic acid encoding a complex, which is in particular a polypeptide or protein, said complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, which is a polypeptide or protein, and at least one TLR peptide agonist, wherein the cell penetrating peptide, the at least one antigen or antigenic epitope, and the at least one TLR peptide agonist are covalently linked, optionally with peptidic spacer(s) or linker(s) as described herein.
  • a complex which is in particular a polypeptide or protein
  • said complex comprising a cell penetrating peptide, at least one antigen or antigenic epitope, which is a polypeptide or protein, and at least one TLR peptide agonist, wherein the cell penetrating peptide, the at least one antigen or antigenic epitope, and the at
  • the more than one antigen or antigenic epitope which is a polypeptide or protein, is comprised by said complex, the more than one antigens or antigenic epitopes are also covalently linked, optionally with peptidic spacer(s) or linker(s) as described herein.
  • the more than one TLR peptide agonist is comprised by said complex, the more than one TLR peptide agonists are also covalently linked, optionally with peptidic spacer(s) or linker(s) as described herein.
  • the nucleic acid (for use) according to the present invention encodes a complex which is a (recombinant) fusion protein comprising (a) a cell penetrating peptide as described above, (b) at least one, preferably at least two, more preferably at least three, even more preferably at least four, particularly preferably at least five, most preferably at least six antigens or antigenic epitopes as described above, preferably arranged in a consecutive manner as described above and (c) at least one TLR agonist as described above.
  • a complex which is a (recombinant) fusion protein comprising (a) a cell penetrating peptide as described above, (b) at least one, preferably at least two, more preferably at least three, even more preferably at least four, particularly preferably at least five, most preferably at least six antigens or antigenic epitopes as described above, preferably arranged in a consecutive manner as described above and (c) at least one TLR agonist as described above.
  • the nucleic acid (molecule) encodes an exemplified complex as described herein or a functional sequence variant thereof. Accordingly, the nucleic acid (molecule) most preferably comprises a polynucleotide encoding an amino acid sequence according to any of SEQ ID NOs: 26-28, 33-34, 37-41, 46, 69, or 72-87 or an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NOs: 26-28, 33-34, 37-41, 46, 69, or 72-87.
  • the nucleic acid (molecule) most preferably comprises a polynucleotide encoding an amino acid sequence according to any of SEQ ID NOs: 26-28, 33-34, 37-41, 46, 69, or 72-91 or an amino acid sequence sharing at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% sequence identity with any of SEQ ID NOs: 26-28, 33-34, 37-41, 46, 69, or 72-91.
  • the nucleic acid (molecule) according to the present invention comprises a polynucleotide encoding an amino acid sequence according to SEQ ID NO: 89, or a functional sequence variant thereof having at least 50% sequence identity (preferably at least 60%, more preferably at least 70%, more preferably at least 75%, even more preferably at least 80%, even more preferably at least 85%, still more preferably at least 90%, particularly preferably at least 95% and most preferably at least 98% or 99% sequence identity).
  • the present invention provides a vector, preferably for use in the prevention and/or treatment of colorectal cancer, in particular a recombinant vector, comprising a nucleic acid as described above.
  • vector refers to a nucleic acid molecule, preferably to an artificial nucleic acid molecule, i.e. a nucleic acid molecule which does not occur in nature.
  • a vector in the context of the present invention is suitable for incorporating or harboring a desired nucleic acid sequence.
  • Such vectors may be storage vectors, expression vectors, cloning vectors, transfer vectors etc.
  • a storage vector is a vector which allows the convenient storage of a nucleic acid molecule.
  • the vector may comprise a sequence corresponding, e.g., to a desired complex according to the present invention.
  • An expression vector may be used for production of expression products such as RNA, e.g.
  • an expression vector may comprise sequences needed for transcription of a sequence stretch of the vector, such as a promoter sequence.
  • a cloning vector is typically a vector that contains a cloning site, which may be used to incorporate nucleic acid sequences into the vector.
  • a cloning vector may be, e.g., a plasmid vector or a bacteriophage vector.
  • a transfer vector may be a vector which is suitable for transferring nucleic acid molecules into cells or organisms, for example, viral vectors.
  • a vector in the context of the present invention may be, e.g., an RNA vector or a DNA vector.
  • a vector is a DNA molecule.
  • a vector in the sense of the present application comprises a cloning site, a selection marker, such as an antibiotic resistance factor, and a sequence suitable for multiplication of the vector, such as an origin of replication.
  • a vector in the context of the present application is a plasmid vector.
  • a vector in the context of the present application is an expression vector.
  • Cells transformed with a vector as described above, preferably for use in the prevention and/or treatment of colorectal cancer, are also included within the scope of the invention.
  • examples of such cells include, but are not limited to, bacterial cells, e.g. E. coli , and eukaryotic cells, e.g., yeast cells, animal cells or plant cells.
  • the cells are mammalian, e.g., human, CHO, HEK293T, PER.C6, NS0, myeloma or hybridoma cells.
  • the present invention also relates to a cell expressing the complex (for use) according to the present invention; or comprising the vector (for use) according to the present invention.
  • a cell may be transfected with a vector as described above, preferably with an expression vector.
  • transfection refers to the introduction of nucleic acid molecules, such as DNA or RNA (e.g. mRNA) molecules, into cells, preferably into eukaryotic cells.
  • RNA e.g. mRNA
  • transfection encompasses any method known to the skilled person for introducing nucleic acid molecules into cells, preferably into eukaryotic cells, such as into mammalian cells. Such methods encompass, for example, electroporation, lipofection, e.g.
  • the introduction is non-viral.
  • chromosomes can be used, including without limitation chromosomes, episomes, and derived viruses.
  • the vector as described above, in particular the recombinant vector used can be derived from bacterial plasmids, transposons, yeast episomes, insertion elements, yeast chromosome elements, viruses such as baculovirus, papilloma viruses such as SV40, vaccinia viruses, adenoviruses, fox pox viruses, pseudorabies viruses, retroviruses.
  • such vectors in particular recombinant vectors, can equally be cosmid or phagemid derivatives.
  • the nucleotide sequence in particular the nucleic acid according to the present invention, may be inserted in the recombinant expression vector by methods well known to a person skilled in the art such as, for example, those described in MOLECULAR CLONING: A LABORATORY MANUAL, Sambrook et al., 4th Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001.
  • the vector in particular the recombinant vector, may also include nucleotide sequences that control the regulation of the expression, in particular of the nucleic acid (for use) according to the present invention, as well as nucleotide sequences permitting the expression, the transcription, and the translation, in particular of the nucleic acid (for use) according to the present invention. Typically, these sequences are selected according to the host cells used.
  • an appropriate secretion signal can be integrated in the vector (for use) according to the present invention, in particular in a recombinant vector, so that the polypeptide or protein encoded by the nucleic acid (for use) according to the present invention, will be directed, for example towards the lumen of the endoplasmic reticulum, towards the periplasmic space, on the membrane or towards the extracellular environment.
  • the choice of an appropriate secretion signal may facilitate subsequent protein purification.
  • the present invention provides a host cell. preferably for use in the prevention and/or treatment of colorectal cancer, the host cell comprising a vector, in particular a recombinant vector, as described herein.
  • the introduction of the vector, in particular the recombinant vector, into a host cell can be carried out according to methods that are well known to a person skilled in the art, such as those described in BASIC METHODS IN MOLECULAR BIOLOGY, Davis et al., 2nd ed., McGraw-Hill Professional Publishing, 1995, and MOLECULAR CLONING: A LABORATORY MANUAL, supra, including for example transfection as described above, e.g. by calcium phosphate, by DEAE dextran, or by cationic lipids; microinjection, electroporation, transduction or infection.
  • the host cell can be, for example, bacterial cells such as E. coli , cells of fungi such as yeast cells and cells of Aspergillus, Streptomyces , insect cells, and/or any cell line, e.g. Chinese Hamster Ovary cells (CHO), C127 mouse cell line, BHK cell line of Syrian hamster cells, Human Embryonic Kidney 293 (HEK 293) cells.
  • the host cell (for use) according to the present invention is mammalian, e.g., human, CHO, HEK293T, PER.C6, NS0, myeloma or hybridoma cells.
  • Dendritic cells and dendritic cell lines are particularly preferred as a host cell.
  • the choice of a culture medium depends in particular on the choice of the cell type and/or the cell line, whereby the skilled person is aware of suitable culture media, which are appropriate for a selected cell type and/or cell line.
  • the host cells can be used, for example, to express a polypeptide or protein, in particular the complex (for use) according to the present invention, on the basis of the vector and/or the nucleic acid as described herein. After purification by standard methods, the expressed polypeptide or protein, in particular the complex (for use) according to the present invention, can be used as described herein.
  • the present invention also provides a method for preparing the complex as defined herein, in particular wherein the complex is a polypeptide or protein. Said method comprises the steps of:
  • the complex obtained by such a method according to the present invention is preferably a complex (for use) according to the present invention as described herein.
  • kits and/or reagents may be used, for example BugBusterTM from Novagen.
  • the method for preparing the complex as defined herein further comprises the following step:
  • the method for preparing the complex as defined herein further comprises the following step:
  • the complex as defined herein may also be prepared by synthetic chemistry methods, for example by solid-phase peptide synthesis.
  • Purification of those peptides or proteins may be carried out by means of any technique known in the art for protein/peptide purification.
  • Exemplary techniques include ion-exchange chromatography, hydrophobic interaction chromatography, and immunoaffinity methods.
  • the present invention also provides a method for preparing the complex as defined herein comprising the steps of:
  • the complex chemically synthesized in step (i) and purified in step (ii) comprises an amino acid sequences as described herein for a cell penetrating peptide, an amino acid sequence as described herein for a TLR peptide agonist, and, optionally if the at least one antigen and/or antigenic epitope is a peptide or a protein, an amino acid sequence as described herein for an antigen or antigenic epitope.
  • the present invention also provides a method for preparing the complex as defined herein, wherein
  • the present invention relates to a cell loaded with the complex as defined herein, preferably for use in the prevention and/or treatment of colorectal cancer.
  • the cells loaded with the complex as defined herein are cells from a subject to be treated, in particular isolated cells from a subject to be treated, i.e. cells isolated from a subject to be treated.
  • the term “subject” refers in particular to mammals.
  • mammals contemplated by the present invention include human, primates, domesticated animals such as cattle, sheep, pigs, horses, laboratory rodents and the like. More preferably, the term “subject” refers to a human subject.
  • treatment and “treating” and the like generally mean obtaining a desired pharmacological and physiological effect.
  • the effect may be prophylactic in terms of preventing or partially preventing a disease, a symptom or a condition thereof and/or may be therapeutic in terms of a partial or complete cure of a disease, a condition, a symptom or an adverse effect attributed to the disease.
  • treatment covers any treatment of a disease in a mammal, in particular in a human, and includes: (a) preventing the disease from occurring in a subject who may be predisposed to the disease but the outbreak of the disease has not yet occurred and/or the disease has not yet been diagnosed in this subject, for example a preventive early asymptomatic intervention; (b) inhibiting the disease, i.e., arresting or slowing down its development; or (c) relieving the disease, i.e., causing an at least partial regression of the disease and/or of at least one of its symptoms or conditions such as improvement or remediation of damage.
  • prevention of a disease or disorder includes the prevention of the appearance or development of a cancer in an individual identified as at risk of developing said cancer, for instance due to past occurrence of said cancer in the circle of the individual's relatives, and prevention of infection with tumor promoting pathogens such as, for example, Epstein-Barr virus (EBV), Human papillomavirus (HPV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpes virus 8 (HHV8), human T-cell leukemia virus type 1 (HTLV-1), Merkel cell polyomavirus (MCV) and Helicobacter pylori .
  • prevention/treatment of a cancer is the stabilization or delay of an already diagnosed cancer in an individual
  • the cell loaded with the complex as defined herein is an antigen-presenting cell (APC).
  • the antigen presenting cell is selected from the group consisting of a dendritic cell (DC), a macrophage and a B-cell.
  • DC dendritic cell
  • B-cell dendritic cells, in particular dendritic cells (conventional and/or plasmacytoid) isolated from a subject to be treated, are more preferred.
  • antigen-presenting cells in particular dendritic cells
  • methods to isolate antigen-presenting cells, in particular dendritic cells, from a subject include harvesting monocytes or hematopoietic stem cells from bone marrow, cord blood, or peripheral blood. They also include the use of embryonic stem (ES) cells and induced pluripotent stem cells (iPS).
  • ES embryonic stem
  • iPS induced pluripotent stem cells
  • Antigen presenting cells, in particular dendritic cells or their precursors can be enriched by methods including elutriation and magnetic bead based separation, which may involve enrichment for CD14 + precursor cells.
  • Methods to load the complex as defined herein into the cells preferably into the above-mentioned antigen presenting cells, more preferably into dendritic cells, and further to prepare such cells before administration to a subject are known to one skilled in the art.
  • preparation of dendritic cells can include their culture or differentiation using cytokines that may include for example GM-CSF and IL-4.
  • Dendritic cell lines may also be employed.
  • Loading of the complex of the invention into the cells, preferably into APC, more preferably into the dendritic cells can involve co-incubation of the complex of the invention with the cells in culture, making use of the intrinsic properties of the cell penetrating peptide comprised by the complex as defined herein (i.e.
  • Further culture of the cells, e.g. the dendritic cells, thus loaded to induce efficient maturation can include addition of cytokines including IL-1 ⁇ , IL-6, TNF ⁇ , PGE2, IFN ⁇ , and adjuvants which may include poly-IC, poly-ICLC (i.e. a synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA), and further TLR agonists and NLR (nucleotide-binding oligomerization domain-like receptors) agonists.
  • cytokines including IL-1 ⁇ , IL-6, TNF ⁇ , PGE2, IFN ⁇
  • adjuvants which may include poly-IC, poly-ICLC (i.e. a synthetic complex of carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA), and further TLR agonists and NLR
  • a method for preparing cells, in particular antigen presenting cells, loaded with the complex as defined herein may comprise the steps of:
  • the cells are loaded with a complex as defined herein, wherein the complex is a polypeptide or a protein and used in the prevention and/or treatment of colorectal cancer.
  • the complex is a polypeptide or a protein and used in the prevention and/or treatment of colorectal cancer.
  • the cells loaded with a complex(es) according as defined herein and used in the prevention and/or treatment of colorectal cancer present the at least one antigen or antigenic epitope comprised by said complex at the cell surface in an MHC class I context and/or in an MHC class II context.
  • the invention provides a composition, preferably for use in the prevention and/or treatment of colorectal cancer, the composition comprising at least one component selected from:
  • composition according to the present invention comprises the complex as defined herein.
  • composition (for use) according to the present invention may also comprises more than one of the above components (i) to (v).
  • the composition (for use) according to the present invention may comprise at least two different complexes under (i), at least two different nucleic acids under (ii), at least two different vectors under (iii), at least two different host cells under (iv), and/or at least two different cells under (v); e.g., the composition (for use) according to the invention may comprise at least two different complexes (i) and/or at least two different nucleic acids (ii).
  • the different complexes (i) comprised by the composition as described above may differ in either component a), i.e. in the cell penetrating peptides, in component b), i.e. in the antigens or antigenic epitopes or in the subsets of more than one antigen or antigenic epitope, or in component c), i.e.
  • the different complexes (i) comprised by the composition as described above may differ in two out of the three components a), b), and c); or the different complexes (i) comprised by the composition as described above may differ in all three components a), b), and c) of the complex.
  • the different nucleic acids (ii) comprised by the composition as described above may differ in that they encode such different complexes; the different vectors (iii) comprised by the composition as described above may differ in that they comprise such different nucleic acids; the different host cells (iv) comprised by the composition as described above may differ in that they comprise such different vectors; and the different cells loaded with a complex (v) comprised by the composition as described above may differ in that they are loaded with such different complexes.
  • the present invention also provides a vaccine, preferably for use in the prevention and/or treatment of colorectal cancer, the vaccine comprising at least one component selected from:
  • the vaccine (for use) according to the present invention comprises the complex as defined herein.
  • composition (for use) according to the present invention regarding more than one of the components (i) to (v), also apply for the vaccine (for use) according to the present invention.
  • the term “vaccine” refers to a biological preparation that provides innate and/or adaptive immunity, typically to a particular disease, preferably cancer.
  • a vaccine supports in particular an innate and/or an adaptive immune response of the immune system of a subject to be treated.
  • the antigen or antigenic epitope of the complex as defined herein typically leads to or supports an adaptive immune response in the patient to be treated, and the TLR peptide agonist of the complex as defined herein may lead to or support an innate immune response.
  • inventive composition in particular the inventive vaccine, may also comprise a pharmaceutically acceptable carrier, adjuvant, and/or vehicle as defined below for the inventive pharmaceutical composition.
  • a pharmaceutically acceptable carrier in the specific context of the inventive composition, in particular of the inventive vaccine, the choice of a pharmaceutically acceptable carrier is determined in principle by the manner in which the inventive composition, in particular the inventive vaccine, is administered.
  • inventive composition, in particular the inventive vaccine can be administered, for example, systemically or locally.
  • Routes for systemic administration in general include, for example, transdermal, oral, parenteral routes, including subcutaneous, intravenous, intramuscular, intraarterial, intradermal and intraperitoneal injections and/or intranasal administration routes.
  • inventive compositions for local administration in general include, for example, topical administration routes but also intradermal, transdermal, subcutaneous, or intramuscular injections or intralesional, intracranial, intrapulmonal, intracardial, intranodal and sublingual injections.
  • inventive composition, in particular the vaccines may be administered by an intradermal, subcutaneous, intranodal or intramuscular route.
  • inventive composition, in particular the vaccine may be administered by subcutaneous, intranodal or intramuscular route.
  • the inventive composition, in particular the vaccines may be administered by subcutaneous or intranodal route.
  • the inventive composition, in particular the vaccines may be administered by subcutaneous route.
  • inventive composition, in particular the inventive vaccines are therefore preferably formulated in liquid (or sometimes in solid) form.
  • the suitable amount of the inventive composition, in particular the inventive vaccine, to be administered can be determined by routine experiments with animal models. Such models include, without implying any limitation, rabbit, sheep, mouse, rat, dog and non-human primate models.
  • Preferred unit dose forms for injection include sterile solutions of water, physiological saline or mixtures thereof. The pH of such solutions should be adjusted to about 7.4.
  • Suitable carriers for injection include hydrogels, devices for controlled or delayed release, polylactic acid and collagen matrices.
  • Suitable pharmaceutically acceptable carriers for topical application include those which are suitable for use in lotions, creams, gels and the like. If the inventive composition, in particular the inventive vaccine, is to be administered orally, tablets, capsules and the like are the preferred unit dose form.
  • the pharmaceutically acceptable carriers for the preparation of unit dose forms which can be used for oral administration are well known in the prior art. The choice thereof will depend on secondary considerations such as taste, costs and storability, which are not critical for the purposes of the present invention, and can be made without difficulty by a person skilled in the art.
  • inventive composition in particular the inventive vaccine, can additionally contain one or more auxiliary substances in order to further increase its immunogenicity.
  • various mechanisms can come into consideration in this respect. For example, compounds that permit the maturation of dendritic cells (DCs), for example lipopolysaccharides, TNF-alpha or CD40 ligand, form a first class of suitable auxiliary substances.
  • DCs dendritic cells
  • TNF-alpha or CD40 ligand form a first class of suitable auxiliary substances.
  • auxiliary substance any agent that influences the immune system in the manner of a “danger signal” (LPS, GP96, etc.) or cytokines, such as GM-CSF, which allow an immune response produced by the immune-stimulating adjuvant according to the invention to be enhanced and/or influenced in a targeted manner.
  • a “danger signal” LPS, GP96, etc.
  • cytokines such as GM-CSF
  • auxiliary substances are cytokines, such as monokines, lymphokines, interleukins or chemokines, that further promote the innate immune response, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IFN-alpha, IFN-beta, IFN-gamma, GM-CSF, G-CSF, M-CSF, LT-beta or TNF-alpha, growth factors, such as hGH.
  • cytokines such as monokines, lymphokines, interleukins
  • emulsifiers such as, for example, Tween®
  • wetting agents such as, for example, sodium lauryl sulfate
  • colouring agents such as, for example, sodium lauryl sulfate
  • taste-imparting agents pharmaceutical carriers
  • tablet-forming agents such as, for example, stabilizers; antioxidants; preservatives.
  • inventive composition in particular the inventive vaccine, can also additionally contain any further compound, which is known to be immune-stimulating due to its binding affinity (as ligands) to human Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, or due to its binding affinity (as ligands) to murine Toll-like receptors TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12 or TLR13.
  • binding affinity as ligands
  • CpG nucleic acids in particular CpG-RNA or CpG-DNA.
  • a CpG-RNA or CpG-DNA can be a single-stranded CpG-DNA (ss CpG-DNA), a double-stranded CpG-DNA (dsDNA), a single-stranded CpG-RNA (ss CpG-RNA) or a double-stranded CpG-RNA (ds CpG-RNA).
  • the CpG nucleic acid is preferably in the form of CpG-RNA, more preferably in the form of single-stranded CpG-RNA (ss CpG-RNA).
  • the CpG nucleic acid preferably contains at least one or more (mitogenic) cytosine/guanine dinucleotide sequence(s) (CpG motif(s)).
  • CpG motif(s) cytosine/guanine dinucleotide sequence(s)
  • at least one CpG motif contained in these sequences in particular the C (cytosine) and the G (guanine) of the CpG motif, is unmethylated. All further cytosines or guanines optionally contained in these sequences can be either methylated or unmethylated.
  • the C (cytosine) and the G (guanine) of the CpG motif can also be present in methylated form.
  • the present invention also provides a pharmaceutical composition, preferably for use in the prevention and/or treatment of colorectal cancer, in particular a vaccine composition as described above, and a method for treating a subject, preferably a mammalian subject, and most preferably a human subject, who is suffering from colorectal cancer.
  • the present invention provides a pharmaceutical composition (for use) in the prevention and/or treatment of colorectal cancer comprising at least one complex as defined herein or at least one cell loaded with a complex as defined herein, and optionally a pharmaceutically acceptable carrier and/or vehicle, or any excipient, buffer, stabilizer or other materials well known to those skilled in the art, in particular the pharmaceutical composition comprising at least one complex as defined herein or at least one cell loaded with a complex as defined herein and a pharmaceutically acceptable carrier.
  • the inventive pharmaceutical composition may in particular comprise a pharmaceutically acceptable carrier and/or vehicle.
  • a pharmaceutically acceptable carrier typically includes the liquid or non-liquid basis of the inventive pharmaceutical composition. If the inventive pharmaceutical composition is provided in liquid form, the carrier will typically be pyrogen-free water; isotonic saline or buffered (aqueous) solutions, e.g phosphate, citrate etc. buffered solutions.
  • water or preferably a buffer preferably an aqueous buffer
  • a sodium salt preferably at least 30 mM of a sodium salt
  • a calcium salt preferably at least 0.05 mM of a calcium salt
  • optionally a potassium salt preferably at least 1 mM of a potassium salt.
  • the sodium, calcium and, optionally, potassium salts may occur in the form of their halogenides, e.g. chlorides, iodides, or bromides, in the form of their hydroxides, carbonates, hydrogen carbonates, or sulfates, etc.
  • examples of sodium salts include e.g.
  • examples of the optional potassium salts include e.g. KCl, KI, KBr, K 2 CO 3 , KHCO 3 , K 2 SO 4
  • examples of calcium salts include e.g. CaCl 2 , CaI 2 , CaBr 2 , CaCO 3 , CaSO 4 , Ca(OH) 2 .
  • organic anions of the aforementioned cations may be contained in the buffer.
  • the buffer suitable for injection purposes as defined above may contain salts selected from sodium chloride (NaCl), calcium chloride (CaCl 2 ) and optionally potassium chloride (KCl), wherein further anions may be present additional to the chlorides.
  • CaCl 2 can also be replaced by another salt like KCl.
  • the salts in the injection buffer are present in a concentration of at least 30 mM sodium chloride (NaCl), at least 1 mM potassium chloride (KCl) and at least 0.05 mM calcium chloride (CaCl 2 ).
  • the injection buffer may be hypertonic, isotonic or hypotonic with reference to the specific reference medium, i.e.
  • the buffer may have a higher, identical or lower salt content with reference to the specific reference medium, wherein preferably such concentrations of the afore mentioned salts may be used, which do not lead to damage of cells due to osmosis or other concentration effects.
  • Reference media are e.g. liquids occurring in “in vivo” methods, such as blood, lymph, cytosolic liquids, or other body liquids, or e.g. liquids, which may be used as reference media in “in vitro” methods, such as common buffers or liquids.
  • Such common buffers or liquids are known to a skilled person. Saline (0.9% NaCl) and Ringer-Lactate solution are particularly preferred as a liquid basis.
  • the (pharmaceutical) composition which comprises the complex as described herein, further comprises arginine, such as L-arginine.
  • one or more compatible solid or liquid fillers or diluents or encapsulating compounds may be used as well for the inventive pharmaceutical composition, which are suitable for administration to a subject to be treated.
  • the term “compatible” as used herein means that these constituents of the inventive pharmaceutical composition are capable of being mixed with the complex as defined herein as defined above in such a manner that no interaction occurs which would substantially reduce the pharmaceutical effectiveness of the inventive pharmaceutical composition under typical use conditions.
  • Pharmaceutically acceptable carriers, fillers and diluents must, of course, have sufficiently high purity and sufficiently low toxicity to make them suitable for administration to a subject to be treated.
  • Some examples of compounds which can be used as pharmaceutically acceptable carriers, fillers or constituents thereof are sugars, such as, for example, lactose, glucose and sucrose; starches, such as, for example, corn starch or potato starch; cellulose and its derivatives, such as, for example, sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; tallow; solid glidants, such as, for example, stearic acid, magnesium stearate; calcium sulfate; vegetable oils, such as, for example, groundnut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil from theobroma ; polyols, such as, for example, polypropylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid.
  • sugars such as, for example, lactose, glucose and sucrose
  • starches such as, for example, corn
  • the inventive pharmaceutical composition may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, intranodal and sublingual injection or infusion techniques.
  • the inventive pharmaceutical composition may be administered intradermally, intramuscularly, intranodally or subcutaneously.
  • inventive pharmaceutical composition may be administered intramuscularly, intranodally or subcutaneously. Even more preferably the inventive pharmaceutical composition may be administered intranodally or subcutaneously. Most preferably, the inventive pharmaceutical composition may be administered subcutaneously. It is also particularly preferred that the inventive pharmaceutical composition may be administered subcutaneously or intradermally.
  • the inventive pharmaceutical composition may be administered by parenteral injection, more preferably by subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, intracranial, transdermal, intradermal, intrapulmonal, intraperitoneal, intracardial, intraarterial, intranodal and sublingual injection or via infusion techniques.
  • Sterile injectable forms of the inventive pharmaceutical compositions may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1.3-butanediol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1.3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation of the inventive pharmaceutical composition.
  • the active ingredient will preferably be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilizers, buffers, antioxidants and/or other additives may be included, as required.
  • administration is preferably in a “prophylactically effective amount” or a “therapeutically effective amount” (as the case may be), this being sufficient to show benefit to the individual.
  • a “prophylactically effective amount” or a “therapeutically effective amount” as the case may be
  • the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated.
  • inventive pharmaceutical composition as defined above may also be administered orally in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • the active ingredient i.e. the inventive transporter cargo conjugate molecule as defined above, is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • the inventive pharmaceutical composition may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, e.g. including diseases of the skin or of any other accessible epithelial tissue. Suitable topical formulations are readily prepared for each of these areas or organs.
  • the inventive pharmaceutical composition may be formulated in a suitable ointment, containing the inventive immunostimulatory composition, particularly its components as defined above, suspended or dissolved in one or more carriers.
  • Carriers for topical administration include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the inventive pharmaceutical composition can be formulated in a suitable lotion or cream.
  • suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • prescription of treatment e.g. decisions on dosage etc. when using the above pharmaceutical composition is typically within the responsibility of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of the techniques and protocols mentioned above can be found in REMINGTON'S PHARMACEUTICAL SCIENCES, 16th edition, Osol, A. (ed), 1980.
  • the inventive pharmaceutical composition typically comprises a “safe and effective amount” of the components of the inventive pharmaceutical composition, in particular of the complex as defined herein as defined above and/or cells loaded with said complex.
  • a “safe and effective amount” means an amount of the complex as defined herein that is sufficient to significantly induce a positive modification of a disease or disorder, i.e. an amount of the complex as defined herein or cells loaded with said complex, that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought.
  • An effective amount may be a “therapeutically effective amount” for the alleviation of the symptoms of the disease or condition being treated and/or a “prophylactically effective amount” for prophylaxis of the symptoms of the disease or condition being prevented.
  • the term also includes the amount of active complex sufficient to reduce the progression of the disease, notably to reduce or inhibit the tumor growth or infection and thereby elicit the response being sought, in particular such response could be an immune response directed against the antigens or antigenic epitopes comprised in by the complex (i.e. an “inhibition effective amount”).
  • an “inhibition effective amount” is small enough to avoid serious side-effects, that is to say to permit a sensible relationship between advantage and risk. The determination of these limits typically lies within the scope of sensible medical judgment.
  • a “safe and effective amount” of the components of the inventive pharmaceutical composition, particularly of the complex as defined herein as defined above, will furthermore vary in connection with the particular condition to be treated and also with the age and physical condition of the patient to be treated, the body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the activity of the specific components a), b), and c) of the complex as defined herein as defined above, the severity of the condition, the duration of the treatment, the nature of the accompanying therapy, of the particular pharmaceutically acceptable carrier used, and similar factors, within the knowledge and experience of the accompanying doctor.
  • the inventive pharmaceutical composition may be used for human and also for veterinary medical purposes, preferably for human medical purposes, as a pharmaceutical composition in general or as a vaccine.
  • compositions in particular vaccine compositions, or formulations according to the invention may be administered as a pharmaceutical formulation which can contain a complex as defined herein in any form described herein.
  • pharmaceutical formulation and “pharmaceutical composition” as used in the context of the present invention refer in particular to preparations which are in such a form as to permit biological activity of the active ingredient(s) to be unequivocally effective and which contain no additional component which would be toxic to subjects to which the said formulation would be administered.
  • an “efficacy” of a treatment can be measured based on changes in the course of a disease in response to a use or a method according to the present invention.
  • the efficacy of a treatment of cancer can be measured by a reduction of tumor volume, and/or an increase of progression free survival time, and/or a decreased risk of relapse post-resection for primary cancer.
  • assessment of efficacy can be by the spectrum of clinical patterns of antitumor response for immunotherapeutic agents through novel immune-related response criteria (irRC), which are adapted from Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria ( J. Natl. Cancer inst.
  • the efficacy of prevention of infectious disease is ultimately assessed by epidemiological studies in human populations, which often correlates with titres of neutralizing antibodies in sera, and induction of multifunctional pathogen specific T cell responses.
  • Preclinical assessment can include resistance to infection after challenge with infectious pathogen.
  • Treatment of an infectious disease can be measured by inhibition of the pathogen's growth or elimination of the pathogen (and, thus, absence of detection of the pathogen), correlating with pathogen specific antibodies and/or T cell immune responses.
  • compositions in particular vaccine compositions, or formulations according to the invention may also be administered as a pharmaceutical formulation which can contain antigen presenting cells loaded with a complex according to the invention in any form described herein.
  • the vaccine and/or the composition (for use) according to the present invention may also be formulated as pharmaceutical compositions and unit dosages thereof, in particular together with a conventionally employed adjuvant, immunomodulatory material, carrier, diluent or excipient as described above and below, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous and intradermal) use by injection or continuous infusion.
  • injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • suitable adjuvants and/or immunomodulatory materials include MPL® (Corixa), aluminum-based minerals including aluminum compounds (generically called Alum), AS01-4, MF59, CalciumPhosphate, Liposomes, Iscom, polyinosinic:polycytidylic acid (polyIC), including its stabilized form poly-ICLC (Hiltonol), CpG oligodeoxynucleotides, Granulocyte-macrophage colony-stimulating factor (GM-CSF), lipopolysaccharide (LPS), Montanide, polylactide co-glycolide (PLG), Flagellin, Soap Bark tree saponins (QS21), amino alkyl glucosamide compounds (e.g.
  • RC529 two component antibacterial peptides with synthetic oligodeoxynucleotides (e.g. IC31), Imiquimod, Resiquimod, Immunostimulatory sequences (ISS), monophosphoryl lipid A (MPLA), Fibroblast-stimulating lipopeptide (FSL1), and anti-CD40 antibodies.
  • synthetic oligodeoxynucleotides e.g. IC31
  • Imiquimod Imiquimod
  • Resiquimod Immunostimulatory sequences
  • MPLA monophosphoryl lipid A
  • FSL1 Fibroblast-stimulating lipopeptide
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention may be liquid formulations including, but not limited to, aqueous or oily suspensions, solutions, emulsions, syrups, and elixirs.
  • the compositions may also be formulated as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain additives including, but not limited to, suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
  • Suspending agents include, but are not limited to, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats.
  • Emulsifying agents include, but are not limited to, lecithin, sorbitan monooleate, and acacia.
  • Preservatives include, but are not limited to, methyl or propyl p-hydroxybenzoate and sorbic acid.
  • Dispersing or wetting agents include but are not limited to poly(ethylene glycol), glycerol, bovine serum albumin, Tween®, Span®.
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention may also be formulated as a depot preparation, which may be administered by implantation or by intramuscular injection.
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention may also be solid compositions, which may be in the form of tablets or lozenges formulated in a conventional manner.
  • tablets and capsules for oral administration may contain conventional excipients including, but not limited to, binding agents, fillers, lubricants, disintegrants and wetting agents.
  • Binding agents include, but are not limited to, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch and polyvinylpyrrolidone.
  • Fillers include, but are not limited to, lactose, sugar, microcrystalline cellulose, maizestarch, calcium phosphate, and sorbitol.
  • Lubricants include, but are not limited to, magnesium stearate, stearic acid, talc, polyethylene glycol, and silica.
  • Disintegrants include, but are not limited to, potato starch and sodium starch glycollate.
  • Wetting agents include, but are not limited to, sodium lauryl sulfate. Tablets may be coated according to methods well known in the art.
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention may also be administered in sustained release forms or from sustained release drug delivery systems.
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention may be adapted for delivery by repeated administration.
  • compositions in particular pharmaceutical compositions and vaccines, (for use) according to the present invention or in the context of their preparation are set out in “Part 5 of Remington's “The Science and Practice of Pharmacy”, 22nd Edition, 2012, University of the Sciences in Philadelphia, Lippincott Williams & Wilkins”.
  • the present invention also relates to a kit-of-parts, preferably for use in the prevention and/or treatment of colorectal cancer, the kit of parts comprising at least one of:
  • the kit-of-parts of the invention may comprise more than one component (i) to (v).
  • the kit-of-parts according to the present invention may comprise at least two different complexes under (i), at least two different nucleic acids under (ii), at least two different vectors under (iii), at least two different host cells under (iv), and/or at least two different cells under (v); e.g., the kit-of-parts of the invention may comprise at least two different complexes (i) and/or at least two different nucleic acids (ii).
  • the different complexes (i) comprised by the kit-of-parts as described above may differ in either component a), i.e. in the cell penetrating peptides, in component b), i.e. in the antigens or antigenic epitopes or in the subsets of more than one antigen or antigenic epitope, or in component c), i.e.
  • the different complexes (i) comprised by the kit-of-parts as described above may differ in two out of the three components a), b), and c); or the different complexes (i) comprised by the kit-of-parts as described above may differ in all three components a), b), and c) of the complex.
  • the different nucleic acids (ii) comprised by the kit-of-parts as described above may differ in that they encode such different complexes;
  • the different vectors (iii) comprised by the kit-of-parts as described above may differ in that they comprise such different nucleic acids;
  • the different host cells (iv) comprised by the kit-of-parts as described above may differ in that they comprise such different vectors;
  • the different cells loaded with a complex (v) comprised by the kit-of-parts as described above may differ in that they are loaded with such different complexes.
  • kit-of-parts may be packaged in one or more containers.
  • the above components may be provided in a lyophilized or dry form or dissolved in a suitable buffer.
  • the kit may also comprise additional reagents including, for instance, preservatives, growth media, and/or buffers for storage and/or reconstitution of the above-referenced components, washing solutions, and the like.
  • additional reagents including, for instance, preservatives, growth media, and/or buffers for storage and/or reconstitution of the above-referenced components, washing solutions, and the like.
  • the kit-of-parts according to the present invention may optionally contain instructions of use.
  • the present invention also provides a vaccination kit for treating, preventing and/or stabilizing colorectal cancer, comprising the pharmaceutical composition as described herein or a vaccine as described herein and instructions for use of said pharmaceutical composition or of said vaccine in the prevention and/or treatment of colorectal cancer.
  • the present invention also provides a kit comprising the complex as described herein, the cell as described herein, the composition as described herein, the vaccine as described herein, and/or the pharmaceutical composition as described herein.
  • such a kit further comprises a package insert or instruction leaflet with directions to treat colorectal cancer by using the complex (for use) according to the present invention as described herein, the cell as described herein, the composition as described herein, the vaccine as described herein, and/or the pharmaceutical composition as described herein.
  • a package insert or instruction leaflet with directions to treat colorectal cancer by using the complex (for use) according to the present invention as described herein, the cell as described herein, the composition as described herein, the vaccine as described herein, and/or the pharmaceutical composition as described herein.
  • the kit comprises a chemotherapeutic agent, a targeted drug and/or an immunotherapeutic agent, such as an immune checkpoint modulator, as described herein in the context of the combination for use as described herein.
  • the present invention provides the use of any one of: (i) a complex as described herein, and/or (ii) cells, such as antigen-presenting cells, loaded with a complex as described herein, (for the preparation of a medicament) for the prevention, treatment or stabilization of colorectal cancer. Accordingly, the present invention provides any one of: (i) a complex as described herein, and/or (ii) cells, such as antigen-presenting cells, loaded with a complex as described herein, for use in the prevention, treatment or stabilization of colorectal cancer.
  • the present invention also provides a complex for use according to the present invention, which allows the transport and presentation of the at least one antigen or antigenic epitope comprised by the complex at the cell surface of antigen presenting cells in an MHC class I and/or MHC class 11 context, for use in vaccination and/or immunotherapy.
  • the present invention provides a method of preventing, treating or repressing colorectal cancer, wherein said method comprises administering any one of: (i) a complex of the invention, (ii) cells, such as antigen-presenting cells, loaded with a complex of the invention, or (iii) a pharmaceutical formulation of (i) to (ii), to said subject.
  • the present invention provides a method for eliciting or improving, in a subject, an immune response against one or multiple epitopes that is dependent on CD4 + helper T cells and/or CD8 + cytotoxic T cells, wherein said method comprises administering any one of: (i) a complex for use according to the present invention, and/or (ii) cells, such as antigen-presenting cells, loaded with said complex, or (iii) a pharmaceutical formulation of (i) to (ii), to said subject.
  • An immune response that is dependent on CD4 + and/or CD8 + response can be determined by evaluating an inflammatory response, a pro-inflammatory cytokine response, including an increase in the expression of one or more of IFN- ⁇ , TNF- ⁇ and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, ELISPOT assays, and delayed type hypersensitivity tests. It can also be indirectly measured by an increase in antigen-specific serum antibodies that are dependent on antigen-specific T helper cells.
  • the present invention also provides a method for eliciting or improving, in a subject, an immune response against one or multiple antigens or antigenic epitopes that is restricted by multiple MHC class I molecules and/or multiple MHC class II molecules, wherein said method comprises administering any one of: (i) a complex for use according to the present invention, and/or (ii) cells, such as antigen-presenting cells, loaded with said complex, or (iii) a pharmaceutical formulation of (i) to (ii), to said subject.
  • a method for eliciting or improving, in a subject, an immune response against multiple epitopes as described herein, that is restricted by multiple MHC class I molecules and/or multiple MHC class II molecules can be determined by evaluating a cytokine response, including an increase in the expression of one or more of IFN- ⁇ , TNF- ⁇ and IL-2 mRNA or protein relative to the level before administration of the compounds of the invention, after in vitro stimulation of T cells with individual peptides binding to discrete MHC class I and class II molecules on antigen presenting cells. Restriction to different MHC molecules can also be validated by using antigen presenting cells expressing different MHC molecules, or by using MHC blocking antibodies. It can also be measured by an increase in the frequency or absolute number of antigen-specific T cells after administration of the compounds of the invention, measured by HLA-peptide multimer staining, which uses multimers assembled with discrete MHC molecules.
  • the immune response is directed against one or multiple epitopes of a tumor-associated antigen or a tumor-specific antigen as, for instance, a combination of epitopes as described herein.
  • the immune response may be directed against multiple epitopes of an antigenic protein from a pathogen.
  • the methods according to the present invention as described herein may be for eliciting or improving, in a subject, an immune response against one or multiple epitopes that is restricted by MHC class I molecules and/or MHC class II molecules.
  • the present invention thus provides a method for preventing and/or treating colorectal cancer or initiating, enhancing or prolonging an anti-tumor-response in a subject in need thereof comprising administering to the subject a complex comprising:
  • the complex (for use) according to the present invention as described herein, the nucleic acid as described herein, the cell as described herein, the composition as described herein, the vaccine as described herein, and/or the pharmaceutical composition as described herein is administered to the subject.
  • the subject has colorectal cancer and/or was diagnosed with colorectal cancer.
  • the present invention provides the use of any one of: (i) a complex as described herein, and/or (ii) cells, such as antigen-presenting cells, loaded with the complex as described herein, for the preparation of an imaging composition for imaging techniques in the context of (diagnosis of) colorectal cancer or for the preparation of a diagnosis composition (“diagnostic compositions”) for diagnosing colorectal cancer.
  • a diagnostic composition for diagnosing colorectal cancer according to the present invention comprises at least one component selected from:
  • the diagnostic composition according to the present invention comprises the complex as described above.
  • the complex (for use) according to the present invention, the nucleic acid as described herein, the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention, the inventive composition, the inventive pharmaceutical composition or the inventive vaccine or, most preferably, the inventive diagnostic composition may be utilized in diagnosis as a diagnostic tool, e.g. in (in vivo or in vitro) assays, e.g. in immunoassays, to detect, prognose, diagnose, or monitor colorectal cancer.
  • (in vitro) assays may be performed by delivering the complex (for use) according to the present invention, the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention, the inventive composition, the inventive pharmaceutical composition or the inventive vaccine or, most preferably, the inventive diagnostic composition to target cells typically selected from e.g. cultured animal cells, human cells or micro-organisms, and to monitor the cell response by biophysical methods typically known to a skilled person.
  • the target cells typically used therein may be cultured cells (in vitro), e.g. cells isolated from human or animal body, such as blood cells isolated from human or animal body, or in vivo cells, i.e.
  • markers or labels which may be contained in the complex (for use) according to the present invention and, in particular, in the diagnostic composition according to the present invention.
  • the invention provides a method of diagnosing colorectal cancer in a subject, wherein said method comprises administering any one of: (i) a complex of the invention, (ii) cells, such as antigen-presenting cells, loaded with the complex of the invention, or (iii) a pharmaceutical formulation of (i) to (ii), to said subject or to said subject's sample ex vivo.
  • uses and methods according to the present invention comprise administration of a complex (for use) according to the invention.
  • uses and methods according to the present invention comprise administration of more than one complex, cells, or pharmaceutical formulation according to the invention.
  • at least two different complexes are used or administered, wherein each complex comprises at least one antigen or antigenic epitope and said antigen or antigenic epitope or (if more than one antigen or antigenic epitope is comprised by said complex) said subset of antigens or antigenic epitopes are different between the two complexes.
  • the different complexes (i) comprised by the composition as described above may differ in either component a), i.e. in the cell penetrating peptides, in component b), i.e. in the antigens or antigenic epitopes or in the subsets of more than one antigen or antigenic epitope, or in component c), i.e.
  • the different complexes (i) comprised by the composition as described above may differ in two out of the three components a), b), and c); or the different complexes (i) comprised by the composition as described above may differ in all three components a), b), and c) of the complex.
  • the different nucleic acids (ii) comprised by the composition as described above may differ in that they encode such different complexes; the different vectors (iii) comprised by the composition as described above may differ in that they comprise such different nucleic acids; the different host cells (iv) comprised by the composition as described above may differ in that they comprise such different vectors; and the different cells loaded with a complex (v) comprised by the composition as described above may differ in that they are loaded with such different complexes.
  • the cells according to the present invention may be antigen presenting cells, in particular dendritic cells, more preferably dendritic cells from the subject to be treated.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered in any manner as described above, including enterally, such as orally or rectally, and parenterally, such as intravenously or combinations thereof.
  • Parenteral administration includes, but is not limited to, intravenous, intra-arterial, intra-peritoneal, subcutaneous, intradermal and intramuscular.
  • the complex for use according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex for use according to the present invention; the inventive composition; the inventive pharmaceutical composition and/or the inventive vaccine are administered via an enteral route of administration, such as oral, sublingual and rectal.
  • the complex (for use) according to the present invention; the nucleic acid ((for use)) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may also be preferably administered via topical, intratumoral, intradermal, subcutaneous, intramuscular, intranasal, or intranodal route.
  • the complex (for use) according to the present invention; the nucleic acid ((for use)) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may also be administered in the form of an implant, which allows slow release of the compositions as well as a slow controlled i.v. infusion.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered subcutaneously or intradermally.
  • the administration of complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may require multiple successive injections/administrations.
  • the administration may be repeated at least two times, for example once as primary immunization injections/administration and, later, as booster injections/administration.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered repeatedly or continuously.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered repeatedly or continuously for a period of at least 1, 2, 3, or 4 weeks; 2, 3, 4, 5, 6, 8, 10, or 12 months; or 2, 3, 4, or 5 years.
  • the complex (for use) according to the present invention may be administered twice per day, once per day, every two days, every three days, once per week, every two weeks, every three weeks, once per month or every two months.
  • the complex (for use) according to the present invention may be administered repeatedly, for example once per week or (once) every two weeks.
  • the cell penetrating peptide, components a), b), and c), i.e. the at least one antigen or antigenic epitope and the at least one TLR peptide agonist, composing the complex (for use) according to the present invention may be contained in separate compositions which are mixed just before administration or which are administered simultaneously to the subject in need thereof.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered directly to a patient using the administration routes as described above, in particular for pharmaceutical compositions.
  • the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine may be administered to a patient using an ex vivo approach, e.g.
  • the pharmaceutical composition, the vaccine or the inventive transporter cargo conjugate molecule as defined above into cells, preferably autologous cells, i.e. cells derived from the patient to be treated, and transplanting these cells into the site of the patient to be treated, optionally subsequent to storing and/or culturing these cells prior to treatment.
  • autologous cells i.e. cells derived from the patient to be treated
  • the dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factors, including pharmacokinetic properties, subject conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired.
  • the therapeutically effective dose of a complex (for use) according to the present invention is from about 0.01 mg to 5 mg per injection, in particular from about 0.1 mg to 2 mg per injection, or from about 0.01 nmol to 1 mmol per injection, in particular from 1 nmol to 1 mmol per injection, preferably from 1 ⁇ mol to 1 mmol per injection.
  • the therapeutically effective dose of an antigen presenting cell loaded with a complex (for use) according to the present invention is from about 0.2 million cells to 2 million cells per injection.
  • the administration of the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine in the methods and uses according to the invention can be carried out alone or in combination with a co-agent useful for treating and/or stabilizing colorectal cancer.
  • the administration of the pharmaceutical compositions in the methods and uses according to the invention can be carried out in combination with substances used in conventional chemotherapy directed against solid colorectal tumors and for control of establishment of metastases or any other molecule that act by triggering programmed cell death e.g. for example a co-agent selected from Tumor Necrosis Family Members including, but not limited, to Fas Ligand and tumor necrosis factor (TNF)-related apoptosis inducing (TRAIL) ligand.
  • TNF tumor necrosis factor
  • TRAIL tumor necrosis factor
  • the administration of the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine in the methods and uses according to the present invention can be carried out in parallel of radiotherapy.
  • the invention encompasses the administration of the complex (for use) according to the present invention; the nucleic acid (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine, wherein it is administered to a subject prior to, simultaneously or sequentially with other therapeutic regimens or co-agents useful for treating, and/or stabilizing a colorectal cancer and/or preventing colorectal cancer relapsing (e.g. multiple drug regimens), in a therapeutically effective amount.
  • Said complex, cell, composition, vaccine or pharmaceutical composition, that is administered simultaneously with said co-agents can be administered in the same or different composition(s) and by the same or different route(s) of administration.
  • Said other therapeutic regimens or co-agents may be selected from the group consisting of radiation therapy, chemotherapy, surgery, targeted therapy (including small molecules, peptides and monoclonal antibodies), and anti-angiogenic therapy.
  • Anti-angiogenic therapy is defined herein as the administration of an agent that directly or indirectly targets tumor-associated vasculature.
  • the present invention also provides a combination of
  • chemotherapeutic agents are cytotoxic, i.e. they act by killing cells that divide rapidly, one of the main properties of most cancer cells.
  • Preferred chemotherapeutic agents for combination with the complex as defined herein are such chemotherapeutic agents known to the skilled person for treatment of colorectal cancer.
  • Preferred chemotherapeutic agents for combination include 5-Fluorouracil (5-FU), Capecitabine (Xeloda®), Irinotecan (Camptosar®) and Oxaliplatin (Eloxatin®).
  • the complex as defined herein is combined with a combined chemotherapy, preferably selected from (i) FOLFOX (5-FU, leucovorin, and oxaliplatin); (ii) CapeOx (Capecitabine and oxaliplatin); (iii) 5-EU and leucovorin; (iv) FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan); and (v) FOLFIRI (5-FU, leucovorin, and irinotecan).
  • a combined chemotherapy preferably selected from (i) FOLFOX (5-FU, leucovorin, and oxaliplatin); (ii) CapeOx (Capecitabine and oxaliplatin); (iii) 5-EU and leucovorin; (iv) FOLFOXIRI (leucovorin, 5-FU, oxaliplatin, and irinotecan); and (v) FOLFIRI (5-FU,
  • a combination with (i) FOLFOX (5-EU, leucovorin, and oxaliplatin); (ii) CapeOx (Capecitabine and oxaliplatin); or (iii) 5-FU and leucovorin is preferred.
  • FOLFOXIRI leucovorin, 5-FU, oxaliplatin, and irinotecan
  • FOLFOX 5-FU, leucovorin, and oxaliplatin
  • FOLFIRI 5-EU, leucovorin, and irinotecan
  • Targeted drugs for combination with the complex as defined herein for treatment of colorectal cancer include VEGF-targeted drugs and EGFR-targeted drugs.
  • VEGF-targeted drugs include Bevacizumab (Avastin®), ramucirumab (Cyramza®) or ziv-aflibercept (Zaltrap®).
  • EGFR-targeted drugs include Cetuximab (Erbitux®), panitumumab (Vectibix®) or Regorafenib (Stivarga®).
  • Immunotherapeutic agents for combination with the complex as defined herein for treatment of colorectal cancer include vaccines, chimeric antigen receptors (CARs), checkpoint modulators and oncolytic virus therapies.
  • Preferred vaccines for combination with the complex as defined herein for treatment of colorectal cancer include TroVax, OncoVax, IMA910, ETBX-011, MicOryx, EP-2101, MKC1106-PP, CDX-1307, V934N935, MelCancerVac, Imprime PGG, FANG, Tecemotide, AlloStim, DCVax, GI-6301, AVX701, OCV-C02.
  • Artificial T cell receptors also known as chimeric T cell receptors, chimeric immunoreceptors, chimeric antigen receptors (CARs) are engineered receptors, which graft an arbitrary specificity onto an immune effector cell. Artificial T cell receptors (CARs) are preferred in the context of adoptive cell transfer. To this end, T cells are removed from a patient and modified so that they express receptors specific to colorectal cancer. The T cells, which can then recognize and kill the cancer cells, are reintroduced into the patient.
  • an immune checkpoint modulator refers to a molecule or to a compound that modulates (e.g., totally or partially reduces, inhibits, interferes with, activates, stimulates, increases, reinforces or supports) the function of one or more checkpoint molecules.
  • an immune checkpoint modulator may be an “immune checkpoint inhibitor” (also referred to as “checkpoint inhibitor” or “inhibitor”) or an “immune checkpoint activator” (also referred to as “checkpoint activator” or “activator”).
  • an “immune checkpoint inhibitor” (also referred to as “checkpoint inhibitor” or “inhibitor”) totally or partially reduces, inhibits, interferes with, or negatively modulates the function of one or more checkpoint molecules.
  • An “immune checkpoint activator” (also referred to as “checkpoint activator” or “activator”) totally or partially activates, stimulates, increases, reinforces, supports or positively modulates the function of one or more checkpoint molecules.
  • Immune checkpoint modulators are typically able to modulate (i) self-tolerance and/or (ii) the amplitude and/or the duration of the immune response.
  • the immune checkpoint modulator used according to the present invention modulates the function of one or more human checkpoint molecules and is, thus, a “human checkpoint inhibitor”.
  • Checkpoint molecules are molecules, such as proteins, are typically involved in immune pathways and, for example, regulate T-cell activation, T-cell proliferation and/or T-cell function. Accordingly, the function of checkpoint molecules, which is modulated (e.g., totally or partially reduced, inhibited, interfered with, activated, stimulated, increased, reinforced or supported) by checkpoint modulators, is typically the (regulation of) T-cell activation, T-cell proliferation and/or T cell function. Immune checkpoint molecules thus regulate and maintain self-tolerance and the duration and amplitude of physiological immune responses.
  • immune checkpoint molecules belong to the B7:CD28 family or to the tumor necrosis factor receptor (TNFR) super family and, by the binding of specific ligands, activate signaling molecules that are recruited to the cytoplasmic domain (cf. Susumu Suzuki et al., 2016: Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016: doi: 10.1093/jjco/hyv201 [Epub ahead of print]; in particular Table 1).
  • the immune checkpoint modulator for combination with the complex as defined herein for treatment of colorectal cancer is an activator or an inhibitor of one or more immune checkpoint point molecule(s) selected from CD27, CD28, CD40, CD122, CD137, OX40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CD40, CTLA-4, IDO, KIR, LAG3, PD-1, TIM-3, VISTA, CEACAM1, GARP, PS, CSF1R, CD94/NKG2A, TDO, GITR, TNFR and/or FasR/DcR3; or an activator or an inhibitor of one or more ligands thereof.
  • one or more immune checkpoint point molecule(s) selected from CD27, CD28, CD40, CD122, CD137, OX40, GITR, ICOS, A2AR, B7-H3, B7-H4, BTLA, CD40, CTLA-4, IDO, KIR, L
  • the immune checkpoint modulator is an activator of a (co-)stimulatory checkpoint molecule or an inhibitor of an inhibitory checkpoint molecule or a combination thereof.
  • the immune checkpoint modulator is more preferably (i) an activator of CD27, CD28, CD40, CD122, CD137, OX40, GITR and/or ICOS or (ii) an inhibitor of A2AR, B7-H3, B7-H4, BTLA, CD40, CTLA-4, IDO, KIR, LAG3, PD-1, PDL-1, PD-L2, TIM-3, VISTA, CEACAM1, GARP, PS, CSF1 R, CD94/NKG2A, TDO, TNFR and/or FasR/DcR3.
  • the immune checkpoint modulator is an inhibitor of an inhibitory checkpoint molecule (but preferably no inhibitor of a stimulatory checkpoint molecule). Accordingly, the immune checkpoint modulator is even more preferably an inhibitor of A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, PDL-1, PD-L2, TIM-3, VISTA, CEACAM1, GARP, PS, CSF1 R, CD94/NKG2A, TDO, TNFR and/or DcR3 or of a ligand thereof.
  • the immune checkpoint modulator is an activator of a stimulatory or costimulatory checkpoint molecule (but preferably no activator of an inhibitory checkpoint molecule). Accordingly, the immune checkpoint modulator is more preferably an activator of CD27, CD28, CD40, CD122, CD137, OX40, GITR and/or ICOS or of a ligand thereof.
  • the immune checkpoint modulator is a modulator of the CD40 pathway, of the IDO pathway, of the CTLA-4 pathway and/or of the PD-1 pathway.
  • the immune checkpoint modulator is preferably a modulator of CD40, CTLA-4, PD-L1, PD-L2, PD-1 and/or IDO, more preferably the immune checkpoint modulator is an inhibitor of CTLA-4, PD-L1, PD-L2, PD-1 and/or IDO or an activator of CD40, even more preferably the immune checkpoint modulator is an inhibitor of CTLA-4, PD-L1, PD-1 and/or IDO and most preferably the immune checkpoint modulator is an inhibitor of CTLA-4 and/or PD-1.
  • the immune checkpoint modulator is a modulator of the CD40 pathway, of the IDO pathway, of the LAG3 pathway, of the CTLA-4 pathway and/or of the PD-1 pathway.
  • the immune checkpoint modulator is preferably a modulator of CD40, LAG3, CTLA-4, PD-L1, PD-L2, PD-1 and/or IDO, more preferably the immune checkpoint modulator is an inhibitor of CTLA-4, PD-L1, PD-L2, PD-1, LAG3, and/or IDO or an activator of CD40, even more preferably the immune checkpoint modulator is an inhibitor of CTLA-4, PD-L1, PD-1, LAG3 and/or IDO, even more preferably the immune checkpoint modulator is an inhibitor of LAG3, CTLA-4 and/or PD-1, and most preferably the immune checkpoint modulator is an inhibitor of CTLA-4 and/or PD-1.
  • the checkpoint modulator for combination with the complex as defined herein for treatment of colorectal cancer may be selected from known modulators of the CD40 pathway, the CTLA-4 pathway or the PD-1 pathway.
  • the checkpoint modulator for combination with the complex as defined herein for treatment of colorectal cancer may be selected from known modulators of the CD40 pathway, the LAG3 pathway, the CTLA-4 pathway or the PD-1 pathway.
  • the immune checkpoint modulator is a PD-1 inhibitor.
  • Preferred inhibitors of the CTLA-4 pathway and of the PD-1 pathway include the monoclonal antibodies Yervoy® (Ipilimumab; Bristol Myers Squibb) and Tremelimumab (Pfizer/Medlmmune) as well as Opdivo® (Nivolumab; Bristol Myers Squibb), Keytruda (Pembrolizumab; Merck), Durvalumab (MedImmune/AstraZeneca), MED14736 (AstraZeneca; cf. WO 2011/066389 A1), MPDL3280A (Roche/Genentech; cf. U.S. Pat. No.
  • More preferred checkpoint inhibitors include the CTLA-inhibitors Yervoy® (Ipilimumab; Bristol Myers Squibb) and Tremelimumab (Pfizer/Medlmmune) as well as the PD-1 inhibitors Opdivo® (Nivolumab; Bristol Myers Squibb), Keytruda® (Pembrolizumab; Merck), Pidilizumab (CT-011; CureTech), MED10680 (AMP-514; AstraZeneca), AMP-224 and Lambrolizumab (e.g. disclosed as hPD109A and its humanized derivatives h409A11, h409A16 and h409A17 in WO2008/156712; Hamid 0.
  • LAG3 inhibitor is the anti-LAG3 monoclonal antibody BMS-986016 (Bristol-Myers Squibb).
  • Other preferred examples of a LAG3 inhibitor include LAG525 (Novartis), IMP321 (Immutep) and LAG3-Ig as disclosed in WO 2009/044273 A2 and in Brumble et al., 2009, Clin. Cancer Res.
  • the immune checkpoint modulator is not a modulator of CD40.
  • the immune checkpoint modulator is not a CD40 ligand. It is also preferred that the immune checkpoint modulator is not an anti-CD40 antibody.
  • the immune checkpoint modulator for combination with the complex as defined herein for treatment of colorectal cancer is selected from the group consisting of Pembrolizumab, Ipilimumab, Nivolumab, MPDL3280A, MEDI4736, Tremelimumab, Avelumab, PDR001, LAG525, INCB24360, Varlilumab, Urelumab, AMP-224 and CM-24.
  • Oncolytic viruses are engineered to cause cell lysis by replicating in tumors, thus activating an antitumor immune response.
  • An oncolytic virus therapy for combination with the complex as defined herein for treatment of colorectal cancer is preferably selected from the group consisting of JX594 (Thymidine Kinase-Deactivated Vaccinia Virus), ColoAd1 (adenovirus), NV1020 (HSV-derived), ADXS11-001 (attenuated Listeria vaccine), Reolysin® (special formulation of the human reovirus), PANVAC (recombinant vaccinia-virus CEA-MUC-1-TRICOM), Ad5-hGCC-PADRE (recombinant adenovirus vaccine) and vvDD-CDSR (vaccinia virus).
  • JX594 Thimidine Kinase-Deactivated Vaccinia Virus
  • ColoAd1 adenovirus
  • NV1020 HSV-derived
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, are administered at about the same time.
  • “At about the same time”, as used herein, means in particular simultaneous administration or that directly after administration of (i) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, (ii) the complex is administered or directly after administration of (i) the complex (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, is administered.
  • directly after includes the time necessary to prepare the second administration—in particular the time necessary for exposing and disinfecting the location for the second administration as well as appropriate preparation of the “administration device” (e.g., syringe, pump, etc.).
  • Simultaneous administration also includes if the periods of administration of (i) the complex and of (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, overlap or if, for example, one component is administered over a longer period of time, such as 30 min, 1 h, 2 h or even more, e.g. by infusion, and the other component is administered at some time during such a long period.
  • Administration of (i) the complex and of (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, at about the same time is in particular preferred if different routes of administration and/or different administration sites are used.
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator are administered consecutively.
  • the complex is administered before or after (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator.
  • the time between administration of the first component and administration of the second component is preferably no more than one week, more preferably no more than 3 days, even more preferably no more than 2 days and most preferably no more than 24 h.
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator are administered at the same day with the time between administration of the first component (the checkpoint modulator of the complex) and administration of the second component (the other of the checkpoint modulator and the complex) being preferably no more than 6 hours, more preferably no more than 3 hours, even more preferably no more than 2 hours and most preferably no more than 1 h.
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator are administered via the same route of administration. It is also preferred that (i) the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator, are administered via distinct routes of administration.
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator are preferably provided in distinct compositions.
  • the complex and (ii) the chemotherapeutic agent, the targeted drug and/or the immunotherapeutic agent, such as an immune checkpoint modulator are preferably provided in the same composition.
  • the present invention provides a pharmaceutical formulation comprising a complex (for use) according to the invention or a cell (for use) according to the invention, in particular an antigen-presenting cell (for use) according to the invention, combined with at least one co-agent useful for treating and/or stabilizing a cancer and/or preventing colorectal cancer relapsing, and at least one pharmaceutically acceptable carrier.
  • the complex (for use) according to the present invention; the cell, such as antigen-presenting cell, loaded with the complex (for use) according to the present invention; the inventive composition; the inventive pharmaceutical composition or the inventive vaccine can be administered after surgery where solid tumors have been removed as a prophylaxis against relapsing and/or metastases.
  • the administration of the imaging or diagnosis composition in the methods and uses according to the invention can be carried out alone or in combination with a co-agent useful for imaging and/or diagnosing colorectal cancer.
  • the present invention can be applied to any subject suffering from colorectal cancer or at risk to develop colorectal cancer.
  • the therapeutic effect of said complex may be to elicit an immune response directed against said antigens or antigenic epitopes, in particular a response that is dependent on CD4 + helper T cells and/or CD8 + cytotoxic T cells and/or that is restricted by MHC class I molecules and/or MHC class II molecules.
  • subjects according to the invention have been subjected to a surgical removal of a tumor.
  • FIG. 1 shows for Example 1 expression of activation marker CD40 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of EDAZ13Mad5, Z13Mad5, Mad5 or 25 ng/ml of LPS during 48h. Isotype staining for each condition was also performed (isotype is not shown in the FIG. 1 ) (one experiment).
  • FIG. 2 shows for Example 1 expression of activation marker CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of EDAZ13Mad5, Z13Mad5, Mad5 or 25 ng/ml of LPS during 48h. Isotype staining for each condition was also performed (isotype is not shown in the FIG. 2 ) (one experiment).
  • FIG. 3 shows for Example 1 expression of activation marker HLADR by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of EDAZ13Mad5, Z13Mad5, Mad5 or 25 ng/ml of LPS during 48h. Isotype staining for each condition was also performed (isotype is not shown in the FIG. 3 ) (one experiment).
  • FIG. 4 shows for Example 1 expression of activation marker CD83 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of EDAZ13Mad5, Z13Mad5, Mad5 or 25 ng/ml of LPS during 48 h. Isotype staining for each condition was also performed (isotype is not shown in the FIG. 4 ) (one experiment).
  • FIG. 5 shows for Example 2 functional MHC class I-restricted cross-presentation in a murine in an vitro system using bone marrow derived dendritic cells (BMDCs) and splenocytes from different TCR transgenic mice.
  • BMDCs bone marrow derived dendritic cells
  • splenocytes from different TCR transgenic mice.
  • BMDCs were loaded overnight with 300 nM of EDAZ13Mad5, EDAMad5 or Mad5.
  • Efficient MHC class 1-restricted presentation of OVACD8 epitope and gp100 epitope was monitored after 4 days with CFSE-labeled OT1 cells and P-Mel cells respectively.
  • Efficient MHC class II-restricted presentation of OVACD4 epitope was monitored after 4 days with CFSE-labeled OT2 cells.
  • BMDCs were pulsed for 1h with 5 uM peptide (one experiment representative of 2 individual experiments).
  • FIG. 6 shows the results for the 2 nmol groups for Example 3.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) with 2 nmol of EDAMad5 or EDAZ13Mad5.
  • Positive control group was vaccinated with Mad5 and MPLA (equimolar to EDA). Mice were bled 7 days after last vaccination and pentamer staining was performed (3-4 mice per group, one experiment).
  • FIG. 7 shows the results for the 10 nmol groups for Example 3.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) with 10 nmol of EDAMad5 or EDAZ13Mad5.
  • Positive control group was vaccinated with Mad5 and MPLA (equimolar to EDA). Mice were bled 7 days after last vaccination and pentamer staining was performed (3-4 mice per group, one experiment).
  • FIG. 8 shows for Example 3 the percentage of pentamer positive CD8+ T cells for all groups tested.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) with 2 nmol or 10 nmol of EDAMad5 or EDAZ13Mad5.
  • Positive control group was vaccinated with Mad5 and MPLA (equimolar to EDA). Mice were bled 7 days after last vaccination and pentamer staining was performed (one experiment with 3-4 mice per group).
  • FIG. 9 shows for Example 4 the tumor growth of 7 mice per group (mean ⁇ SEM); *, p ⁇ 0.05 EDAZ13Mad5 versus control group (2-way Anova test).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and d13) by subcutaneous injection of 10 nmol of EDAZ13Mad5, EDAMad5, Mad5 or Mad5 and MPLA (equimolar to EDA) s.c. in the right flank. Tumor size was measured with a caliper.
  • FIG. 10 shows for Example 4 individual tumor growth curves (7 individual mice per group).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and dl 3) by subcutaneous injection of 10 nmol of EDAZ13Mad5, EDAMad5, Mad5 or Mad5 and MPLA (equimolar to EDA) s.c. in the right flank. Tumor size was measured with a caliper.
  • FIG. 11 shows for Example 4 (A) the survival curve of 7 mice per group; *, p ⁇ 0.05 EDAZ13Mad5 versus control group (Log-rank test) and (B) the tumor-free progression curve of 7 mice per group; *, p ⁇ 0.05 EDAZ13Mad5 versus control group (Log-rank test).
  • FIG. 12 shows for Example 5 the number of metastasis for every experimental group.
  • C57BL/6 mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells and vaccinated twice (d0 and d9) by subcutaneous injection of 2 nmol of EDAZ13Mad5, EDAMad5 or Z13Mad5 MPLA (equimolar to EDA) or MPLA alone s.c. in the right flank. Mice were euthanized at day 13 and lung recovered. Number of metastasis foci was counted for each lung. **, p ⁇ 0.01; ****, p ⁇ 0.0001 (Unpaired T test).
  • FIG. 13 shows for Example 6 the number of metastasis for every experimental group.
  • C57BL/6 mice were vaccinated twice (d-21 and d-7) by subcutaneous injection of 2 nmoles of EDAZ13Mad5, EDAMad5 or Z13Mad5 MPLA (equimolar to EDA) s.c. in the right flank.
  • mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells.
  • Mice were euthanized at day 14 and lung recovered. Number of metastasis foci was counted for each lung. *, p ⁇ 0.05.
  • ***, p ⁇ 0.001 Unpaired T test).
  • FIG. 14 shows the results for Example 8.
  • HEK-hTLR2 cell lines were seeded in flat 96-well plate in culture medium, stimulated with 0.3 ⁇ M, 1 ⁇ M or 3 ⁇ M of AnaxaZ13Mad5 or Z13Mad5Anaxa and incubated at 37° C. for 24h. Positive control was performed with 500 ng/ml of Pam3CSK4.
  • A Twenty microliters of supernatant were added to QuantiBlue® detection medium and incubated at 37° C. for 1 h before OD reading (620 nm).
  • B Quantification of IL-8 secretion (by ELISA) in the supernatant.
  • FIG. 15 shows the results for Example 9.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) with 2nmoles of Z13Mad5Anaxa or AnaxaZ13Mad5. Mice were bled 7 days after last vaccination and pentamer staining was performed (one experiment).
  • FIG. 16 shows the results for Example 9.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) with 2nmoles Z13Mad5Anaxa or AnaxaZ13Mad5. Mice were bled 7 days after last vaccination and pentamer staining was performed (one experiment with 4 mice per group). *, p ⁇ 0.05.
  • FIG. 17 shows for Example 10 the tumor growth of 7 mice per group (mean ⁇ SEM).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-0VA tumor cells in the left flank and vaccinated twice (d5 and d13) by subcutaneous injection of 10 nmol of either AnaxZ13Mad5, Z13Mad5Anaxa or co-injection of Z13Mad5+Pam3CSK4 (equimolar to Anaxa) in the right flank.
  • Tumor size was measured with a caliper. *, p ⁇ 0.05; ***, p ⁇ 0.001, ****, p ⁇ 0.0001.
  • FIG. 18 shows for Example 10 the individual tumor growth curves (7 individual mice per group).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (c15 and d13) by subcutaneous injection of 10 nmol of either AnaxZ13Mad5, Z13Mad5Anaxa or co-injection of Z13Mad5+Pam3CSK4 (equimolar to Anaxa) s.c. in the right flank. Tumor size was measured with a caliper.
  • FIG. 19 shows for Example 10 the survival curve of 7 mice per group.
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and dl 3) by subcutaneous injection of 10 nmol of either AnaxZ13Mad5, Z13Mad5Anaxa or co-injection of Z13Mad5+Pam3CSK4 (equimolar to Anaxa) in the right flank. Tumor size was measured with a caliper. *, p ⁇ 0.05, **, p ⁇ 0.01, ****, p ⁇ 0.0001 (Log-rank test).
  • FIG. 20 shows for Example 11 the tumor growth of 7 mice per group (mean ⁇ SEM).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-0VA tumor cells in the left flank and vaccinated twice (d5 and d13) by subcutaneous injection of 2nmoles of Hp91Z13Mad5, EDAZ13Mad5, Z13Mad5Anaxa, Z13Mad5EDA or Z13Mad5 and MPLA (equimolar to EDA) in the right flank.
  • FIG. 21 shows for Example 11 the individual tumor growth curves (7 individual mice per group).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and d13) by subcutaneous injection of 2nmoles of Hp91Z13Mad5, EDAZ13Mad5, Z13Mad5Anaxa, Z13Mad5EDA or Z13Mad5 and MPLA (equimolar to EDA) s.c. in the right flank.
  • FIG. 22 shows for Example 11 the survival curves of all 7 mice per group. Median survival is indicated on the graph (m.s.). *, p ⁇ 0.05; **, p ⁇ 0.01 (Log-rank test).
  • FIG. 23 shows for Example 12 the tumor growth of 7 mice per group (mean ⁇ SEM); ****, p ⁇ 0.0001 (Log-rank test).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (once at d5 and once at d13) by subcutaneous injection of either 0.5 nmol, 2 nmol or 10 nmol of Z13Mad5Anaxa in the right flank. Tumor size was measured with a caliper.
  • FIG. 24 shows for Example 13 the SIINFEKL-specific CD8 T cell responses detected in the blood of C57BL/6 mice vaccinated three times (once at Wk0, once at Wk2 and once at Wk4) s.c., i.d. or i.m. with 0.5 nmol (A) or 2nmol (B) of Z13Mad5Anaxa. Blood was obtained from mice 7 days after the 2nd and the 3rd vaccination and multimer staining was performed (one experiment with 4 mice per group). *, p ⁇ 0.05.
  • FIG. 25 shows for Example 13 KLRG1 expression (A) and PD-1 expression (B), which were analyzed on multimer-positive CD8 T cells (one experiment with 4 mice per group). Briefly, C57BL/6 mice were vaccinated three times (once at Wk0, once at Wk2 and once at Wk4) s.c., i.d. or i.m. with 2nmol of Z13Mad5Anaxa. Blood was obtained from mice 7 days after the 2nd and the 3rd vaccination and FACS staining was performed.
  • FIG. 26 shows for Example 14 SIINFEKL-specific CD8 T cell responses in C57BL/6 mice vaccinated two times (once at Wk0 and once at Wk2) intranodally with 0.5 nmol of Z13Mad5Anaxa. Blood was obtained from mice 7 days after the 2nd vaccination and multimer staining was performed (3 mice per group).
  • FIG. 27 shows for Example 15 the percentage of pentamer-positive cells among CD8 T cells (A and B; *, p ⁇ 0.05) and KLRG1 geomean of pentamer-positive CD8 T cells (C and D).
  • C and D C57BL/6 mice were vaccinated 3 times (A and C: Wk0, Wk2 and Wk4; B and D: Wk0, Wk2 and Wk8) s.c. with 2 nmol of Z13Mad5Anaxa. Mice were bled 7 days after last vaccination and pentamer staining was performed (one experiment with 4 mice per group).
  • FIG. 28 shows for Example 15 the percentage of multimer-positive cells among CD8 T cells (A and D); KLRG1 geomean of multimer-positive CD8 T cells (B and E) and PD1 geomean of multimer-positive CD8 T cells (C and F).
  • A-C C57BL/6 mice were vaccinated 3 times at Day0, Day3 and Day7 and bled at Day7 and Day14.
  • D-F C57BL/6 mice were vaccinated 3 times at Day0, Day7 and Day14 and bled at Day14 and Day21.
  • Vaccination was performed s.c. with 0.5 nmol of Z13Mad5Anaxa. Multimer staining was performed on blood samples (one experiment with 4 mice per group).
  • FIG. 29 shows for Example 16 the IL-6 secretion indicating the APC activation after incubation of BMDCs with various constructs as indicated in the Figure.
  • BMDCs were seeded in flat 96-well plate in culture medium, stimulated with 1 ⁇ M of Z13Mad5Anaxa, Mad5Anaxa, Z13Mad5, EDAZ13Mad5 or EDAMad5 and incubated for 24h at 37° C.
  • IL-6 secretion was quantified by ELISA in the supernatant. Mean ⁇ SEM of 2 to 3 individual experiments.
  • FIG. 30 shows for Example 16 the TNF- ⁇ secretion indicating the APC activation after incubation of Raw 264.7 cells with various constructs as indicated in the Figure. Briefly, Raw 264.7 cells were seeded in flat 96-well plate in culture medium, stimulated with 1 ⁇ M of Z13Mad5Anaxa, Mad5Anaxa or Z13Mad5 and incubated for 24h at 37° C. TNF- ⁇ secretion was quantified by ELISA in the supernatant. Mean ⁇ SEM of 2 to 3 individual experiments.
  • FIG. 31 shows for Example 17 the IL-8 secretion indicating TLR4 binding after incubation of HEK-hTLR4 cells with various constructs as indicated in the Figure.
  • HEK-hTLR4 were seeded in flat 96-well plate in culture medium, stimulated with 1 ⁇ M of Z13Mad5Anaxa, Mad5Anaxa, Z13Mad5, EDAZ13Mad5 or EDAMad5 and incubated 24h at 37° C.
  • IL-8 secretion was quantified by ELISA in the supernatant. Mean ⁇ SEM of 2 individual experiments.
  • FIG. 32 shows for Example 18 the number of metastasis in a lung metastasis model with semitherapeutic settings. Briefly, C57BL/6 mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells and vaccinated twice (d0 and d9) by subcutaneous injection of 2 nmol of EDAZ13Mad5, Z13Mad5 MPLA (equimolar to EDA) or MPLA alone s.c. in the right flank. Mice were euthanized at day 13 and lung recovered. Number of metastasis foci was counted for each lung. **, p ⁇ 0.01 (One-way Anova with Tukey's multiple comparisons test).
  • FIG. 33 shows for Example 19 the number of metastasis in a lung metastasis model with semitherapeutic settings.
  • C57BL/6 mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells and vaccinated twice (d0 and d9) by subcutaneous injection of 0.5 nmol of Z13Mad5Anaxa, Mad5Anaxa or Z13Mad5+Pam3CSK4 (equimolar to Anaxa) s.c. in the right flank. Mice were euthanized at day 21 and lung recovered. Number of metastasis foci was counted for each lung. *, p ⁇ 0.05; **, p ⁇ 0.01 (Unpaired t-test).
  • FIG. 34 shows for Example 20 the quantification of SIINFEKL-specific CD8 T cells in a Quad-GI261 glioblastoma model. Briefly, C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa. SIINFEKL-specific CDS T cells were quantified in blood and in BILs at d28 by multimer staining (5-8 mice per group).
  • FIG. 35 shows for Example 20 the cytokine secretion.
  • C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa.
  • BILs were isolated and cultured during 6h with matured BMDCs loaded or not with SIINFEKL peptide in presence of BrefeldinA before intracellular staining for cytokines.
  • % of CD8 T cells secreting cytokine (5-8 mice per group).
  • FIG. 36 shows for Example 21 the effect of Z13Mad5Anaxa on survival in the Quad-G1261 glioblastoma model. Briefly, C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated three times (d7, d21 and d35) by s.c. injection of 2 nmol of Z13Mad5Anaxa. Mice were weight daily and euthanized when weight loss reached more than 15%.
  • FIG. 37 shows for Example 22 the effect of Z13Mad5Anaxa on tumor growth and survival in subcutaneous EG7-OVA tumor model in a prophylactic setting.
  • C57BL/6 mice were vaccinated twice (d-21 and d-7) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa in the right flank and then implanted at day0 s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank. Tumor size was measured with a caliper.
  • A Tumor growth of 7 mice per group (mean ⁇ SEM); ****, p ⁇ 0.0001 (2-way Anova test at day 30).
  • B Survival curve of 7 mice per group. Median survival is indicated on the graph (m.s.). ***, p ⁇ 0.001 (Log-rank test).
  • FIG. 38 shows for Example 23 the effect of Z13Mad5Anaxa on tumor growth and survival in subcutaneous B16-OVA tumor model in a therapeutic setting on an established tumor.
  • C57BL/6 mice were implanted s.c. with 1 ⁇ 10 5 B16-OVA tumor cells in the left flank and vaccinated twice (d14 and d21) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa in the right flank.
  • A Tumor growth of 7 mice per group (mean ⁇ SEM); *, p ⁇ 0.05 (2-way Anova test at day 32).
  • FIG. 39 shows for Example 24 the effect of the CPP in Z13Mad5Anaxa on tumor growth and survival in subcutaneous EG7-OVA tumor model.
  • C57BL/6 mice were implanted at day0 s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and then vaccinated twice (d5 and d13) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa or Mad5Anaxa in the right flank. Tumor size was measured with a caliper.
  • A Tumor growth of 7 mice per group (mean ⁇ SEM); ****, p ⁇ 0.0001.
  • B Survival curve of 7 mice per group. Median survival is indicated on the graph (m.s.). **, p ⁇ 0.01; ***, p ⁇ 0.001.
  • FIG. 40 shows for Example 25 the effect of complexes having different CPPs on the immune response.
  • C57BL/6 mice were vaccinated five times (Wk0, Wk2, Wk4, Wk6 and Wk8) s.c. with either 2 nmol (A) or 0.5 nmol (B) of Z13Mad5Anaxa, Z14Mad5Anaxa or Z18Mad5Anaxa.
  • Mice were bled 7 days after the 2 nd , 3 rd , 4 th and 5 th vaccination and multimer staining was performed (one experiment with 4 mice per group).
  • * p ⁇ 0.05 between vaccinated versus na ⁇ ve mice at each time point except after Vac2 for Z18Mad5Anaxa-vaccinated mice.
  • FIG. 41 shows for Example 26 the effect of complexes having different CPPs on CD8 T cells in spleen (A), draining lymph nodes (B) and bone marrow (C).
  • C57BL/6 mice were vaccinated five times (Wk0, Wk2, Wk4, Wk6 and Wk8) s.c. with 2 nmol of Z13Mad5Anaxa or Z14Mad5Anaxa.
  • mice were euthanized, organs recovered and multimer staining was performed.
  • FIG. 42 shows for Example 26 the effect of complexes having different CPPs on T cells in spleen (CD8 T cell response (A) and CD4 T cell response (B)).
  • C57BU6 mice were vaccinated five times (Wk0, Wk2, Wk4, Wk6 and Wk8) s.c. with 2 nmol of Z13Mad5Anaxa or Z14Mad5Anaxa.
  • Elispot assay was performed on spleen cells stimulated with SIINFEKL OVACD8 peptide.
  • Elispot assay was performed on spleen cells stimulated with OVACD4 peptide.
  • FIG. 43 shows for Example 26 the effect of complexes having different CPPs on CD8 T cell effector function.
  • C57BL/6 mice were vaccinated five times (Wk0, Wk2, Wk4, Wk6 and Wk8) s.c. with 2 nmol of Z13Mad5Anaxa or Z14Mad5Anaxa.
  • intracellular staining was performed on spleen cells stimulated with SIINFEKL OVACD8 peptide.
  • FIG. 44 shows for Example 27 the effect of complexes having different CPPs on tumor growth (A) and survival rates (B).
  • C57BU6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and d13) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa or Z14Mad5Anaxa in the right flank.
  • A Tumor growth of 7 mice per group (mean ⁇ SEM); *, p ⁇ 0.05; **** p ⁇ 0.0001 (2-way Anova test at day 28).
  • FIG. 45 shows for Example 28 the effect of complexes having different CPPs on the immune response.
  • C57BL/6 mice were vaccinated three times (Wk0, Wk2 and Wk4) s.c. with 2 nmol (A) or 0.5 nmol (B) of EDAZ13Mad5, EDAZ14Mad5 or EDAZ18Mad5.
  • Mice were bled 7 days after the 3rd vaccination and multimer staining was performed (one experiment with 4 mice per group). *, p ⁇ 0.05
  • FIG. 46 shows for Example 29 the effect of EDAZ14Mad5 on tumor growth (A) and survival rates (B).
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and d13) by s.c. injection of 2nmoles of EDAZ14Mad5 in the right flank.
  • Left panel Tumor growth of 7 mice per group (mean ⁇ SEM); **, p ⁇ 0.01 (2-way Anova test at day 27).
  • Right panel Survival curve of 7 mice per group. Median survival is indicated on the graph (m.s.).
  • FIG. 47 shows for Example 30 the quantification of SIINFEKL-specific CD8 T cells in a Quad-GI261 glioblastoma model. Briefly, C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa. SIINFEKL-specific CD8 T cells were quantified in blood and in BILs at d28 by multimer staining (7-16 mice per group).
  • FIG. 48 shows for Example 30 the cytokine secretion. Briefly, C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa. BILs were isolated and cultured during 6h with matured BMDCs loaded or not with SIINFEKL peptide in presence of BrefeldinA before intracellular staining for cytokines. % of CD8 T cells secreting cytokine (7-16 mice per group).
  • FIG. 49 shows for Example 31 the effect of Z13Mad8Anaxa on T cells in spleen (CD8 T cell response (A) and CD4 T cell response (B)).
  • C57BL/6 mice were vaccinated four times (Wk0, Wk2, Wk4 and Wk6) s.c. with 2 nmol of Z13Mad8Anaxa.
  • Elispot assay was performed on spleen cells stimulated gp70CD8 peptide.
  • Elispot assay was performed on spleen cells stimulated with gp70CD4 peptide.
  • FIG. 50 shows for Example 32 the effect of Z13Mad11Anaxa on the number of metastasis in the B16 lung metastasis model (A) and on the T cell response in spleen (B).
  • C57BL/6 mice were vaccinated two times (day0, day10) s.c. with 1 nmol of Z13Mad11Anaxa.
  • FIG. 51 shows for Example 33 the effect of Z13Mad9Anaxa on T cells in spleen (CD8 T cell response.
  • C57BL/6 mice were vaccinated four times (Wk0, Wk2, Wk4 and Wk6) s.c. with 2 nmol of Z13Mad9Anaxa.
  • Elispot assay was performed on spleen cells stimulated with adpgk peptide.
  • FIG. 52 shows for Example 34 the effect of complexes having different CPPs on the immune response.
  • C57BL/6 mice were vaccinated two times (Wk0 and Wk2) s.c. with 2 nmol of either 713Mad5Anaxa or TatFMad5Anaxa. Mice were bled 7 days after the 2 nd vaccination and multimer staining was performed (one experiment with 8 mice per group).
  • FIG. 53 shows for Example 35 the quantification of SIINFEKL-specific CD8 T cells in naive mice. Briefly, C57BL/6 mice were vaccinated once (day0) by s.c. injection of 2 nmol of Z13Mad5Anaxa (group “Z13Mad5Anaxa”) or 2 nmol of Z13Mad5 and 2 nmol of Anaxa (group “Z13Mad5+Anaxa”). SIINFEKL-specific CD8 T cells were quantified in blood at d7 by multimer staining (4-8 mice per group).
  • FIG. 54 shows for Example 36 the effect of Z13Mad12Anaxa on T cells in blood (CD8 T cell response).
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2) s.c. with 2 nmol of Z13Mad12Anaxa.
  • Wk0 and Wk2 the number of mice in blood cells.
  • multimer staining for the neoantigen reps was performed on blood cells.
  • FIG. 55 shows for Example 37 expression of activation marker HLA-DR, CD83, CD80 and CD86 (from left to right) by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of Z13Mad5Anaxa (lower panels) or Z13Mad5 (upper panels) during 48h. Isotype staining for each condition was also performed as shown.
  • FIG. 56 shows for Example 38 the percentage of multimer-positive cells (% of CD8 T cells) over the course of repeated vaccination. Briefly, C57BL/6 mice were vaccinated subcutaneously 6 times (weeks 0, 2, 4, 8, 12, 16) with 2 nmol of Z13Mad5Anaxa. Mice were bled 7 days after each vaccination or before vaccination and pentamer staining was performed (two experiment with 4 mice per group). The arrows under the time axis indicate the vaccination time points.
  • FIG. 57 shows for Example 39 the tumor volume (A) and the survival rate (B) of mice vaccinated with Z13Mad11Anaxa and control mice in the MC-38 tumor model. Briefly, C57BL/6 mice were implanted s.c. with 2 ⁇ 10 5 MC38 tumor cells in the left flank and vaccinated twice ( ⁇ d21 & ⁇ d7 before tumor implantation) by s.c. injection of 2 nmol of Z13Mad11Anaxa in the right flank. (A) Tumor growth and (B) Survival curve of 7 mice per group. Median survival is indicated on the graph (m.s.). *, p ⁇ 0.05; **, p ⁇ 0.01 (Log-rank test).
  • FIG. 59 shows for Example 41 neoantigen adpgk-specific immune response at the tumor site (Tumor-infiltrating cells, TILs) for control (column (A)) and Z13Mad12Anaxa-vaccinated mice (column (B)). FACS dot plots of TILs are shown. Percentage of multimer-positive cells (in % of CD8 T cells) is indicated for each dot plot.
  • FIG. 60 shows for Example 41 neoantigen reps1-specific immune response at the tumor site (Tumor-infiltrating cells, TILs) for control (column (A)) and Z13Mad12Anaxa-vaccinated mice (column (B)). FACS dot plots of blood cells are shown. Percentage of multimer-positive cells (in % of CD8 T cells) is indicated for each dot plot.
  • FIG. 61 shows for Example 41 neoantigen-specific immune response at the tumor site (Tumor-infiltrating cells, TILs) for control and Z13Mad12Anaxa-vaccinated mice. Percentage of multimer-positive cells (in % of CD8 T cells) is shown for each epitope (adpgk (A) and reps1 (B)).
  • FIG. 62 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP110 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 63 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP112 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 64 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP115 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 65 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATM 17 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 66 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATM 18 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 67 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP119 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 68 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP120 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 69 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATM 22 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 70 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 300 nM of ATP123 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 71 shows for Example 42 expression of activation markers HLA-DR, CD83, CD80 and CD86 by human blood monocyte-derived dendritic cells (DCs) from one single buffy.
  • the DCs were stimulated with 600 nM of ATP125 during over night. Isotype staining for each condition was also performed as shown.
  • FIG. 72 shows for Example 43 the tumor growth (A) and the survival rate (B) of 13 to 14 mice per group (mean ⁇ SEM).
  • C57BL/6 mice were implanted s.c. with 2 ⁇ 10 5 MC-38 tumor cells on the back.
  • Mice of the groups “Z13Mad12Anaxa” and “Z13Mad12Anaxa+anti-PD1” were vaccinated 3 times (d3, dl 0 and d17) by subcutaneous injection of 2 nmol of Z13Mad12Anaxa at the tail base. 200 ⁇ g of anti-PD1 antibody were administered i.p.
  • FIG. 73 shows for Example 43 individual tumor growth curves of 13 to 14 mice per group.
  • C57BL/6 mice were implanted s.c. with 2 ⁇ 10 5 MC-38 tumor cells on the back.
  • Mice of the groups “Z13Mad12Anaxa” and “Z13Mad12Anaxa+anti-PD1” were vaccinated 3 times (d3, d10 and d17) by subcutaneous injection of 2 nmol of Z13Mad12Anaxa at the tail base.
  • 200 ⁇ g of anti-PD1 antibody were administered i.p. on each of days 6, 10, 13, 17, 20, 24 and 27 to mice of groups “anti-PD1” and “Z13Mad12Anaxa+anti-PD1”. Tumor size was measured with a caliper.
  • FIG. 74 shows for the results for Example 44.
  • C57BL/6 mice were vaccinated once with 4nmol of ATP128. Mice were bled 7 clays later and Elispot assay was performed on blood cells stimulated with dendritic cells loaded with ATP128 (one experiment).
  • FIG. 75 shows for Example 45 the Activation Index of human blood monocyte-derived dendritic cells (DCs) from ten different buffys.
  • the DCs were stimulated with 300 nM of ATP128 overnight.
  • Negative and positive controls were performed by incubating cells with buffer and MPLA, respectively.
  • FIG. 76 shows for Example 46 the regions of ATP128 containing peptides that were found presented on MHC class I (A) and class II (B) at the surface of human dendritic cells from two different donors, donor 9 (solid line) and donor 10 (dotted line), after overnight loading with ATP128 and the respective number of peptides presented on MHC class I and class II (C). Underlined numbers correspond to peptides previously described in the literature as immunogenic peptides.
  • the complex for use according to the present invention is a fusion protein, comprising the cell-penetrating peptide “Z13”, a protein “MAD5”, which consists of different CD8 + and CD4 + epitopes from various antigens, and the TLR4 peptide agonist “EDA”. Accordingly, a fused protein with the EDA peptide at the N-terminal position and different control conjugated proteins without Z13 or EDA or both were designed.
  • the EDAZ13Mad5, Z13Mad5 and Mad5 proteins were investigated for their capacity to induce human dendritic cell (DC) maturation. After incubation during 48h with 300 nM of protein, activation markers expression (CD86, CD40, CD83 and HLA-DR) was assessed on the human DCs by FACS ( FIGS. 1-4 ). Specific buffers of each protein were used as negative controls.
  • Results are shown for CD40 in FIG. 1 , for CD86 in FIG. 2 , for HLADR in FIG. 3 , and for CD83 in FIG. 4 .
  • EDAZ13Mad5 induced maturation of human DCs
  • Z13Mad5 and Mad5 proteins were not able to activate human DCs.
  • BMDCs were loaded overnight with 300 nM of with the EDAMad5, EDAZ13Mad5 and Mad5 proteins containing OVACD8, OVACD4 and gp100 epitopes. Processing and presentation of these MHC I-restricted OVACD8 and gp100 epitopes were monitored by measuring the in vitro proliferation of na ⁇ ve OVA 257-264 -specific CD8 + T cells from OT-1 T cell receptor (TCR) transgenic mice and gp100-specific CD8 + T cells from P-mel T cell TCR transgenic mice respectively.
  • TCR OT-1 T cell receptor
  • MHC class I-restricted presentation of OVACD8 epitope and gp100 epitope was monitored after 4 days with CFSE-labeled 011 cells and P-Mel cells respectively.
  • Processing and presentation of MHC II-restricted OVACD4 epitope was monitored by measuring the in vitro proliferation of na ⁇ ve OVA 323-339 -specific CD4 + T cells from OT-2 T cell receptor (TCR) transgenic mice.
  • efficient MHC class II-restricted presentation of OVACD4 epitope was monitored after 4 days with CFSE-labeled OT2 cells.
  • BMDCs were pulsed for 1h with 5 uM peptide (one experiment representative of 2 individual experiments).
  • Results are shown in FIG. 5 . Similar cross-presentation and processing capacity of all assessed Mad5-based proteins were observed.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2), by subcutaneous injection of either 2 nmol or 10 nmol of the constructs EDAZ13Mad5 or EDAMad5 (described in Examples 1 and 2).
  • Positive control group was vaccinated with Mad5 and the TLR4 agonist MPLA (equimolar to EDA).
  • Two doses were assessed 2 nmol of the construct ( FIG. 6 ) and 10 nmol of the construct ( FIG. 7 ). 3-4 mice were used per group.
  • mice Seven days after the last vaccination, mice were bled and pentamer staining was performed to monitor the OVA-specific immune response in the blood.
  • pentamer staining was performed to monitor the OVA-specific immune response in the blood.
  • FIG. 8 the percentage of pentamer positive CD8+ T cells is shown for all groups and both doses tested.
  • mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank. After tumor implantation, mice were vaccinated at day 5 and 13 with 10 nmol of one of the following constructs (cf. Examples 1 and 2 for construct description): EDAZ13Mad5, EDAMad5, Mad5, or Mad5 and MPLA (equimolar to WA) s.c. in the right flank. Tumor size was measured with a caliper.
  • FIG. 9 shows the tumor growth of 7 mice per group (mean ⁇ SEM); *, p ⁇ 0.05 EDAZ13Mad5 versus control group (2-way Anova test).
  • FIG. 10 shows individual tumor growth curves (7 individual mice per group).
  • FIG. 11 A shows the survival curve of 7 mice per group; *, p ⁇ 0.05 EDAZ13Mad5 versus control group (Log-rank test).
  • FIG. 11 B shows the tumor-free progression curve of 7 mice per group; *, p ⁇ 0.05 EDAZ13Mad5 versus control group (Log-rank test).
  • EDAZ13Mad5 was the only protein vaccine to significantly control the tumor growth compared to the control group with a significant better tumor free progression curve and survival curve.
  • construct protein EDAZ13Mad5 is a highly potent vaccine for controlling the tumor growth in a therapeutic setting.
  • EDAMad5 EDAZ13Mad5
  • Z13Mad5+MPLA cf. Examples 1 and 2 for design of the constructs
  • MPLA alone C57BL/6 mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells and at the same time (d0) 2 nmol of the vaccine (EDAMad5, EDAZ13Mad5, Z13Mad5+ MPLA, MPLA alone) was administered by subcutaneous injection in the right flank. Nine days later, mice were vaccinated a second time with the same dose.
  • Example 6 Vaccine Efficacy on Tumor Growth in a Melanoma Metastasis Model—Prophylactic Setting
  • mice were vaccinated 21 and 7 days before implantation of tumor cells (d-21 and d-7) by subcutaneous injection of 2 nmol of EDAZ13Mad5, EDAMad5 or Z13Mad5+MPLA (equimolar to EDA) s.c. in the right flank.
  • mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells. Mice were euthanized at day 14 and lung recovered. Results are shown in FIG. 13 .
  • Example 7 Design of Further Constructs Comprising a TLR2 Peptide Agonist
  • the complex for use according to the present invention is again a fusion protein, comprising the cell-penetrating peptide “Z13”, the protein “MAD5”, which consists of different CD8 + and CD4 + epitopes from various antigens, and the TLR2 peptide agonist “Anaxa”. Accordingly, fused proteins with the Anaxa peptide at the C-terminal or N-terminal position were designed.
  • Endotoxin level 3.1 EU/mg
  • HEK-BlueTM hTLR2 were seeded in flat 96-well plate in culture medium, stimulated with 0.3 ⁇ M, 1 ⁇ M or 3 ⁇ M of AnaxaZ13Mad5 or Z13Mad5Anaxa and incubated at 37° C. for 24h. Positive control was performed with 500 ng/ml of Pam3CSK4, a TLR2 agonist.
  • C57BL/6 mice were vaccinated twice (Wk0 and Wk2), by subcutaneous injection of 2 nmol of AnaxaZ13Mad5 or 2 nmol of Z13Mad5Anaxa. Seven clays after the last vaccination, mice were bled and to monitor the OVA-specific immune response in the blood, pentamer staining was performed (one experiment with 4 mice per group). Results are shown in FIGS. 15 and 16 .
  • Example 7 To evaluate the effect of the Anaxa-conjugated construct proteins designed in Example 7 on tumor growth control, a benchmark tumor model was used, namely the s.c. implantation of EG.7-OVA thymoma cells.
  • mice C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank. After tumor implantation, the three groups of 7 mice each were vaccinated s.c. in the right flank at day 5 and 13 by subcutaneous injection of 10 nmol of either AnaxZ13Mad5 (group 1), Z13Mad5Anaxa (group 2) or Z13Mad5 and Pam3CSK4 (equimolar to Anaxa; group 3). In order to compare the effect to a protein mixed with an external adjuvant, a control group was vaccinated with Z13Mad5 and Pam3CSK4 (equimolar to Anaxa). Tumor size was measured with a caliper. Results are shown in FIG. 17-19 .
  • Z13Mad5Anaxa and AnaxaZ13Mad5 are better protein vaccines for controlling tumor growth compared to the control group, i.e. co-injection of Z13Mad5 and Pam3CSK showing a significant better survival curve.
  • Z13Mad5Anaxa and AnaxaZ13Mad5 demonstrate significantly higher efficacy than Z13Mad5 administrated separately with Pam3CSK4. The results therefore suggest that the construct proteins Z13Mad5Anaxa and AnaxaZ13Mad5 are promising conjugate-vaccines for controlling the tumor growth in a therapeutic setting.
  • mice C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG.7-OVA thymoma cells in the left flank as described previously in Example 10.
  • Mice (7 individual mice per group) were vaccinated s.c. in the right flank at day 5 and 13 with 2 nmol of either EDAZ13Mad5, Z13Mad5Anaxa or co-injection of Z13Mad5+MPLA (equimolar to EDA).
  • Results are shown in FIGS. 20, 21 and 22 .
  • Z13Mad5Anaxa, EDAZ13Mad5, and Z13Mad5+MPLA were similarly able to significantly control tumor growth.
  • Z13Mad5Anaxa is the best construct to significantly control tumor growth and EDAZ13Mad5 was slightly better than Z13Mad5+MPLA in this experimental setting.
  • Z13Mad5Anaxa three different doses (0.5 nmol, 2 nmol and 10 nmol) of Z13Mad5Anaxa (cf. Example 7) were assessed for their ability to control tumor growth.
  • the dose effect of Z13Mad5Anaxa construct was evaluated in the s.c. model of EG.7-OVA thymoma cells as described previously in Example 10. After tumor implantation, mice were vaccinated twice (at day 5 and at day 13 after tumor implantation) in a therapeutic setting at 0.5, 2 or 10 nmol of Z13Mad5Anaxa.
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and vaccinated twice (d5 and d13) by subcutaneous injection of either 0.5 nmol, 2 nmol or 10 nmol of Z13Mad5Anaxa in the right flank. Tumor size was measured with a caliper. The tumor growth of 7 mice per group is depicted in FIG. 23 . Those data show that the doses of 0.5 and 2 nmol are at least as efficacious as 10 nmol for controlling tumor growth.
  • mice were vaccinated three times every two weeks (Wk0, Wk2 and Wk4) with 0.5 or 2 nmol of 713Mad5Anaxa (cf. Example 7).
  • the 1st and the 3rd vaccinations were performed in the right flank whereas the 2nd was done in the left flank.
  • SIINFEKL-specific CD8+T cell response was analyzed 1 week after the 2nd and the 3rd vaccination in the blood.
  • FIG. 24 shows the SIINFEKL-specific CD8 T cell responses after each vaccination detected in the blood of C57BU6 mice vaccinated three times (Wk0, Wk2 and Wk4) s.c., i.d. or i.m.
  • FIG. 24 A 0.5 nmol
  • FIG. 24 B 2nmol
  • Z13Mad5Anaxa Blood was obtained from mice 7 days after the 2nd and the 3rd vaccination and multimer staining was performed (one experiment with 4 mice per group).
  • results indicate that at the two doses assessed (0.5 and 2nmol), (i) all routes of administration tested elicited a SIINFEKL-specific CD8 immune response and (ii) the subcutaneous vaccination elicited the strongest SIINFEKL-specific CD8 immune response.
  • the maximum response was reached after the 3nd vaccination and still maintained after the 3rd vaccination.
  • the SIINFEKL-specific CD8 immune response after the 2nd vaccination elicited by intradermal and intramuscular vaccinations is lower compared to subcutaneous vaccination and is not enhanced after the 3rd vaccination.
  • mice were vaccinated three times (Wk0, Wk2 and Wk4) s.c., i.d. or i.m. with 2nmol of Z13Mad5Anaxa (cf. Example 7).
  • Blood was obtained from mice 7 days after the 2nd and the 3rd vaccination and FACS staining was performed.
  • KLRG1 and PD-1 expression were analyzed on multimer-positive CD8 T cells (one experiment with 4 mice per group). Results are shown in FIG. 25 .
  • KLRG 1 is strongly increasing on SIINFEKL-specific CD8 T cells after subcutaneous vaccination. After i.d. or i.m. vaccination, the observed effects were lower. The percentage of KLRG 1-positive cells among SIINFEKL-specific CD8 T cells is also enhanced after s.c. vaccination (data not shown).
  • PD-1 expression is decreasing with the time and the vaccinations, for subcutaneous and intramuscular vaccination routes. This suggests that SIINFEKL-specific CD8 T cells are not exhausted. The percentage of PD1-positive cells among SIINFEKL-specific CD8 T cells is also reduced after s.c. and i.m. vaccination (data not shown). It is important to note that PD-1 expression is higher after the 2nd vaccination when mice were vaccinated subcutaneously, reflecting the early activation status of specific T cells (Keir, M. E., et al., PD -1 and its ligands in tolerance and immunity . Annu Rev Immunol, 2008. 26: p. 677-704).
  • Tim-3 The expression of the late exhaustion marker Tim-3 was also analyzed. A very low expression as observed for all groups.
  • results indicate that subcutaneous vaccination elicits the best specific CD8 immune response compared to intramuscular or intradermal injections.
  • Example 13 Based on the previous experiments (Example 13), the intranodal route of administration was additionally investigated. To this end, the immune response elicited by intranodal injection of Z13Mad5Anaxa (cf. Example 7) was investigated.
  • mice were first injected with Evans Blue subcutaneously in order to allow easily visualizing the lymph nodes for injection and inject intranodally without invasive surgery, for example as described in Jewell, C. M., S. C. Lopez, and D. J. Irvine, In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant - releasing polymer particles . Proc Natl Acad Sci USA, 2011. 108(38): p. 15745-50.
  • C57BL/6 mice were vaccinated two times every two weeks (Wk0 and Wk2) intranodally with 0.5 nmol of Z13Mad5Anaxa (cf. Example 7).
  • the 1st vaccination was performed in the right inguinal lymph node, whereas the second vaccination was done in the left inguinal lymph node.
  • Blood was obtained from mice 7 days after the 2nd vaccination and multimer staining was performed (3 mice per group).
  • SIINFEKL-specific CD8+T cell response was analyzed one week after the 2nd vaccination in the blood.
  • FIG. 26 shows the SIINFEKL-specific CD8 T cell responses. Those data indicate that also intranodal injection was able to elicit SIINFEKL-specific CD8 T cells.
  • the vaccination schedule evaluation work was initiated with the objective to identify the impact of the third vaccination using the same Z13Mad5Anaxa construct as described above (cf. Example 7).
  • the subcutaneous route was chosen given the previous results.
  • SIINFEKL-specific CD8+T cell response was analyzed one week after the 2nd and the 3rd vaccination ( FIGS. 28A and D). Additionally, the effector function of SIINFEKL-specific T cells was evaluated by analyzing the expression of KLRG 1 on specific CD8 T cells (FIGS. 28 B and 28 E) and the exhaustion status by analyzing the PD-1 expression of specific T cells ( FIGS. 28C and 28F ).
  • vaccination schedule data set indicates that the Wk0-Wk2-Wk4 vaccination schedule is the best vaccination schedule for inducing potent OVA-specific CD8 immune response with high effector function.
  • Example 16 Capacity of TLR Agonist-CPP Conjugate Constructs to Activate Murine Antigen-Presenting Cells (APCs)
  • control peptide is also a fusion protein and which comprises the protein “MAD5”, which consists of different CD8 + and CD4 + epitopes from various antigens, and the TLR2 peptide agonist “Anaxa” (i.e. without cell penetrating peptide). Accordingly, the following control construct was additionally designed:
  • the aim of this study was to evaluate the capacity of two exemplary complexes according to the present invention, namely EDAZ13Mad5 (cf. Example 1) and Z13Mad5Anaxa (cf. Example 7), to promote antigen-presenting cells activation in comparison to reference complexes lacking either the cell penetrating peptide component Z13 (Mad5Anaxa, cf. above; EDAMad5, cf. Example 2) or the TLR agonist (Z13Mad5, cf. Example 1).
  • BMDCs bone marrow-derived dendritic cells
  • BMDCs were seeded in flat 96-well plate in culture medium, stimulated with 1 pM of either Z13Mad5Anaxa (cf. Example 7), Mad5Anaxa (cf. above), Z13Mad5 (cf. Example 1), EDAZ13Mad5 (cf. Example 1) or EDAMad5 (cf. Example 2) and incubated for 24h at 37° C.
  • the APC activation was investigated by monitoring the secretion of IL-6 in the culture supernatant of BMDCs. IL-6 secretion was quantified by ELISA in the supernatant.
  • Raw 264.7 cells were seeded in flat 96-well plate in culture medium, stimulated with 1 ⁇ M of either Z13Mad5Anaxa (cf. Example 7), Mad5Anaxa (cf. above) or Z13Mad5 (cf. Example 1) and incubated for 24h at 37° C.
  • the CPP may facilitate the entry of the molecule into the cells, allowing a better targeting of intracellular TLR.
  • a complex for use according to the present invention comprising the Anaxa peptide as TLR agonist, for example Z13Mad5Anaxa, is able to bind to human TLR2 and to promote the secretion of IL-8 by HEK-hTLR2 cells (cf. Example 8, FIG. 14 ).
  • HEK cells transfected with human TLR4 were seeded in flat 96-well plate in culture medium, stimulated with 1 ⁇ M of either Z13Mad5Anaxa (cf. Example 7), Mad5Anaxa (cf. above), Z13Mad5 (cf. Example 1), EDAZ13Mad5 (cf. Example 1) or EDAMad5 (cf. Example 2) and incubated for 24h at 37° C.
  • IL-8 secretion was quantified by ELISA in the supernatant.
  • Results are shown in FIG. 31 .
  • incubation of HEK-hTLR4 with EDAZ13Mad5 resulted in remarkable IL-8 secretion, indicating binding of EDAZ13Mad5 to TLR4.
  • the IL-8 secretion of EDAMad5 was remarkably lower as compared to EDAZ13Mad5, showing the effect of the presence of a CPP.
  • the Z13Mad5 construct which does not comprise a TLR agonist, showed no IL-8 secretion, indicating—as expected—a lack of binding to TLR4.
  • Example 18 Vaccine Efficacy on Tumor Growth in a Lung Metastasis Model—Semi-Therapeutic Setting: TLR Agonist EDA
  • Example 6 shows the efficacy of a complex for use according to the present invention, namely EDAZ13Mad5, in a melanoma lung metastasis model in a prophylactic setting (cf. FIG. 13 ).
  • mice were vaccinated at the same time as tumor cells were implanted (d0) and, for a second time, at nine days after implantation (d9).
  • Vaccination was performed by subcutaneous injection of 2 nmol of EDAZ13Mad5, Z13Mad5+MPLA (equimolar to EDA) or MPLA s.c. in the right flank. At day 0, mice were implanted i.v.
  • Example 19 Vaccine Efficacy on Tumor Growth in a Lung Metastasis Model—Semi-Therapeutic Setting: TLR Agonist Anaxa
  • Example 18 This study is based on Example 18 with the same model (semitherapeutic settings) and experimental schedule. However, the effect of complexes according to the present invention comprising the “Anaxa” peptide as TLR agonist were investigated—instead of the EDA TLR agonist as in Example 18.
  • mice C57BL/6 mice were implanted i.v. with 1 ⁇ 10 5 B16-OVA melanoma tumor cells and vaccinated twice (d0 and d9) by subcutaneous injection of 0.5 nmol of Z13Mad5Anaxa, Mad5Anaxa or Z13Mad5+Pam3CSK4 (equimolar to Anaxa) s.c. in the right flank. Mice were euthanized at day 21 and the lung was recovered. Number of metastasis foci was counted for each lung. The results are shown in FIG. 33 .
  • GBM glioblastoma multiforme
  • the G1261 glioma is a carcinogen-induced mouse glioma model.
  • This model represents one of the very few brain tumor models developed in immunocompetent animals, that has growth characteristics similar to human GBM (Newcomb, E. and D. Zagzag, The murine GL 261 glioma experimental model to assess novel brain tumor treatments , in CNS Cancer Models, Markers, Prognostic, Factors, Targets, and Therapeutic Approaches , E.G. Van Meir, Editor. 2009, Humana Press: Atlanta. p. 227-241; Jacobs, V. L., et al., Current review of in vivo GBM rodent models: emphasis on the CNS -1 tumour model . ASN Neuro, 2011.
  • GI261 model (Ohlfest, J. R., et al., Vaccine injection site matters: qualitative and quantitative defects in CDB T cells primed as a function of proximity to the tumor in a marine glioma model . J Immunol, 2013. 190(2): p. 613-20) by transfecting GI261 cell line with the “Quad Cassette” expressing four peptides presented by H-2b class I or II molecules: human gp100 25-33 , chicken OVA 257-264 , chicken OVA 323-339 , and mouse I-E ⁇ 52-68 .
  • the Quad-GI261 cell line also stably expresses luciferase, which allows the follow-up of tumor growth by bioluminescence.
  • the goal of this study was to assess the efficacy of a complex for use according to the present invention in the Quad-GI261 glioblastoma model.
  • Z13Mad5Anaxa The effect of a complex for use according to the present invention, namely Z13Mad5Anaxa (cf. Example 7) was evaluated in the above described glioblastoma model. T cell homing at the tumor site was therefore analyzed in GI261-Quad tumor-bearing mice vaccinated twice (Wk1 and Wk3) with Z13Mad5Anaxa vaccine. A group vaccinated with Z13Mad5 and Anaxa (equimolar to Z13Mad5Anaxa) administrated separately was used as control. Briefly, C57BL/6 mice were implanted i.c.
  • SIINFEKL-specific CD8 T cells In general, low frequency of SIINFEKL-specific CD8 T cells was quantified in the blood. However, a higher percentage of SIINFEKL-specific CD8 T cells was observed in the blood of Z13Mad5Anaxa-vaccinated mice. In all groups, there was a sensibly stronger accumulation of SIINFEKL-specific CD8 T cells in the BILs.
  • cytokine secretion was assessed.
  • C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa.
  • BILs were isolated and cultured during 6h with matured BMDCs loaded or not with SIINFEKL peptide in presence of BrefeldinA before intracellular staining for cytokines. Results are shown in FIG. 35 .
  • Z13Mad5Anaxa is efficacious for eliciting high brain infiltrating SIINFEKL-specific CD8 immune response.
  • Z13Mad5Anaxa is able to promote the secretion of cytokine by antigen-specific CD8 T cells in the brain.
  • mice C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 GI261-Quad tumor cells and vaccinated three times (d7, d21 and d35) by s.c. injection of 2 nmol of Z13Mad5Anaxa. Mice were weight daily and euthanized when weight loss reached more than 15%. Results are shown in FIG. 36 .
  • Example 22 Vaccine Efficacy in a Subcutaneous Tumor Model—Prophylactic Setting
  • Example 7 To evaluate the effect of the Anaxa-conjugated construct proteins designed in Example 7 on tumor growth control, a benchmark tumor model was used, namely the s.c. implantation of EG.7-OVA thymoma cells. In contrast to Example 10, wherein vaccination was performed on clays 5 and 13, in the present study a prophylactic setting was evaluated, wherein mice were vaccinated 21 and 7 clays before tumor implantation.
  • C57BL/6 mice were vaccinated twice (d-21 and d-7) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa in the right flank and then implanted at day0 s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and. Tumor size was measured with a caliper.
  • FIG. 37 The results are shown in FIG. 37 with tumor volume ( FIG. 37 A) and survival rate ( FIG. 37 B).
  • the data is showing that prophylactic vaccination with Z13Mad5Anaxa is highly efficacious for controlling tumor growth and survival rate.
  • the volume of the tumor is highly significantly decreased in mice treated with Z13Mad5Anaxa as compared to control mice.
  • the survival rate is highly significantly increased in mice treated with Z13Mad5Anaxa as compared to control mice.
  • Example 23 Vaccine Efficacy in a Subcutaneous Tumor Model—Therapeutic Setting with Established Tumor
  • Example 7 This study is based on the results obtained in Example 10 as shown in FIGS. 17-19 and on the results obtained in Example 22 shown in FIG. 37 . It was the goal of this study to evaluate the effect of Z13Mad5Anaxa (cf. Example 7) on an established tumor.
  • the s.c. model of B16-OVA melanoma cells was used.
  • tumor cells are spreading slowly, therefore allowing a bigger vaccination time window.
  • the first vaccination with the low dose of 0.5 nmol of Z13Mad5Anaxa was performed once the tumor was established and visible i.e. at day 14 after tumor cell implantation.
  • C57BL/6 mice were implanted s.c. with 1 ⁇ 10 5 B16-OVA tumor cells in the left flank and vaccinated twice (d14 and d21) by s.c. injection of 0.5 nmol of Z13Mad5Anaxa in the right flank. Tumor growth and survival curves were monitored. Results are shown in FIG. 38 .
  • the protocol of this study corresponds to the study described in Example 10, with the difference that an additional group “Mad5Anaxa” (cf. Example 16) was evaluated.
  • a benchmark tumor model was used, namely the s.c. implantation of EG.7-OVA thymoma cells.
  • C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank.
  • groups of 7 mice each were vaccinated s.c. in the right flank at day 5 and 13 by subcutaneous injection of 0.5 nmol of either Z13Mad5Anaxa (group 1) or Mad5Anaxa (group 2) and compared to a control group. Tumor size was measured with a caliper. Results are shown in FIG. 39 .
  • mice treated with Z13Mad5Anaxa show a significantly decreased tumor volume and a significantly increased survival rate compared to both, control mice and mice treated with Mad5Anaxa, i.e. a construct without CPP.
  • These results indicate that the presence of a CPP results in significantly decreased tumor volume and a significantly increased survival rate, i.e. in increased efficiency of vaccination. Therefore, the results indicate—together with the results obtained in Example 10—that the presence of a CPP and the TLR agonist exert a synergic effect on tumor growth and survival rate.
  • fusion proteins which comprise CPPs other than Z13—namely Z14 (SEQ ID NO: 7) or Z18 (SEQ ID NO: 11).
  • Those fusion proteins also comprise the protein “MAD5”, which consists of different CD8 + and CD4 + epitopes from various antigens, and the TLR2 peptide agonist “Anaxa”. Accordingly, the following constructs were additionally designed:
  • mice were assigned to eight different groups (4 mice per group): three groups receiving 2 nmol of either Z13Mad5Anaxa, Z14Mad5Anaxa or Z18Mad5Anaxa and a respective control and three groups receiving 0.5 nmol of Z13Mad5Anaxa, Z14Mad5Anaxa or Z18Mad5Anaxa and a respective control.
  • the mice were vaccinated five times (Week0, Week2, Week4, Week6 and Week8) s.c. Mice were bled 7 days after the 2 nd , 3 rd , 4 th and 5 th vaccination and multimer staining was performed (one experiment with 4 mice per group).
  • C57BL/6 mice were assigned to three different groups (3-4 mice per group): naive, Z13Mad5Anaxa or Z14Mad5Anaxa.
  • C57BL/6 mice of the Z13Mad5Anaxa group and of the Z14Mad5Anaxa group were vaccinated five times (Week0, Week2, Week4, Week6 and Week8) s.c. with 2 nmol of either Z13Mad5Anaxa (cf. Example 7) or Z14Mad5Anaxa (cf. Example 25).
  • mice Nine days after the 5th vaccination, mice were euthanized, organs recovered and multimer staining was performed to identify the percentage of SIINFEKL-specific CD8 T cells in the spleen, bone marrow and draining lymph nodes (inguinal and axillary).
  • mice vaccinated with Z13Mad5Anaxa or with Z14Mad5Anaxa showed a similar increase in multimer-positive cells, in particular in the spleen and bone marrow as well as a slight increase in draining lymph nodes.
  • mice vaccinated with Z13Mad5Anaxa showed a significant increase in IFN- ⁇ producing cells compared to na ⁇ ve mice.
  • Mice vaccinated with Z14Mad5Anaxa showed also an increase in IFN- ⁇ producing cells compared to na ⁇ ve mice, however, the increase was not significant, which may be due to the low number of mice (3 mice in Z14Mad5Anaxa group).
  • mice vaccinated with Z13Mad5Anaxa showed a highly significant increase in IFN- ⁇ producing cells compared to na ⁇ ve mice.
  • Mice vaccinated with Z14Mad5Anaxa showed also an increase in IFN- ⁇ producing cells compared to na ⁇ ve mice, however, the increase was not significant, which may be due to the low number of mice (3 mice in Z14Mad5Anaxa group).
  • mice intracellular staining was performed on spleen cells stimulated with SIINFEKL OVACD8 peptide (SEQ ID NO: 35) to identify CD107a + IFN- ⁇ + TNF- ⁇ + cells. Results are shown in FIG. 43 . Mice vaccinated with Z13Mad5Anaxa or with Z14Mad5Anaxa showed a similar increase in CD107a + IFN- ⁇ + JNF- ⁇ + cells.
  • mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and assigned to three different groups (na ⁇ ve, Z13Mad5Anaxa and Z14Mad5Anaxa). Mice were vaccinated twice at d5 and d13 after tumor implantation by s.c. injection of either 0.5 nmol of Z13Mad5Anaxa or Z14Mad5Anaxa in the right flank.
  • Results are shown in FIG. 44 .
  • Vaccination with Z13Mad5Anaxa or with Z14Mad5Anaxa resulted in significantly decreased tumor volumes compared to control mice ( FIG. 44 A) as well as to significantly increased survival rates compared to control mice ( FIG. 44 B).
  • Those results indicate that both complexes, Z13Mad5Anaxa and Z14Mad5Anaxa, are able to significantly decrease tumor growth and to significantly prolong survival.
  • Example 28 Comparison of the Immune Responses after Vaccination with Complexes Having Different Cell Penetrating Peptides
  • fusion proteins which comprise CPPs other than Z13—namely Z14 (SEQ ID NO: 7) or Z18 (SEQ ID NO: 11).
  • Those fusion proteins also comprise the protein “MAD5”, which consists of different CD8 + and CD4 + epitopes from various antigens, and the TLR4 peptide agonist “EDA”. Accordingly, the following constructs were additionally designed:
  • mice were assigned to eight different groups (4 mice per group): three groups receiving 2 nmol of either EDAZ13Mad5, EDAZ14Mad5 or EDAZ18Mad5 and a respective control and three groups receiving 0.5 nmol of either EDAZ13Mad5, EDAZ14Mad5 or EDAZ18Mad5 and a respective control group.
  • the mice were vaccinated three times (Week0, Week2 and Week4) s.c. Mice were bled 7 days after the 2 nd and 3 rd vaccination and multimer staining was performed (one experiment with 4 mice per group).
  • mice On d0 C57BL/6 mice were implanted s.c. with 3 ⁇ 10 5 EG7-OVA tumor cells in the left flank and assigned to two different groups (naive and EDAZ14Mad5). Mice were vaccinated twice at d5 and dl 3 after tumor implantation by s.c. injection of 0.5 nmol of EDAZ14Mad5 in the right flank.
  • Results are shown in FIG. 46 .
  • EDAZ13Mad5 cf. Example 4, FIGS. 9-11
  • vaccination with EDAZ14Mad5 resulted in significantly decreased tumor volumes compared to control mice ( FIG. 46 A) as well as to significantly increased survival rates compared to control mice ( FIG. 46 B).
  • Those results indicate that EDAZ14Mad5 is able to significantly decrease tumor growth and to significantly prolong survival—similarly to EDAZ13Mad5 (cf. Example 4, FIGS. 9-11 ).
  • Example 30 Superior Efficacy of Z13Mad5Anaxa Fusion Construct Compared to Z13Mad5 and Anaxa in a Glioblastoma Model
  • glioblastoma model was chosen (cf. Example 20). Namely, Z13Mad5Anaxa (cf. Example 7; SEQ ID NO: 28) was administered to one group of mice, whereas Z13Mad5 (SEQ ID NO: 29) and Anaxa (SEQ ID NO: 15) were administered (both together) to another group of mice.
  • T cell homing at the tumor site was analyzed in G1261-Quad tumor-bearing mice (7-16 mice per group) vaccinated twice, namely at day 7 and at day 21 after tumor implantation (day 0), with 2 nmol Z13Mad5Anaxa vaccine.
  • a group vaccinated with both, Z13Mad5 and Anaxa was used as control.
  • C57BL/6 mice were implanted i.c. (intracranially) with 5 ⁇ 10 5 G1261-Quad tumor cells and vaccinated twice (at d7 and d21 following implantation) by s.c.
  • FIG. 47 Results are shown in FIG. 47 .
  • a significantly higher percentage of SIINFEKL-specific CD8 T cells was observed in the blood of Z13Mad5Anaxa-vaccinated mice as compared to mice vaccinated with both, Z13Mad5 and Anaxa ( FIG. 47A ).
  • cytokine secretion was assessed.
  • C57BL/6 mice were implanted i.c. with 5 ⁇ 10 5 G1261-Quad tumor cells and vaccinated twice (d7 and 21) by s.c. injection of 2 nmol of Z13Mad5Anaxa or 2 nmol of Z13Mad5 and 2 nmol of Anaxa.
  • BILs were isolated and cultured during 6h with matured BMDCs loaded or not with SIINFEKL peptide (SEQ ID NO: 35) in presence of BrefeldinA before intracellular staining for cytokines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US16/331,398 2016-09-21 2017-09-21 Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer Abandoned US20190255165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2016072475 2016-09-21
EPPCT/EP2016/072475 2016-09-21
PCT/EP2017/073954 WO2018055060A1 (fr) 2016-09-21 2017-09-21 Fusion comprenant un peptide de pénétration cellulaire, un multi-épitope et un agoniste des peptides tlr pour le traitement du cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/073954 A-371-Of-International WO2018055060A1 (fr) 2016-09-21 2017-09-21 Fusion comprenant un peptide de pénétration cellulaire, un multi-épitope et un agoniste des peptides tlr pour le traitement du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/104,786 Continuation US11338027B2 (en) 2016-09-21 2020-11-25 Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

Publications (1)

Publication Number Publication Date
US20190255165A1 true US20190255165A1 (en) 2019-08-22

Family

ID=60037562

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/331,398 Abandoned US20190255165A1 (en) 2016-09-21 2017-09-21 Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer
US17/104,786 Active US11338027B2 (en) 2016-09-21 2020-11-25 Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US17/718,975 Pending US20220305101A1 (en) 2016-09-21 2022-04-12 Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/104,786 Active US11338027B2 (en) 2016-09-21 2020-11-25 Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US17/718,975 Pending US20220305101A1 (en) 2016-09-21 2022-04-12 Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer

Country Status (13)

Country Link
US (3) US20190255165A1 (fr)
EP (1) EP3515476B1 (fr)
JP (1) JP7346291B2 (fr)
KR (2) KR20230131498A (fr)
CN (1) CN109963585B (fr)
AU (1) AU2017331949A1 (fr)
CA (1) CA3031170A1 (fr)
CL (3) CL2019000694A1 (fr)
DK (1) DK3515476T3 (fr)
IL (1) IL265479B (fr)
MX (1) MX2019002968A (fr)
PL (1) PL3515476T3 (fr)
WO (1) WO2018055060A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087363A1 (en) * 2018-09-17 2020-03-19 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
US11338027B2 (en) * 2016-09-21 2022-05-24 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141084A1 (fr) * 2019-06-12 2020-12-17 Vikram JUNEJA Compositions de neoantigenes et utilisations associees
CN110448689A (zh) * 2019-08-06 2019-11-15 太仓美诺恒康生物技术有限公司 mRNA疫苗及其试剂盒、应用
EP3827840A1 (fr) * 2019-11-29 2021-06-02 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Variante peptidique teipp et ses utilisations
AU2021276332A1 (en) 2020-05-19 2022-11-17 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2022079175A1 (fr) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Association d'un agoniste de sting et d'un complexe comprenant un peptide de pénétration cellulaire, une cargaison et un agoniste peptidique de tlr
CN113480666B (zh) * 2021-08-13 2024-01-26 郑州伊美诺生物技术有限公司 Ca153融合蛋白及其制备方法和ca153检测质控品或校准品
CN113786481A (zh) * 2021-09-27 2021-12-14 深圳市中佳生物医疗科技有限公司 一种抗肿瘤疫苗及其制备方法
WO2023174998A1 (fr) * 2022-03-16 2023-09-21 Boehringer Ingelheim International Gmbh Antigènes tumoraux, composés comprenant les antigènes tumoraux kras, tpx2 ou aurka et leurs utilisations
KR20240021995A (ko) 2022-08-10 2024-02-20 강원대학교산학협력단 Pde5 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도
KR20240053098A (ko) 2022-10-14 2024-04-24 강원대학교산학협력단 mTOR 억제제 특이적 결합 도메인, 재조합 단백질 및 이의 용도
GB202216453D0 (en) * 2022-11-04 2022-12-21 Lisziewicz Julianna Identification of antigens which induce t-cell responses
WO2024196664A1 (fr) * 2023-03-17 2024-09-26 University Of Washington Vaccin à adn ciblant des antigènes surexprimés dans le cancer colorectal

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2728904B1 (fr) 1995-01-04 1997-03-14 Pasteur Institut Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
EP3214175A1 (fr) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Anticorps ctla-4 humains et leurs utilisations
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
CA2427858A1 (fr) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Methodes et compositions destinees a inhiber grb7
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
GB0218821D0 (en) 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
MXPA05004022A (es) 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
WO2005039632A1 (fr) 2003-10-15 2005-05-06 Istituto Superiore di Sanità Antigene du cancer colorectal
EP1768698A4 (fr) 2004-06-17 2009-01-28 Medimmune Inc Compositions immunogeniques comprenant des polypeptides hmgb1
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
JP2008528643A (ja) 2005-02-04 2008-07-31 スルバック アーぺーエス サバイビンペプチドワクチン
ES2291071B1 (es) 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
EP2170959B1 (fr) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
PT2660248E (pt) 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
CN102046198A (zh) 2008-04-25 2011-05-04 系统生物学研究所 鞭毛蛋白多肽疫苗
NO2119726T3 (fr) 2008-05-14 2015-05-23
EP3766517B1 (fr) 2008-06-20 2022-11-02 Duke University Compositions, procédés et kits permettant de provoquer une réponse immunitaire
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR101040281B1 (ko) * 2008-08-22 2011-06-10 가톨릭대학교 산학협력단 Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물
US8074880B2 (en) 2008-12-01 2011-12-13 Research In Motion Limited Method, system and mobile device employing enhanced fingerprint authentication
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
KR20120014054A (ko) * 2009-05-27 2012-02-15 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃａｓｂ7439 작제물
KR20120090037A (ko) 2009-07-31 2012-08-16 메다렉스, 인코포레이티드 Ｂｔｌａ에 대한 완전 인간 항체
CN102741279A (zh) 2009-08-31 2012-10-17 艾普利穆恩公司 B7-h4融合蛋白和其使用方法
EP2476440B1 (fr) 2009-09-11 2017-08-02 Proyecto de Biomedicina Cima, S.L. Compositions thérapeutiques pour le traitement de maladies provoquées par le pvh
WO2011036211A1 (fr) 2009-09-23 2011-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides et acides nucléiques pour traiter des cancers dépendants de l'erbb2
DK3279215T3 (da) 2009-11-24 2020-04-27 Medimmune Ltd Målrettede bindemidler mod b7-h1
WO2011101332A1 (fr) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions basées sur le domaine extracellulaire a de fibronectine pour le traitement d'un mélanome
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
WO2011135222A2 (fr) 2010-04-26 2011-11-03 Universite Joseph Fourier Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
MX353165B (es) 2010-08-24 2017-12-20 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
US9340622B2 (en) 2010-09-14 2016-05-17 Council Of Scientific & Industrial Research Synthetic immunogen useful for generating long lasting immunity and protection against pathogens
WO2012048190A1 (fr) 2010-10-08 2012-04-12 Regents Of The University Of Minnesota Composition d'annexine ii et procédés
KR101760464B1 (ko) 2010-10-13 2017-07-24 사회복지법인 삼성생명공익재단 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
US9187534B2 (en) 2011-03-11 2015-11-17 Universite De Geneve Multi-epitopic vaccine
TWI454478B (zh) 2011-05-13 2014-10-01 Academia Sinica 類鐸受體-２ 增效劑及其用於刺激免疫反應之用途
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
EP2773651B1 (fr) 2011-11-03 2020-12-23 The Trustees of the University of Pennsylvania Compositions spécifiques de b7-h4 isolé et procédés d'utilisation associés
AP2014007638A0 (en) 2011-11-16 2014-05-31 Amgen Inc Methods of treating epidermal growth factor deletion mutant VIII related disorders
WO2013120073A1 (fr) 2012-02-09 2013-08-15 Av Therapeutics, Inc. Agonistes peptidiques synthétiques du récepteur 4 de type toll (tlr-4)
RU2650709C2 (ru) 2012-07-13 2018-04-17 С-Таргет Терапевтикс Гмбх Иммунорегуляторная вакцина
CA2884677C (fr) * 2012-09-13 2020-06-23 Universite De Geneve Peptides penetrant la cellule derives du virus epstein barr, compositions et methodes associees
WO2014070663A1 (fr) 2012-10-29 2014-05-08 Anderson David E Compositions et procédés pour le diagnostic et le traitement de gliomes malins
EP2968407A4 (fr) 2013-03-13 2017-01-04 Neostem Oncology, LLC Cellules souches de carcinome du côlon individualisées, de pureté élevée, procédés et utilisation associés
AU2014346658A1 (en) 2013-11-06 2016-06-02 Solstice Biologics, Ltd. Polynucleotide constructs having disulfide groups
CA2930567C (fr) * 2013-11-13 2023-09-26 Regents Of The University Of Minnesota Compositions de variants d'annexine ii et methodes
RU2707530C2 (ru) 2014-01-02 2019-11-27 Мемориал Слоан Кеттеринг Кэнсер Сентер Детерминанты ответа раковой опухоли на иммунотерапию
JP2017522046A (ja) 2014-06-06 2017-08-10 ソルスティス バイオロジクス，リミティッド 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
KR20170074235A (ko) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
AU2015346295A1 (en) * 2014-11-13 2017-05-25 The Johns Hopkins University Checkpoint blockade and microsatellite instability
WO2016146143A1 (fr) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Peptides pénétrant dans les cellules et complexes comprenant ceux-ci
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição
AU2017234192B2 (en) 2016-03-16 2024-04-04 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
KR20230131498A (ko) * 2016-09-21 2023-09-13 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
WO2022079175A1 (fr) * 2020-10-14 2022-04-21 Boehringer Ingelheim International Gmbh Association d'un agoniste de sting et d'un complexe comprenant un peptide de pénétration cellulaire, une cargaison et un agoniste peptidique de tlr

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11338027B2 (en) * 2016-09-21 2022-05-24 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
US20200087363A1 (en) * 2018-09-17 2020-03-19 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
US11945850B2 (en) * 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Also Published As

Publication number Publication date
IL265479A (en) 2019-05-30
RU2019111160A (ru) 2020-10-22
WO2018055060A1 (fr) 2018-03-29
JP7346291B2 (ja) 2023-09-19
RU2019111160A3 (fr) 2021-01-19
KR20230131498A (ko) 2023-09-13
EP3515476B1 (fr) 2024-05-22
CL2019000694A1 (es) 2019-06-07
US20210085768A1 (en) 2021-03-25
CN109963585B (zh) 2024-10-15
MX2019002968A (es) 2019-10-15
PL3515476T3 (pl) 2024-09-30
IL265479B (en) 2022-09-01
CL2021001541A1 (es) 2022-02-04
US20220305101A1 (en) 2022-09-29
US11338027B2 (en) 2022-05-24
CA3031170A1 (fr) 2018-03-29
CL2023002252A1 (es) 2024-03-01
KR20190057345A (ko) 2019-05-28
DK3515476T3 (da) 2024-09-02
EP3515476A1 (fr) 2019-07-31
CN109963585A (zh) 2019-07-02
JP2019528693A (ja) 2019-10-17
AU2017331949A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
US20220031850A1 (en) Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of Colorectal Cancer
US11338027B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
RU2807135C2 (ru) Слитая конструкция, содержащая проникающий в клетку пептид, полиэпитоп и пептидный агонист tlr, предназначенная для лечения рака

Legal Events

Date Code Title Description
AS Assignment

Owner name: AMAL THERAPEUTICS SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEROUAZI, MADIHA;BELNOUE, ELODIE;REEL/FRAME:048809/0896

Effective date: 20190322

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION